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1
Introduction
The life of mammalian organisms starts from a single fertilized cell, referred to as the 
‘zygote’. During development, the zygote divides repeatedly resulting in a large increase 
in cell numbers. Simultaneously, the growing number of cells form a wide variety of 
cell types that contribute to dierent organs, ultimately resulting in the formation of 
a new organism. This process of development is highly complex and as such requires 
very specic programs and tight regulation on which cell types to form and when. The 
information required for proper development is stored in the so-called genome which 
contains the genetic information of an organism in the form of DNA1, consisting of 
Adenine, Cytosine, Thymine and Guanine nucleotides (A, C, T, G, respectively). Within 
this DNA, specic sequences of nucleotides called genes encode for the information 
required for a cell to execute basic processes. In humans, roughly 25.000 genes2 are rst 
transcribed to small templates (‘RNA’) that provide the information needed for cells to 
produce proteins, which are the main eector molecules of the cell3. To t all the DNA, 
which is almost two meters in size, into the cell’s center (the nucleus), it is compacted 
around small protein octamers called histones. The histone octamer consists of two 
copies of proteins called histone H2A, H2B, H3 and H4, which are held together by the 
H1 linker histone4. Together, the histones and the DNA are called chromatin, which is the 
main focus of this thesis. 
The epigenome
All approximately 200 dierent cell types in the body are genetically identical. However, 
each cell type is morphologically dierent and exerts distinct functions. This is the result 
of dierent genes and proteins being used in each cell type, which the cell achieves 
through actively transcribing the genes required and switching o those that are 
redundant5. Changing the transcription of genes can be realized in several ways. At rst, 
to actually transcribe a gene, a large protein complex called RNA Polymerase II (Poll II) 
binds the DNA sequence upstream of a gene (called the ‘promoter’), after which it 
transcribes the essential information of the gene (the ‘gene body’)6. The functionality 
of Pol II is highly sensitive to environmental changes and as such modulation of Pol II 
function can aect transcription, which can occur on many levels7. For example, the 
histones around which the DNA is wrapped have protruding tails of which specic 
amino acids can be chemically modied to directly aect gene transcription8,9. Notable 
examples include addition of three methyl groups (me3) to the lysine (K) on position 4 of 
the tail of histone H3 (in short H3K4me3), which is associated with active transcription. 
On the other hand, when the lysine on position 27 of histone H3 contains three methyl 
groups (H3K27me3), the chromatin is compacted which is associated with silencing of 
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genes. To date, nearly 140 dierent histone modications (hPTMs) have been discovered, 
which provide a highly complex landscape which we call the Histone Code10. 
Next to histone modications, there is a large number of proteins present on the chromatin 
that can modulate gene transcription in several ways, which we call transcription factors. 
These include proteins involved in communication through the Histone Code, by either 
placing histone modications (‘writers’), reading of these modications (‘readers’) or 
removing histone modications (‘erasers’)11. Next, a group of proteins termed ‘chromatin 
remodellers’ actively modulate the position of histones, which is essential to achieve 
for example a greater distance between histones which is favourable for transcription 
by Pol II12. Further, there are proteins that can fold the chromatin in 3D to bring two 
regions closer together, such as DNA elements called ‘enhancers’ which when placed in 
close proximity of a gene promoter can enhance that transcription of the corresponding 
gene13. In addition, there are proteins that bind these enhancers or other regulatory 
DNA elements that contribute to their functionality. Altogether, it is evident that the 
chromatin is highly complex with many proteins and chemical modications aecting its 
functionality, which we collectively refer to as the ‘epigenome’. 
Transcription of genes can also be aected after the RNA has been produced, which is 
called posttranscriptional regulation. For example, similar to DNA, RNA can be chemically 
modied resulting in enhanced translation to protein or accelerated breakdown, which 
is referred to as the ‘epitranscriptome’14. Moreover, proteins can be chemically modied 
similar to histones, which collectively are called post-translational modications 
(PTMs). These PTMs can aect protein function by for example enhancing protein 
stability, facilitating protein-protein and protein-DNA interactions or marking them for 
degradation15,16. Altogether, cells contain a tightly controlled regulatory program to exert 
their function. Moreover, these programs are at the foundation of the specication of all 
somatic cell lineages during early embryonic development of all organisms. 
Embryonic development in vivo and in vitro
During very early embryonic development, the zygote migrates from the ovary through 
the fallopian tube towards the uterus and undergoes several cell divisions seemingly 
without committing (dierentiating) to any specic cell lineage. The capacity of these 
cells to propagate indenitely without dierentiating is referred to as ‘pluripotency’17. In 
case of a mouse embryo, the rst commitment occurs around 3 days post fertilization, 
when the outer cells of the early embryo commit to trophectoderm and the inside 
forms the pluripotent founder population which is the inner cell mass (ICM)18,19. At day 
4.0, a clear distinction occurs between the primitive endoderm and the cells that retain 
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Figure 1 | Development of mouse embryos. A fertilized oocyte (the zygote) divides 
multiple times during the rst days of development to eventually form the early blastocyst 
at day 3.5 post fertilization. After the blastocyst implants into the wall of the uterus, the 
developing embryo is exposed to a plethora of external cues, resulting in priming of the 
pluripotent cell population. This time point (E5.5) also marks a drastic morphologic change 
of the previously round-shaped blastocyst. 
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their pluripotency, the epiblast20. At this point the partitioned epiblast cells enter the 
developmental “ground state”, the origin of all future embryonic lineages21. An important 
commitment of the developing embryo takes place upon implantation in the wall 
of the uterus around day 5.0, upon which the transition towards a “primed” phase of 
pluripotency starts in which the embryo is sensitive to external cues to further develop 
lineage-specication programs (Figure 1)22. 
Studies using for example uorescent imaging have provided essential information 
on the molecular pathways sustaining early embryonic development. However, a 
signicant proportion of cell faith decisions are mediated through epigenetic modiers 
and transcription factors. Conversely, this is challenging to study using imaging and 
understanding the constructive signals resulting from the epigenome and the protein 
landscape (the ‘proteome’) underlying developmental specication is critical to further 
understand embryonic development. To comprehensively study early embryonic 
development without the need for animal experiments, a method has been developed in 
which the developing embryo at the blastocyst stage was taken into culture outside the 
uterus, being successful for the rst time in 1981. It became evident that cells from the 
inner cell mass (ICM) of the embryo could be propagated indenitely in a dish (in vitro) 
when grown in the presence of serum. These cells are called embryonic stem cells (ESCs). 
First, the culture of ESCs was supported by an inactive cell population called feeders, 
which provided the necessary growth factors to sustain ESCs. Later, the feeders were 
replaced by the small molecule Leukemia inhibitory factor (LIF)17,23. When maintained 
under permissive conditions, ESCs can self-renew indenitely without losing their 
Zygote 4-Cell Morula Early blastocyst Late blastocyst Egg cylinder
E0.5 E2.0 E3.0 E3.5 E4.5 E5.5Time after fertilization
Pre-implantation Post-implantation
Epiblast Trophoblast Primitive endoderm
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cellular identity and as such represent a surrogate model of the naive epiblast that can 
be propagated in culture for a prolonged time. Moreover, even after excessive in vitro 
expansion ESCs can, when injected into the early embryo, undergo lineage specication 
and e¦ciently contribute to all aspects of embryonic development24. Additionally, when 
ESCs are introduced in a tetraploid donor blastocyst that on itself is unable to complete 
embryonic development, healthy adult mice can be obtained that are exclusively formed 
from the ESCs25. This greatly underlines the unrestricted potency of ESCs and these 
unique properties make them an invaluable model to study developmental processes in 
health and disease. Moreover, as ESCs can be maintained in vitro and can be grown in vast 
amounts, this provides a unique opportunity to use in-depth molecular proling of all 
regulatory levels of cells mimicking their in vivo origin. 
Although ESCs grown in the presence of serum (as such referred to as ‘serum ESCs’) 
have been instrumental in the studies of preimplantation development, soon it became 
apparent that these ESCs did not re§ect their in vivo origin well. This was evident on all 
layers of function, from epigenome to cell morphology26,27. In 2008, the group of Austin 
Smith used knowledge obtained form in vivo models on the molecular circuitry sustaining 
pluripotency to pioneer the culture of ESCs in a serum-free, chemically dened medium 
with inhibitors for two kinases (referred to as ‘2i ESCs’). Through the inhibition of ERK 
signaling and inhibition of the GSK3 protein, an ESC population could be maintained that 
was markedly dierent from serum ESCs28. 
2i and serum ESCs as in vitro models for in vivo 
development
Although both serum and 2i ESCs are functionally pluripotent, extensive research has 
revealed that 2i ESCs re§ect the ICM well and are as such considered developmentally 
unrestricted and proposed to exist in the ground state, whereas serum ESCs were found 
to represent a version of pluripotency close to post-implantation which we refer to as 
‘early primed’ 21,29,30. As such, comparison of 2i and serum ESCs in vitro can provide critical 
information on processes occurring within the early pluripotency continuum in vivo31. The 
notion that 2i and serum ESCs represent distinct states of pluripotency is already apparent 
when inspecting their morphology. Specically, while serum ESCs form heterogeneously 
shaped colonies and show signs of premature dierentiation, colonies of 2i ESCs are round 
and homogeneous without clear signs of dierentiation28,32. Application of state-of-the-art 
technologies to 2i and serum ESCs has provided critical information demonstrating that 
these ESCs are distinct on the epigenetic and transcriptional level as well. For example, 2i 
ESCs are characterized by low levels of DNA methylation (the addition of methyl groups 
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Figure 2 | Dynamic epigenetic features during the pluripotency continuum in vivo and 
in vitro. A) Embryonic stem cells can be derived from the inner cell mass in the blastocyst 
around day E4.5. These ESCs can be cultured in 2i or serum conditions, resulting in distinct 
pluripotent states. Also, ESCs from the day E5.5 primed epiblast can be cultured in vitro 
(EpiSCs). B) The dierent pluripotent states are epigenetically and functionally distinct. A 
darker colour shade indicates higher levels compared to a light shade. 
Chapter 1
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to cytosine bases of the DNA), whereas serum ESCs are hypermethylated33–35. This is 
accompanied by lower levels of DNA methylation associated proteins such as DNMT1 and 
DNMT3A/B/L, UHRF1 as well as the related histone modication H3K9me2 in 2i ESCs36. In 
relation to this, serum ESCs display enhanced deposition of H3K27me3 on promoters of 
developmental genes, whereas in 2i ESCs this histone modication is present genome-
wide and is not conned to promoters32 (discussed in Chapter 4). Furthermore, serum 
ESCs are hallmarked by expression of lineage-specifying genes and display enhanced 
focal adhesion32,37. Also regarding the 3D folding of the genome 2i ESCs are distinct from 
serum ESCs, exemplied by the absence of extreme long range interactions (ELRIs) in 
2i ESCs38. Finally, serum ESCs display a less §exible and more compacted genome39,40. 
Collectively, these distinctions likely render 2i ESCs with a highly stabilized pluripotent 
state, and in addition some lines of evidence suggest that 2i ESCs might have a higher 
colony formation potential and can more e¦ciently contribute to the early developing 
embryo32,41. 
Altogether, application of state-of-the-art techniques revealed many molecular 
distinctions between 2i and serum ESCs. Together, these resulted in the dogma that 
serum ESCs represent a metastable state intermediate of 2i ESC and more primed Epiblast 
Stem Cells (EpiSCs), which are derived from the post-implantation blastocyst. The value 
of the model systems as developed in vitro is underlined by the conrmation of a number 
B
la
st
oc
ys
t (
E
4.
5)
E
gg
 c
yl
in
de
r (
E
5.
5)
ESCs
2i ESCs
Serum ESCs
EpiSCs
Naive pluripotency
Primed pluripotency
D
N
A m
ethylation
H
3K
9m
e2
H
3K
27m
e3
Lineage specification
A B
533641-L-bw-Mierlo
Processed on: 23-7-2019 PDF page: 14
General introduction
14
of observations in vivo. Notable examples include the gain of DNA methylation and 
H3K9me2 upon implantation as well as the increased expression of lineage specication 
genes in the implanting blastocyst30,33–35 (Figure 2). 
An important feature of the use of 2i and serum ESCs as a mirror of in vivo development is 
their interconvertibility. Specically, ESCs grown in 2i medium can be switched to serum 
medium and vice versa which after two weeks results in complete rewiring of the cellular 
state33. Together with the ability to grow a large of number of cells and the resemblance to 
dierent time points of in vivo development, this makes 2i and serum ESCs a powerful and 
widely adopted system to study mechanisms at work in early embryonic development31. 
Studying epigenetics and pluripotency using omics 
tools
‘Omics’ technologies adopt a holistic view of the molecules that make up a cell, tissue or 
organism. These include the study of the genome (genomics), RNAs (transcriptomics), 
proteins (proteomics) and metabolites (metabolomics) of a biological sample in an 
unbiased and non-targeted manner. Integration of multiple omics-technologies is 
commonly referred to as ‘systems biology’42. Essentially, these techniques aim to 
understand complex organisms as a whole through measurement of as many individual 
components as possible. This makes systems biology fundamentally dierent from 
‘classical’ research which is mainly hypothesis driven. Using a hypothesis-generating 
approach, studies using omics generate a large amount of data on multiple layers of 
regulation in the same sample or tissue. These data can consequently be used to generate 
hypotheses for further research43. The application of such omics-tools has greatly 
advanced our knowledge of essential processes sustaining life, including embryonic 
development and pluripotency in vitro and in vivo (as also described above). Below, I will 
discuss that main omics-technologies that have been instrumental for the data obtained 
in this thesis. 
Epigenomics
Important features that are studied using epigenomics technologies include the 
localization of DNA methylation as well as histone modications and transcription 
factors on the genome, the 3D genome organization and association of the chromatin 
with the nuclear membrane. The techniques that have been important for the data in this 
thesis will be discussed below.
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DNA methylation
The process in which a methyl (-CH3) group is added to bases of the DNA is referred 
to as DNA methylation. The addition of these methyl groups, which mainly occurs in a 
CpG (a Cytosine followed by a Guanine) context, can change the ‘functionality’ of a DNA 
segment without changing the DNA sequence. For example, when many cytosines in the 
promoter of a gene are methylated (a methylated CpG island), the proteins important 
for the initiation of transcription can generally no longer bind resulting in silencing of 
the gene. Conversely, when DNA methylation is strongly present in the gene body, this 
aids transcription by Pol II and hence results in gene activation44–46. DNA methylation is 
important for all cells to ensure gene silencing, which is underscored by its essentiality 
for normal embryonic development and its association with many biological processes 
such as X-chromosome inactivation, aging and cancer47. 
Nowadays, a plethora of technologies have been developed to study DNA methylation. 
The most comprehensive technologies to date are whole genome bisulte sequencing 
(WGBS) and reduced representation bisulte sequencing (RRBS). For WGBS, genomic 
DNA is isolated from cells or tissue and treated with sodium bisulte followed by next 
generation sequencing, which provides single-base resolution of methylated cytosines in 
the genome48. By bisulte treatment of the DNA, unmethylated cytosines are deaminated 
to uracils which, upon sequencing, are converted to thymines. Simultaneously, 
methylated cytosines resist deamination and are read as cytosines. The location of the 
methylated cytosines can then be determined by comparing treated and untreated 
sequences (Figure 3). WGBS requires a high number of sequencing reads to establish 
su¦cient coverage of the genome. RRBS provides an alternative to WGBS, in which a 
specic restriction enzyme is used to enrich for regions with a high amount of cytosines 
(mainly promoter elements)49. This approach reduces the amount of sequencing reads 
required and is more cost-eective compared to WGBS in the study of cytosine-rich DNA 
elements50. However, RRBS only provides a reduced representation of the genome.
 
Figure 3 | Schematic workow for whole genome bisulte sequencing. Genomic DNA 
is isolated from a cell type or tissue of interest and sheared into small fragments. These 
fragments are subjected to bisulte treatment, resulting in conversion of unmethylated 
cytosines to thymine (indicated in red), while methylated cytosines are unaected by the 
treatment. The resulting DNA fragments can be measured using high throughput sequencing 
and aligned with a reference genome to obtain base-pair resolution of methylated cytosines 
genome-wide. 
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Histone modications and transcription factor binding sites
Figure 4 | Schematic workow of ChIP-sequencing experiments. Chromatin is harvested 
from a cell population and sheared into small fragments. An antibody specic to either a 
transcription factor or a histone modication of interest is used to purify the factor together 
with the associated DNA from the pool of chromatin fragments. DNA is released from the 
isolated fraction and prepared for sequencing. Aligning these DNA fragments to the genome 
provides information on the localization of the factor of interest on the genome. 
Transcriptomics
Y
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To understand epigenetic regulation in detail, it is important to understand the binding 
sites of transcription factors on the genome as well as the localization of hPTMs. 
Chromatin-immunoprecipitation followed by massive parallel sequencing (ChIP-seq) is 
a widely adopted technology that allows mapping of global binding sites of transcription 
factors and histone modications of interest51–53. The method relies on crosslinking the 
cells or tissue of interest using formaldehyde to preserve the in vivo interactions between 
transcription factors and the chromatin. The chromatin is sheared into small pieces and 
incubated with an antibody against a factor of interest. Hereby, the transcription factor 
or histone modication plus the associated DNA fragments are specically separated 
from the total chromatin pool. These DNA fragments can be isolated and analysed using 
massive parallel sequencing. The DNA fragments can be mapped to a reference genome 
which provides information on the position of the factor of interest relative to genes, 
DNA elements and other epigenetic factors on the genome (Figure 4). 
Isolation of all RNAs in the cell followed by high throughput sequencing can give 
information on which genes are transcribed and their expression level. This technique, 
referred to as RNA-seq, provides the opportunity to investigate RNAs originating from 
genes, but also those from non-coding regions (ncRNA), enhancers (eRNA) and small 
interfering RNAs (miRNAseq)54. 
ATCGA
TAGCA
Cell population Chromatin Shear chromatin
Enrichment using antibodyIsolate DNADNA SequencingMap to genome
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Proteomics
The large scale study of proteins is called proteomics55. Nowadays the most used 
method to comprehensively study proteins and post translational modications is mass 
spectrometry. For mass spectrometry work§ows, proteins of interest (for instance the 
proteins from a cell population) are cut into small pieces called peptides. This process is 
highly versatile and the size range of the peptides can be controlled depending on the 
cutting enzyme used. The resulting peptides can be measured in a mass spectrometer. 
There are many dierent types of mass spectrometers and sample preparation work§ows 
depending on the purpose of the experiment. For example, mass spectrometry is 
frequently used to obtain information on the abundance of proteins. For this purpose, 
the samples are digested with the enzyme Trypsin to obtain small peptides (max ~20 
amino acids), which is referred to as bottom up mass spectrometry. However, this method 
is not well suited to obtain information on post-translational modications. Therefore, 
mass spec work§ows have been developed that can quantify bigger peptides (up to 50 
amino acids) or even whole proteins, which is referred to as middle down or top down 
mass spectrometry, respectively. Collectively, the §exibility of the mass spec work§ow 
provides a unique toolbox to study the proteome landscape of any cell type or tissue of 
interest. Although relatively large amounts of proteins are required for standard mass 
spectrometry work§ows (~10 µg of protein for proteomes equivalent to ~35000 cells), 
eorts are ongoing to reduce the required sample size, which has already resulted in the 
measurement of single cell proteomes of oocytes56. 
Proteomics is not only used to determine the abundance of proteins, but also to 
understand how they work together. As proteins rarely function on their own, 
they aggregate into protein complexes57. Notable examples of these include well-
studied epigenetic complexes such as Polycomb Repressor complexes and tra¦cking 
complexes such as the Exocyst complex. These complexes can be studied using an 
endogenous antibody against one member of the complex, after which the antibody-
protein complexes can be puried and studied using mass spectrometry. An alternative 
approach is to attach a ‘tag’ (e.g. green §uorescent protein (GFP) or FLAG-tag) to a 
protein of interest which can be used for the isolation of protein complexes58. Both these 
approaches are referred to as a¦nity purication followed by mass spectrometry (AP-
MS) or protein pulldown. More recent advances have provided the opportunity to also 
study the 3D conrmation of such a puried complex. This method relies on crosslinking 
closely positioned amino acids during the pulldown procedure (XL-MS)59. Using mass 
spectrometry and computational approaches these crosslinks can be retrieved, as such 
providing information on the specic localization of protein-protein interactors within 
a complex60. Finally, mass spectrometry can be used to determine which proteins 
bind a specic substrate of interest, for example DNA with a specic sequence (‘DNA 
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Figure 5 | Overview of frequently used mass spectrometry approaches. For total 
proteomes, all proteins are isolated and measured in the mass spectrometer which provides 
information on the total abundance of each protein in a cell lysate. AP-MS work§ows rely on 
the purication of protein complexes from a cellular extract using endogenous antibodies 
or tag-specic antibodies (black circle with extensions), which provides information on 
the proteins that are present the same complex. XL-MS is similar to AP-MS but involves 
a crosslinking step after the purication of a protein complex of interest. Crosslinks 
between specic peptides can be computationally identied and used to reconstitute the 
3D conformation of a protein complex in silico. For DNA pulldowns, a strand of DNA with 
a sequence of interest is incubated with cellular extracts resulting in binding of proteins 
with high a¦nity for that specic piece of DNA. Through comparison with a probe with a 
scrambled sequence, specic binders for the sequence of interest can be identied.
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pulldown’)61. By incubating a protein extract with DNA of a sequence of interest or a 
scrambled version, sequence-specic binders can be identied (Figure 5). 
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Altogether, integration of these omics approaches is a powerful approach to fully 
understand the biology of a given sample or tissue. Only by understanding all layers of 
regulation it is possible to understand the eects of environmental changes, chemicals 
perturbations or genetic manipulation in detail. As such, systems biology has greatly 
advanced our knowledge of (developmental) biology. Systems biology was fundamental 
for the knowledge on stem cell biology obtained in this Thesis. 
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Abstract
Pluripotency can be captured in vitro in the form of Embryonic Stem Cells (ESCs). These 
ESCs can be either maintained in the unrestricted ‘naïve’ state pluripotency, adapted to 
the developmentally more constrained ‘primed’ pluripotency or dierentiated towards 
of the three germ layers. Epigenetic protein complexes and transcription factors have 
been shown to specify and instruct transitions from ESCs to distinct cell states. In this 
study, we use proteomic proling of the chromatin landscape by chromatin enrichment 
for proteomics (ChEP) to survey the chromatin in mouse naive pluripotent ESCs, primed 
pluripotent Epiblast stem cells (EpiSCs) and cells in early stages of dierentiation. We 
provide a comprehensive overview of epigenetic protein complexes associated with 
the chromatin and identify proteins associated with the maintenance and loss of 
pluripotency. Our data reveal major compositional alterations of epigenetic complexes 
during priming and dierentiation of naïve pluripotent ESCs. These results contribute to 
the understanding of ESC dierentiation and provide a framework for future studies of 
lineage commitment of ESCs.  
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Introduction
Pluripotency is a transient state during embryonic development in which cells in the 
epiblast are capable of forming all somatic cell types and germ cells62. After implantation 
in the uterus, pluripotent cells progressively gain restrictive epigenetic features that 
constrain their developmental potential29. This resulted in the dogma that there is no 
single pluripotent state, but rather a spectrum of pluripotent states ranging from 
‘naïve’ to ‘primed’, with the major discriminator being that primed ESCs are receptive 
to dierentiation-inducing cues from the environment63,64. Several distinct populations 
of pluripotent cells can be maintained in vitro, each re§ecting a particular time point in 
embryonic development29. Naïve Embryonic Stem Cells (ESCs) of mice can be derived 
from pre-implantations embryos and can be maintained in fetal calf serum supplemented 
with Leukemia Inhibitory Factor (LIF)17,65, which mediate activation of the SMAD and 
JAK-STAT signaling, respectively[2]. These cells can be injected into pre-implantation 
embryos and can subsequently contribute to all germ layers and the germline63. The in 
vitro cultured equivalents of post-implantation pluripotent cells are Epiblast stem cells 
(EpiSCs), of which the maintenance relies on stimulation of SMAD and ERK signaling by 
FGF2 and Activin A, respectively66,67. EpiSCs are more developmentally constrained and 
represent the ‘primed’ state of pluripotency, as EpiSCs are not germline-competent and 
do not contribute e¦ciently to embryos in chimaera assays68,69. However, EpiSCs retain 
the ability to form teratomas, demonstrating their pluripotency67, although EpiSCs cannot 
revert to the naïve state of pluripotency. When primed ESCs progress with dissolution of 
the pluripotent state, they initiate lineage specication programs during dierentiation 
and as such are no longer considered pluripotent70.
The transition from naive to primed and subsequently dierentiation requires extensive 
rewiring of the cellular state, exemplied by major changes in cell morphology and distinct 
metabolic, transcriptional and epigenetic states71. Some of these changes, such as the 
activation of lineage-priming genes, and increase of DNA methylation, are readily initiated 
in primed pluripotency72,73. Another notable example includes bivalent chromatin domains, 
which are decorated with both repressive and activating histone marks74, that are resolved 
when the pluripotent state is lost, starting upon priming of ESCs75. 
Epigenetic processes play a substantial role in regulation of cell faith decisions. The 
eector proteins on the chromatin, Transcription Factors (TFs), often exhibit a role as 
‘master regulator’ by binding to and regulating many genes, thereby driving cell state 
transitions76. Despite their low abundance, transcription factors make up a signicant 
portion of the variation in the mammalian proteome77, and exert critical roles in 
mammalian development76. Several regulatory TFs have been discovered that drive 
early priming or dierentiation in the embryo, such as Otx2 and Zeb1/2, respectively78. 
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In addition, recent reports have highlighted dramatic rewiring of epigenetic complexes 
between ESCs and early dierentiated cell types such as neural progenitor cells (NPCs)79,80. 
However, a comprehensive overview of the chromatin environment during priming and 
dierentiation is currently lacking. Such an overview would provide valuable information 
on TFs and other epigenetic factors in the process of dierentiation. Here, we set out to 
provide a comprehensive overview of the chromatin proteome during pluripotency and 
early dierentiation. 
Results
As epigenetic factors and TFs are generally lowly abundant77, their detection is challenging 
when using proteomics approaches that prole total cell lysates81. However, these factors 
can be brought into the dynamic range of mass spectrometer through enrichment of 
the chromatin fraction82. Simultaneously, this provides information on the levels of these 
factors in their relevant context. To gain insight in dynamics of epigenetic regulators 
and transcription factors during pluripotency and dierentiation, we collected a range of 
cell types representing naïve pluripotency (‘serum ESCs’), primed pluripotency (‘EpiSCs’), 
and early neuronal dierentiation (‘END’), which is a widely adopted dierentiation 
system83 (Fig 1A). First, we conrmed that the various cell types were morphologically 
distinct. In particular, ESCs formed small colonies, EpiSCs formed large, §atter colonies, 
and END cells were hallmarked by a more stretched morphology84 (Fig 1B). In terms 
of expression of known marker genes, the naïve pluripotency marker Rex1 was highly 
expressed in ESCs, but not in other cell types. EpiSC culture conditions showed high 
expression of EpiSC markers Otx2, Fgf5, and Zic285. Ectodermal dierentiation markers 
Pax6 and Sox1 were upregulated in END cells (Fig 1C)85. These results validated our in vitro 
dierentiation protocol.
Next, we isolated the chromatin of these cells using Chromatin Enrichment for Proteomics 
(ChEP) (Fig 2A). The chromatin enrichment was validated by strong enrichment of 
histones as compared to whole cell lysates (Fig S1A). We performed mass spectrometry 
analyses of the chromatin fraction, in which we reproducibly quantied a total of 4174 
proteins (Fig S1B). Replicates showed high correlation (R2 > 0.95), which was further 
conrmed using Principle Component Analysis (PCA) (Fig 2B,2C). Furthermore, the PCA 
showed a clear distinction between the dierent cell types. As chromatin enrichment 
procedures can be prone to contamination from organelles such as the mitochondria86, 
we used a compiled list of proteins with known chromatin function (Methods)87. Of 
the detected proteins, 2169 had a known chromatin function (Fig S1C), which matches 
published data and validated enrichment of chromatin82. Further analysis was performed 
with this subset of the data.
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Figure 1 | Generation of distinct cell types using specic culture conditions. 
A) Schematic overview of the culture conditions and work§ow used. B) Colonies of the 
various cell types as used in this study. C) Gene expression for selected markers to validate 
the distinct molecular signature. Error bars represent SEM, n=2.
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Next, we plotted the LFQ values of known markers of EpiSCs and early dierentiation, 
which included naïve markers (TBX3 and KLF4), priming markers (DNMT3B and GRHL2) 
and neuronal markers (FOXP1 and HMGN3), which further validated the cell types on the 
chromatin level (Fig 2D). Of all proteins included in the analysis, ANOVA statistics revealed 
682 proteins (31.4%) to be signicantly dierentially abundant between the three cell types. 
We clustered these proteins using k-means clustering. This approach revealed distinct 
clusters with GO terms associated with their particular cell state. Notable examples include 
the term “telomere maintenance” being enriched on the chromatin in ESCs, whereas END 
chromatin was enriched with factors associated with neuro-ectodermal processes such as 
“neurogenesis” and “epithelial dierentiation” (Fig 2E). 
After validation of the samples, we aimed to provide a comprehensive overview of the 
abundance of major epigenetic complexes on the chromatin in these cells. Notably, we 
previously showed that the abundance of chromatin-associated proteins corresponds 
to the levels of the respective proteins as observed in protein complexes using protein 
complex pulldowns88. We focused on major epigenetic protein complexes including 
the Polycomb Repressive Complex 2 (PRC2), Nucleosome Remodeling and Deacetylase 
(NuRD) Complex, and the Brg/Brahma-associated factors (BAF) complex. We observed 
large changes within these epigenetic complexes. For example, we observed a 
downregulation of many PRC2 components including the core complex consisting of 
EED, EZH2 and SUZ12, which we also validated using western blot for EED (Fig S1E). This 
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Figure 2 | ESCs, EpiSCs and END cells show distinct chromatin proteome signatures. 
A) Schematic overview of work§ ow that was applied for ChEP-MS. B) Unsupervised clustering 
of the correlation matrix showing R2 values between each sample. C) PCA analyses using 
di erential proteins. D) log2 LFQ values for proteins associated with di erent cell states: 
TBX3 and KLF4 with naïve pluripotency, DNMT3B and GRHL2 with primed pluripotency, 
and FOXP1 and HMGN3 with neuronal development. E) Heatmap showing all di erential 
proteins (ANOVA, BH-corrected FDR<0.05) clustered on z-score. Number of proteins per 
cluster is marked, relevant GO terms associated with each cluster are mentioned. 
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observation is in line with previous reports highlighting a major rewiring of the PRC2 
complex during dierentiation resulting in a strong reduction of many components in 
neural progenitor cells79,89 (Fig 3A). The BAF complex is known to change composition 
during dierentiation90. In line, we observe an increase of subunits that characterize 
neuronal dierentiation (npBAF) such as SMARCC2 in EpiSCs, and these levels increase 
to a larger extent in END cells. In contrast, subunits that dene the ESC version of the 
BAF complex (esBAF; SMARCC1, SMARCD2 and ACTL6A) remain at similar levels while 
exiting the naïve state 90, indicating a balance shift towards npBAF, although the esBAF 
complex remains present as well. In addition, several other BAF complex subunits display 
strong dynamics upon dierentiation. For example, SMARCA4 (also known as BRG1) is 
strongly upregulated in END cells, which is likely related to the requirement of SMARCA4 
for induction of enhancers during lineage commitment91. On the other hand, SS18 
seems to be mainly present in pluripotency, which could indicate that the embryonic 
lethality observed in mice lacking SS18 is readily caused by defects in very early 
embryonic development92. Finally, we focused on the NuRD complex as a very recent 
report suggested altered NuRD complex composition in ESCs and NPCs80. In line with this 
previous report, we observe more ZFP296 on chromatin in ESCs and more ZMYND8 and 
ZNF687 on chromatin during early dierentiation. Interestingly, some changes such as 
the gain of ZMYND8 are readily present in EpiSCs, indicating this switch occurs during 
pluripotency (Fig 3A, S1F), whereas the increase of CHD3 and MBD2 mainly occurs after 
the pluripotent state is lost. As such, these results further indicate that NuRD changes 
composition upon ESC dierentiation. 
Next, we focused on DNA methylation as this is a major driver of dierentiation93. We 
observed higher levels of DNMT3B in EpiSCs, in line with previous reports94, but an 
increase in DNMT3A in END cells (Fig 3A), which could indicate a switch in DNMT3 proteins 
during initiation of dierentiation. We also observed a drastic downregulation TET1/2 
in both EpiSCs and END cells, which ts previous reports reporting the downregulation 
of TET1/2 during embryoid body dierentiation95. In addition, this further indicates that 
the altered DNA methylation landscape in dierentiating cells may be the result of a 
shift in TET1/2 and DNMT3A/B balance, rather than a unilateral increase in depositing 
enzymes93,96.
The last category of proteins we focused on are pluripotency factors as these comprise 
dynamic regulators of cell fate and dierentiation. We observed that both EpiSCs and 
END cells displayed an overall downregulation of pluripotency markers, tting the loss 
of the naïve state (Fig S1D). In addition, EpiSCs were characterized by increased levels 
of LIN28A/B which is characteristic for primed pluripotency97 (Fig S1D). Collectively, our 
analysis reveals strong rewiring of chromatin-associated epigenetic complexes upon 
induction of dierentiation. 
533641-L-bw-Mierlo
Processed on: 23-7-2019 PDF page: 28
Figure 3 | Rewiring of epigenetic complexes. A) Log2 fold change (relative to ESCs) of 
epigenetic complexes and DNA methylation associated factors in both EpiSCs and END cells. 
B) Candidate regulators of priming and dierentiation. Proteins of interest with p<0.05 
(ANOVA) and >2-fold dierential have been highlighted. Further details on remaining 
proteins not labelled by name are present in Table S2.
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Finally, we aimed to use our chromatin proteomes to identify candidate TFs that 
regulate dierentiation. We ltered our protein list for TF activity using a combination of 
published TF databases98,99 and identied dierential TFs (p<0.05 and >2-fold dierence) 
relative to ESCs. These analyses identied known naïve pluripotency factors such as 
ESRRB and KLF2 to be more abundant in ESCs (Fig 3B). Conversely, factors associated 
with neural development such as FOXC1/2 and ZEB1 are enriched in END cells100,101, and 
priming factors such as GRHL2 and LIN28B in EpiSCs 97,102. Next to identication of 
known regulators, we identify several TFs such as SMAD2, ZFHX3, HIC1 and ZHX1 that 
could be candidate regulators for priming or dierentiation. 
Discussion
In summary, we here provide a comprehensive overview of the chromatin during 
transition from the naïve pluripotent state towards primed and dierentiating cell-
states. Focusing on the chromatin proteome enabled detection of low abundant 
transcription factors, which allowed us to eectively explore these regulatory factors 
during maintenance and exit of pluripotency. This dataset recapitulates known dynamics 
in epigenetic complexes such as PRC2 and can be used to identify novel candidate 
proteins for future studies. To facilitate this, we have included an extensive table with 
protein abundances identied in this study. In addition, we have highlighted whether a 
protein is considered a chromatin factor (Table S2). Overall, these data provide a useful 
resource for future studies on the chromatin environment during maintenance and exit 
of pluripotency. 
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Methods
Cell Culture and dierentiation
ESCs were cultured in DMEM supplemented with 15% Fetal Bovine serum (Hyclone), 
1000U/mL Lif (Merck), β-mercaptoethanol and Sodium Pyruvate. Cells were passaged 
every 2-3 days using Trypsin-EDTA (Gibco, cat. no 25300120). Mycoplasm was conrmed 
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to be absent in the cell cultures. Epiblast Stem Cells were generated by culturing ESCs in 
NDi medium supplemented with 5ng/µl FGF5 (Peprotech, cat. no 100-18B) and 8ng/
µl Activin A (R&D Systems, cat. no 338-AC) for 5 days, after which cells were passaged 
in clumps every 2-3 days using collagenase type II (Worthington, cat. no LS004176)103. 
Neuro-ectoderm dierentiation was induced by adapting serum-grown ESCs to NDi 
without any further supplements for at least 7 days. Cells were split 1:1 using Accutase 
(Gibco, cat. no A11105-01). 
Chromatin Enrichment for Proteomics
Chromatin was harvested and enriched as described in Kustatscher et al.82. Cells were 
cross-linked on plates using 1% formaldehyde and incubated at 37 °C for 10 min. Cross-
linking reaction was stopped by adding glycine to a concentration of 0.25 M for 5 min. 
Plates were rinsed with Phosphate Buered Saline (PBS) and scraped in 5-10 mL of PBS. 
Tubes were centrifuged at 1,000g for 3 min, supernatant was aspirated and cells were 
resuspended and homogenized in 1 mL cold lysis buer (25 mM TRIS pH 7.4, 0.1% Triton 
X-100, 85 mM KCl, 1X Roche protease inhibitor). Suspensions were centrifuged at 2,300g 
for 5 min at 4 °C, supernatant was aspirated and pellets were resuspended in 500 µL of 
lysis buer and incubated at 37 °C for 15 min. Suspensions were centrifuged at 2,300g 
for 10 min at 4 °C, supernatant was aspirated, pellets were resuspended in 500 µL of 
SDS buer (10 mM TRIS pH 7.4, 10 mM EDTA, 4% SDS, 1X Roche protease inhibitor) and 
incubated at room temperature for 10 min. 1.5 mL of urea buer (10 mM TRIS pH 7.4, 1 
mM EDTA, 8 M urea) was mixed with samples and they were centrifuged at 16,100g for 
30 min at room temperature. Supernatant was aspirated and pellets were resuspended 
in 500 µL SDS buer, after which 1.5 mL urea buer was added and suspsensions were 
centrifuged at 16,100g for 25 min at room temperature, this step was performed twice. 
Supernatant was discarded and pellets were carefully resuspended in 100-500 µL of 
storage buer (10 mM TRIS pH 7.4, 1 mM EDTA, 25 mM NaCl, 10% glycerol, 1X Roche 
protease inhibitor) and sonicated for 6 min at high intensity (30s on/o alternation). 
Protein concentration was determined using a Qubit assay (Invitrogen). Samples were 
subjected to mass spectrometry sample preparation or western blot.
Western Blot
ChEP samples were diluted in 4X SDS buer (10% SDS, 10 mM β-mercaptoethanol, 20% 
glycerol, 200 µM TRIS-HCl pH 6.8, 0.05% bromophenolblue) and incubated at 95 °C for 
30 minutes to reverse cross-linking. Samples were loaded onto a 8% or 12% acrylamide 
separating gel (3.2 ml H2O, 4 ml acrylamide, 2.6 ml 1.5M TRIS pH 8.8, 200 µl 10% SDS, 
200 µl 10% ammonium persulfate (AP), 20 µl TEMED) topped with stacking gel (2.975 
ml H2O, 1.25 ml 0.5 M TRIS-HCl pH 6.8, 50 µl 10% SDS, 670 µl acrylamide, 50 µl 10% 
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AP, 5 µl TEMED). This was blotted on Polyvinylidene di§uoride (PVDF) membranes and 
blocked for 1h in 5% milk in TBST. Membranes were then incubated in 2.5% milk in TBST 
containing primary antibody o/n at 4 °C. Primary antibodies used are a-ZMYND8 (Atlas, 
Cat# HPA020949), a-H3 (Abcam, Cat# 1791), a-H3K27me3 (Millipore, Cat# 07-449) and 
a-EED (Millipore, Cat# 09-774). After washing with TBST, membranes were incubated 
in 2.5% milk in TBST containing Horse Radish Peroxidase (HRP) conjugated secondary 
antibody (for rabbit: Dako, cat. no P0161; for mouse: Dako, cat. no P0217) for 1h at room 
temperature. Antibodies were visualized via chemiluminescence (SuperSignal West Pico 
Plus, Thermo Fisher). 
RT-qPCR
Cell pellets were generated by taking a small volume of cells in suspension and 
centrifuging samples for 3 min at 1,000g. RNA was extracted using the RNeasy Mini 
Kit (Qiagen). cDNA was synthesized via reverse transcription and PCR. Quantitative 
PCR was performed using SYBR Green (Bio-Rad, cat. no 1708886). Primers are listed in 
Supplementary Table 1.
Mass spectrometry sample preparation
Sample preparation for mass spectrometry was adapted from published methods104. 
All centrifuge steps were performed at 20°C unless specied otherwise. Cross-linked 
samples were incubated at 95 °C for 30 min in decrosslink buer (10.5 µM TRIS pH 8.8, 
1.95% SDS, 60 µM β-mercaptoethanol). After decrosslinking, 20 µg of protein in 30 µl 
volume was loaded onto Centrifugal Filters (Microcon, cat. no MRCF0R030) and 200 µl of 
UA (8M urea, 0.1M HEPES pH 8.5) was added. This was centrifuged for 15 min at 14,000g. 
Another 200 µl of UA was added, and the same centrifugation step was applied. 100 µl 
fresh IA (0.05M iodoacetamide (IAA) in UA) was added to samples, and this was mixed 
in a thermo-mixer for 1 min, after which it was incubated for 20 minutes in the dark. 
Samples were then centrifuged for 10 minutes at 14,000g. To wash, 100 µl of UA was 
added and samples were centrifuged for 15 min at 14,000g. The wash step was repeated 
twice. Filters were washed with 100 µl ABC (0.05M ammonium bicarbonate) and spun 
for 10 minutes at 14,000g. The wash step with ABC was repeated twice. Filters were 
then transferred to a new collecting tube, and 40 µl of ABC with trypsin (1:100 enzyme to 
protein ratio) were loaded onto the lter. This was mixed at 600 rpm in a thermo-mixer 
for 1 min. Filters were sealed with paralm to prevent evaporation, and incubated at 37 
°C o/n. After trypsin digestion, lters were centrifuged for 10 minutes at 14,000g. 50 µl 
of 0.5M NaCl was added and lters were centrifuged for 10 minutes at 14,000g. 4 µl of 
tri§uoroacetic acid (TFA) was added to acidify samples. Samples were then subjected to 
stage tip preparation. Stage tips were generated by stacking 200 µl pipet tips with three 
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layers of C18. Tips were washed with 100 µl MeOH and spun for 2 min at 2500g, washed 
with 100 µl Buer B (80% acetonitrile, 0.1% formic acid in H2O) and spun for 2 min at 
2500g and washed with 200 µl Buer A (0.1% formic acid in H2O) and spun for 4 minutes 
at 2500g. Samples were loaded onto stage tips and centrifuged for 4 min at 1500g. Tips 
were washed with 100 µl Buer A and spun for 2 min at 2500g, which was repeated once. 
Samples were then eluted in 40 µl Buer B, speedvacced to 5 µl and lled up to 12 µl with 
buer A. 
Mass spectrometry analysis
5µl digested peptides was injected into an Easy-nLC1000 (Thermo) connected online to 
an LTQ-Orbitrap-Fusion mass spectrometer from Thermo by developing a gradient from 
7 to 30% Buer B for 214 min before washes at 60% then 95% Buer B, for 240 min of 
total data collection time. The §ow rate was 250 nl / min. Full MS scans were collected 
from 400 to 1500 m/z with an Orbitrap resolution of 120,000 and an AGC target of 3e5. 
MS/MS spectra were recorded in the Ion trap using higher-energy collision dissociation 
fragmentation. The ion trap scan rate was set at Rapid. An AGC target of 2e4 was used 
with HCD collision energy at 30% and an intensity threshold of 1e4. Scans were recorded 
in data-dependent top-speed mode of a 3-s cycle with dynamic exclusion set at 60 s with 
a mass tolerance of 5 ppm. Ions of charge state 2-7+ were considered. Thermo RAW les 
were searched against the curated UniProt human proteome database (release December 
2015) with MaxQuant105 (version 1.5.1.0) and its integrated search engine Andromeda. 
Cysteine carbamidomethyl was used as a xed modication, and N-terminal acetylation 
and methionine oxidation were used as variable modications. The mass tolerance for 
precursor ions was set to 20 ppm and the mass tolerance for fragment ions to 0.5 Da. The 
match between runs feature was enabled and LFQ and IBAQ values were calculated for 
each protein. The output Proteingroups le containing all detected proteins was loaded 
into Perseus106. Proteins were rst ltered against a reverse and contaminant database. 
Next, the conditions were grouped in Perseus and any protein that was not detected in all 
replicates of a single condition was discarded. Next, missing values were imputed from the 
random distribution with default parameters (width = 0.3, Down shift =1.8). The proteins 
in the resulting list were annotated as chromatin-associated or not chromatin associated 
(Table S2). This was done by comparing to a list of factors that were experimentally and 
in silico determined to be chromatin associated[28]. As this list was generated in non-
pluripotent human cells, we converted the names to mouse names and we manually 
included known mouse pluripotency factors. In addition, we called all zinc nger proteins 
chromatin-associated as these are known to possess nucleic acid binding domains. To 
specically identify transcription factors, our detected proteins were matched with two 
published lists of murine transcription factors98,99. Downstream analysis was done with 
Python3 and Jupyter Notebook. GO analysis was performed using DAVID107.
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Data deposition
Figure S1 | Supplemental Figure complementing Figure 2 and 3. (A) Coomassie staining 
on ESC ChEP sample and ESC whole cell lysate (WCL), with the arrow marking histones. 
B) VENN diagram showing the number of proteins detected in at least two replicates of 
indicated samples (all proteins together totals to 4174). C) Number of reproducibly 
quanti ed proteins with or without a known chromatin function. The top 5 GO terms for the 
given subset are listed. D) Log2 fold changes of proteins associated with pluripotency. E)
Western blot validation for EED. F) Western blot validation for ZMYND8. 
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The mass spectrometry proteomics data have been deposited to the ProteomeXchange 
Consortium via the PRIDE partner repository with the dataset identi er PXD011782108.
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Table S1 | Primers used for RT-qPCR
Primer Sequence
Gapdh FW TTCACCACCATGGAGAAGGC
Gapdh RV CCCTTTTGGCTCCACCCT
Rex1 FW AGGCCAGTCCAGAATACCAG
Rex1 RV TAGGTATCCGTCAGGGAAGC 
Otx2 FW GGAAGAGGTGGCACTGAAAA
Otx2 RV GAAGTGGACAAGGGGTCAGA
Fgf5 FW CCTTGCGACCCAGGAGCTTA
Fgf5 RV CCGTCTGTGGTTTCTGTTGAGG
Zic2 FW TCTGCTTCTGGGAGGAGTGT
Zic2 RV TGCATGTGCTTCTTCCTGTC
Sox2 FW GACCGTTTTCGTGGTCTTGT
Sox2 RV ACGATATCAACCTGCATGGAC
Pax6 FW CGCGGATCTGTGTTGCTCAT
Pax6 RV CTTAAATCCATGGCAAATCTTGTCG
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Abstract  
The ground state of pluripotency is dened as a minimal unrestricted state as present in 
the Inner Cell Mass. Mouse embryonic stem cells (ESCs) grown in a dened serum-free 
medium with two kinase inhibitors (“2i ESCs”) have been postulated to re§ect ground-
state pluripotency, whereas ESCs grown in the presence of serum (“serum ESCs”) share 
more similarities with post-implantation epiblast cells. Pluripotency results from an 
intricate interplay between cytoplasmic, nuclear and chromatin-associated proteins. 
Here, we perform quantitative (sub)cellular proteomics to gain insight in the molecular 
mechanisms sustaining the pluripotent states re§ected by 2i and serum ESCs. We describe 
a full SILAC work§ow and quality controls for proteomic comparison of 2i and serum 
ESCs, allowing subcellular proteomics of the cytoplasm, nucleoplasm and chromatin. 
The obtained quantitative information revealed increased levels of naïve pluripotency 
factors on the chromatin of 2i ESCs. Surprisingly, the cytoplasmic proteome suggests 
that 2i and serum ESCs utilize distinct metabolic programs, which include upregulation 
of free radical buering by the glutathione pathway in 2i ESCs. Through induction of 
intracellular radicals, we show that the altered metabolic environment renders 2i ESCs 
less sensitive to oxidative stress. Altogether, this work provides novel insights into the 
proteome landscape underlying ground state pluripotency. 
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Introduction
Transient pluripotent states of the embryo can be stably captured in vitro in the form 
of embryonic stem cells (ESCs). Conventionally, ESCs were derived and maintained by 
the use of serum and leukemia-inhibitory factor (referred to as “serum ESCs”) which 
maintain pluripotency via JAK/STAT3 and SMAD signaling17,23. More recently, a dened 
minimal culture condition for ESC maintenance has been pioneered relying on two 
small-molecule inhibitors of the mitogen-activated protein kinase (MEK) and glycogen-
synthase kinase (GSK3), respectively, referred to as “2i ESCs”28. Over the last years, 
important dierences in the transcriptome and epigenome have been uncovered 
between serum- and 2i-cultured ESCs. The features characteristic for 2i ESCs compared 
to serum ESCs include loss of H3K27me3 over bivalent genes, a global reduction of 
H3K9me2, the absence of extreme long-range chromosomal interactions (ELRIs) as well 
as global DNA hypomethylation32–36,38,63,109. Due to the high resemblance of 2i ESCs to pre-
implantation Inner Cell Mass (ICM) cells in the embryo it was postulated that 2i ESCs exist 
in a distinct state of pluripotency, the so-called “ground state”. On the other hand, the 
hypermethylated serum ESCs exist in a metastable state that shares features with the 
more primed post-implantation embryo21,28. 
Recent work implicated that, next to the features mentioned above, also the proteome 
between 2i and serum ESCs is markedly dierent. For example, it was shown that 2i ESCs 
are hallmarked by higher levels of core pluripotency factors such as PRDM14, KLF2, KLF4 
and NANOG, which is in correspondence to the ‘enhanced’ pluripotency of 2i ESCs63,109–
111. On the other hand, serum ESCs possess higher levels of de novo methyltransferases 
(DNMTs) and UHRF1, resulting in higher DNA methylation, and increased levels of 
focal adhesion and cytoskeletal proteins, all signs of early developmental priming33,37. 
As pluripotency results from an intricate interplay between cytoplasmic, nuclear and 
chromatin-associated proteins, the subcellular distribution of proteins can greatly aect 
the pluripotent state. A notable example comprises the transcription factor TFE3, an 
important regulator for ESRRB. TFE3 localizes in both the cytoplasm and nucleus in 2i 
ESCs, but upon 2i withdrawal is sequestered in the cytoplasm resulting in developmental 
priming112. Other examples include the Hippo signaling mediators YAP and TAZ, that 
sustain primed pluripotency when present in the cytoplasm, but induce dierentiation 
upon nuclear translocation113. To further extend our understanding of the molecular 
mechanisms and pathways that dene the pluripotent ground state, quantitative 
information of the (subcellular) proteome landscape is critical. 
To obtain quantitative proteome information, it is important to minimize variations 
introduced during sample handing, in particular for subcellular proteomics. Therefore, 
early mixing of samples during the experimental work§ow is highly preferable. One of 
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the most powerful approaches for high-throughput quantitative proteomics that allows 
for early mixing represents Stable Isotope Labeling with Amino acids in Cell culture 
(SILAC). SILAC relies on the labeling of proteins with heavy versions of arginine and 
lysine (the ‘heavy’ sample). Before downstream processing, cell pellets of heavy labelled 
samples can be mixed with cell pellets from a sample in which the proteins contain 
normal arginine and lysine (the ‘light’ sample). Notably, SILAC labeling approaches for 
proteomic characterization of 2i and serum ESCs have not been described thus far. 
Here, we provide quantitative information on the subcellular proteomes of 2i and serum 
ESCs using an optimized SILAC work§ow. We rst conrm that SILAC labeled 2i ESCs 
have preserved their self-renewing status as well as pluripotent characteristics based on 
well-known markers and show that we can robustly generate whole cell proteomes of 
2i and serum ESCs using our SILAC approach. Next, we apply our work§ow to generate 
subcellular proteomes of the cytoplasm, nucleoplasm and chromatin-bound fraction of 2i 
and serum ESCs. Using the information of the proteins as quantied by this approach we 
present evidence that 2i ESCs are hallmarked by increased nuclear and chromatin levels 
of naïve transcription factors such as KLF4. Furthermore, the cytoplasmic proteome 
suggests that the activity of several metabolic pathways between 2i and serum ESCs 
is changed. Interestingly, these dierential pathways render 2i ESCs more resistant to 
metabolic stress compared to serum ESCs. Altogether, this work provides quantitative 
insights into the subcellular proteome landscape of the pluripotent ground state.
Results
The use of SILAC for whole proteome comparison between 2i and 
serum ESCs
SILAC-based approaches generally require dialysis of serum to remove the natural 
arginine and lysine amino acids. During this process, other low-molecular factors 
including growth factors are removed as well which might interfere with the cellular 
identity of sensible cell types114. To measure the proteomes of 2i and serum ESCs using 
SILAC, we take advantage of the serum-free growth conditions of 2i ESCs. For the SILAC 
experiments, we culture 2i ESCs in custom dened medium lacking regular arginine and 
lysine (Fig S1) but supplemented with heavy lysine and arginine. The “heavy” labeling 
of 2i ESCs allows a SILAC-based comparison to serum ESCs that are grown in normal 
medium (i.e. ‘light’ labeled). First, we evaluated whether culturing in SILAC medium 
did not result in unanticipated changes to the 2i ESCs. During culturing for multiple 
passages, the 2i ESCs retained their typical round morphology (Fig 1A)28. Also, the growth 
rate of 2i ESCs in normal medium or SILAC medium supplemented with either ‘light’ 
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(‘normal’) or ‘heavy’ amino acids was similar (Fig 1B). In light of the fact that global DNA 
hypomethylation is a major hallmark of 2i ESCs33, we measured the DNA methylation 
levels of SILAC 2i ESCs using mass spectrometry. This revealed that 2i ESCs in both normal 
medium and SILAC medium exhibit a similar degree of DNA hypomethylation (Fig 1C). 
Finally, we measured the expression of key pluripotency factors Oct4, Nanog, Rex1 and 
the stem cell maintenance gene Prdm16 using RT-qPCR. This showed that the expression 
of these genes is not aected by the SILAC medium formulation (Fig 1D). Altogether, this 
indicates the SILAC medium does not aect the pluripotent state of 2i ESCs. 
Next, we evaluated the e¦ciency of labeling with heavy amino acids of 2i ESCs grown 
in SILAC medium (Fig 1E). We performed a single LC-MS experiment of 2i ESCs grown 
in heavy medium for six passages and inspected the heavy/light ratios in this sample. 
This led to a unimodal distribution of high incorporation ratios of heavy amino acids 
(incorporation rate >97%), demonstrating that 2i ESCs can be e¦ciently labeled. We also 
queried the spectra for heavy proline in light of recent work reporting conversion of heavy 
arginine to heavy proline115. However, at the arginine concentration used for the current 
study we did not detect any signicant conversion of heavy arginine into heavy proline 
(data not shown). Finally, to test the reproducibility of the work§ow, we generated SILAC 
proteomes of two independent experiments. This allowed quantication of over 4000 
proteins with high reproducibility (R=0.88) between the experiments, as well as the 
identication of dierential proteins (Fig 1F,G). Altogether, we concluded that our SILAC 
work§ow is robust and applicable for quantitative proteomics of 2i and serum ESCs. 
Subcellular proteomes of 2i and serum ESCs using SILAC
An important advantage of SILAC over other MS approaches such as label-free 
quantication (LFQ) or dimethyl labeling is the early mixing of dierent cell populations, 
which minimizes variations introduced by sample preparation prior to LC-MS analysis116. 
As such, SILAC is highly suitable for LC-MS experiments that require subcellular 
fractionation. To obtain subcellular information of 2i and serum ESCs, we separated 
the cytoplasm, nuclei and chromatin of SILAC-labeled 2i ESCs and serum ESCs (Fig 2A). 
We validated proper separation of the fractions using western blot for known protein 
markers that are mainly cytoplasmic (b-actin), nuclear (Topoisomerase I), nuclear and 
chromatin-associated (HDAC2) and chromatin only (H3K9me3) (Fig 2B). After mass 
spectrometry, gene ontology (GO) analysis of the proteins as identied within each of the 
fractions revealed GO-terms relevant to the specic subcellular fractions: these included 
mainly metabolic terms for the cytoplasmic fraction, RNA-splicing and transport for the 
nuclear fraction and chromatin-modication and gene expression for the chromatin 
fraction (Fig 2C). Taken together, this demonstrates that the subcellular fractions were 
adequately separated. 
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Figure 1 | Validation of proteomics by the use of SILAC in 2i and serum ESCs. A) Cell 
morphology of 2i ESCs grown in regular or SILAC medium for 12 days. B) Cumulative cell 
number of 2i ESCs grown in regular medium or in SILAC medium supplemented with light 
(‘normal’) or heavy amino acids for several passages. C) Representative DNA methylation 
percentages as measured via LC-MS. Serum ESCs are included as control and are known to be 
globally hypermethylated33. D) Delta Ct values relative to Gapdh from qPCR measurements 
of the same cells as in (B). E) Distribution of peptide ratios of a single shot LC-MS run of 
heavy labeled 2i ESCs. F) Ratio heavy / light of two independent SILAC whole proteome 
measurements of 2i and serum ESCs. Pearson correlation between the two replicates 
is indicated in left top. Blue dots are proteins signicantly higher in serum ESCs in both 
replicates and green dots are proteins signicantly higher in 2i ESCs (p < 0.05; signicance 
B). Proteins that are analyzed in Fig 1G are labeled by their name. G) Representative SILAC 
spectra for a peptide derived from GAPDH (equal between 2i and serum), UTF1 (higher 
serum) and GSS (higher 2i). Y-axis indicates intensity, x-axis represent mass/charge values. 
Blue triangle indicates elution from the light peptide (“serum-ESC derived”) and the green 
triangle indicates the heavy peptide (“2i derived”).  
For all three fractions, we identied ~2000 proteins per fraction with high reproducibility 
(Fig 2D, 2E). Focusing on dierential proteins (p < 0.05 in both replicates), 158 proteins 
were signicantly dierent in both replicates between 2i and serum ESCs in the 
cytoplasmic fraction, 192 in the nuclear fraction and 131 in the chromatin fraction (Fig 2D; 
Supplementary Table 1). Notably, we observed limited overlap in detected and dierential 
proteins between the various fractions (Fig 2E, 2F), further highlighting the importance 
of subcellular fractionation. The dierential proteins that we identify included notable 
markers for ground state pluripotency such as DAZL, ESRRB and TFCP2l1 enriched 
in 2i ESCs. Proteins signicantly enriched in serum ESCs include the DNA methylation 
associated DNMT3A/B/L and UHRF1, which is in line with the higher DNA methylation 
levels in serum ESCs, as well as the early-dierentiation associated proteins LIN28A 
and UTF1, which is in agreement with the metastable state of serum ESCs (Fig 2D; 
Supplementary Table 1)97,117. Also GO terms related to the dierential proteins included 
priming-related terms for serum ESCs such as embryo development and neural tube 
closure in the nucleoplasm and DNA methylation for the chromatin-associated proteins 
(Fig 2D). We also evaluated the levels of the factors TFE3 and YAP1 (as mentioned in the 
introduction). TFE3 was present in the cytoplasm and nucleus of 2i and serum ESCs, in 
line with previous reports (Supplementary Table 1). We also observed YAP in all fractions 
in 2i and serum ESCs, which seems to be tolerated by ESCs. In summary, these results 
show that the SILAC work§ow is suitable to obtain subcellular proteomes of 2i and serum 
ESCs with high resolution. 
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Figure 2 | Generation of subcellular proteomes using SILAC. A) Schematic work§ow for 
subcellular fractionation of 2i and serum ESCs. B) Western blot analysis of the subcellular 
fractionation of two independent SILAC experiments. C) GO terms of proteins enriched in 
the cytoplasmic, nuclear and chromatin-associated fraction as determined via DAVID107. 
D) Scatter plot of fold changes heavy / light in the subcellular fractions of two independent 
SILAC experiments. Pearson correlation between the two replicates is indicated in left top. 
Blue dots are proteins signicantly higher in serum ESCs in both replicates and green dots 
are proteins signicantly higher in 2i ESCs (p < 0.05; signicance B). Dierential proteins of 
interest have been highlighted. Bottom: Numbers and GO terms belonging to the dierential 
proteins (p < 0.05 using signicance B in both replicates) in the subcellular fractions. E) Venn 
diagram representing the overlap between identied proteins (at least 2 peptides) in the 
various fractions. F) Venn diagrams representing the overlap between dierential proteins 
in the various fractions.
SILAC identies pluripotency modules enriched in ground state 
pluripotency 
The obtained quantitative information on the subcellular proteome of 2i and serum ESCs 
provides the unique opportunity to investigate how the dierentially activated pathways 
in the cytoplasm aect the abundance of individual members of the core pluripotency 
network on the chromatin. First, we inspected the cytoplasmic levels of the direct 
targets of extracellular signaling cues, which comprise SMAD1/5/8 and STAT3 in serum 
ESCs and GSK3, STAT3 and ERK1/2 in 2i ESCs29. The total abundance of these proteins is 
not dierent between 2i and serum ESCs (Fig 3), which is in line with previous reports 
showing the state of phosphorylation and/or the capacity to phosphorylate is aected 
rather than the abundance of these proteins28. Next, we focused on the abundance of 
the core pluripotency network on the chromatin making use of a comprehensive list of 
pluripotency factors118. This revealed that the levels of OCT4 and SOX2 are equal between 
2i and serum ESCs, which ts with their fundamental importance for the maintenance of 
pluripotency119. The pluripotency factor REX1 was also similarly present on the chromatin 
in 2i and serum ESCs. We observed that, although LIF is present in the culture conditions 
of both 2i and serum ESCs, the main downstream eectors KLF4 and TFCP2L1 were 
strongly enriched in 2i ESCs, suggesting their expression level is aected by factors other 
than LIF (Fig 3). Further, we noted 2i ESCs are hallmarked by increased levels of the ESRRB, 
which is the key target of b-catenin120, TBX3 and NANOG. Individually these factors are 
dispensable for the maintenance of pluripotency, but they are considered ancillary factors 
that strengthen the pluripotency network118. Hence, the increased chromatin occupancy 
of these factors is in line with previous observations on the pluripotent state of 2i ESCs21. 
Interestingly, we observed that the ancillary factors KLF5 and SALL4 are enriched on the 
chromatin in serum ESCs (Fig 3). Removal of KLF5 and SALL4 results in dierentiation of 
serum ESCs, whereas at least SALL4 ablation is well tolerated by 2i ESCs. This suggests 
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Figure 3 | 2i and serum ESCs are characterized by dierences in the pluripotency 
network. Simplied overview of the exogenously activated pathways in 2i and serum ESCs. 
Colors represent the log2 fold changes as found in our study using SILAC proteomics. In 
brief: serum contains Bmp4 that functions via SMAD1/5/8 to stimulate the transcription of 
ID (inhibitor of dierentiation) proteins, which inhibit dierentiation in serum ESCs. LIF is 
present in both 2i and serum ESCs, which primarily acts via STAT3-promoted transcription 
of KLF4 and TFCP2L1. CHIRON in 2i ESCs inhibits b-catenin degradation, nally resulting in 
enhanced transcription of its key target Esrrb, which in turn strengthens the pluripotency 
network. The inhibition of ERK signaling in 2i ESCs (by PD) is important to suppress 
dierentiation cues. Proteins with an asterisk were not reliably quantied in our work§ow 
and their levels were inferred from literature . Protein ratios in the nuclear and 
chromatin fraction were similar and for visual purposes these are visualized as one fraction.
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that these factors become more important upon dissolution of the pluripotent state121,122. 
Altogether, these analyses reveal that the pluripotency network is plastic and changes 
between pluripotent states. 
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Ground state and metastable pluripotency are supported by 
distinct metabolic programs. 
Next to epigenetic changes, changes on the metabolic level are starting to be uncovered 
between 2i and serum ESCs124. Subcellular fractionation brings lower abundant 
metabolic proteins into the dynamic range of the mass spectrometer. Therefore, our 
study provides a unique opportunity to comprehensively prole proteins belonging to 
metabolic pathways125. To obtain a detailed overview of the metabolic pathways that 
distinguish 2i and serum ESCs, we analyzed the dierential proteins in the cytoplasmic 
fraction for metabolic gene ontology (GO) terms using the Metaboanalyst software126. 
This revealed that GO terms characterizing 2i ESCs were mainly related to fatty acid 
and sugar metabolism, whereas GO-terms related to serum ESCs included acetyl-CoA 
biosynthesis and glycolysis (Fig 4A). The enrichment of glycolysis factors in serum ESCs, 
as exemplied by the upregulation of key factors PDK1, LDHA and ZIC3, ts with their 
metastable state as the enhancement of glycolysis is a hallmark for induction of primed 
pluripotency (Fig 4B)127. Interestingly, we observed that one of the top enriched terms 
in 2i ESCs is glutathione metabolism (Fig 4A; indicated in red). Together with Catalase 
(Cat), Peroxiredoxins (PRX) and Thioredoxins (TRX), the Glutathione system is of critical 
importance for reducing oxidative stress by scavenging free radicals such as H2O2. This is 
established through restoring of glutathione, oxidized by free radicals (GSSG), to reduced 
glutathione (GSH) (Fig 4C)128. Most of the scavenging proteins involved in glutathione 
metabolism as well as catalase are signicantly upregulated in 2i ESCs (Fig 4C). To 
investigate whether the upregulated glutathione pathway proteins also indicated more 
synthesis of the glutathione molecule, we measured the total levels of the glutathione 
(the sum of GSH and GSSG), which was similar between 2i and serum ESCs (Fig 4D). Next, 
as the glutathione pathway is involved in ROS scavenging and 2i ESCs are characterized 
by upregulation of metabolic programs, this could result in increased reactive oxygen 
species (ROS) levels as these are by-products of metabolic processes129. Therefore we also 
measured intracellular ROS levels, which revealed a signicant increase of ROS levels in 
2i ESCs as compared to serum ESCs (Fig 4E). As free radicals can attack peptide backbones 
resulting in oxidized proteins, this could implicate a higher presence of oxidized proteins 
in 2i ESCs. To evaluate this, we used the dependent peptide search in Maxquant to search 
for mono-, di- and trioxidized peptides130. However, there was no signicant increase of 
oxidized proteins in 2i ESCs (Fig 4F).
To further investigate these ndings, we assayed whether the increased glutathione 
pathway proteins would re§ect more e¦cient ROS buering in 2i ESCs. To this end, we 
treated 2i and serum ESCs with the chemical compounds doxorubicin (induction of DNA 
damage), 5-azacytidine (induction of DNA hypomethylation) and MG132 (a proteasome 
inhibitor) that can induce intracellular ROS131–133. After exposure to these compounds, we 
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observed that the survival rate of 2i ESCs was higher than that of serum ESCs. In addition, 
doxorubicin and 5-azacytidine induced more ROS in serum ESCs as compared to 2i ESCs 
(Fig 4G-H, S2A-B), which further suggests that 2i ESCs are more e¦cient in eliminating 
ROS. Notably, although 2i ESCs showed better survival to proteasome inhibition, this 
treatment did not induce ROS (Fig S2B), suggesting that this might be mediated through 
other mechanisms. To further substantiate the enhanced buering capacity of 2i ESCs, 
we added the same concentration of the radical H2O2 to the culture medium of 2i and 
serum ESCs. This resulted in signicantly more intracellular ROS in serum ESCs compared 
to 2i ESCs, further demonstrating the enhanced metabolic buering in 2i ESCs (Fig 4I). 
Unexpectedly, we observed a slightly compromised survival of 2i ESCs to the addition 
of exogenous H2O2 as compared to serum ESCs (Fig S2C). As intracellular ROS levels in 
treated 2i ESCs were only marginally higher compared to control cells, this is likely the 
result of interference of H2O2 with other processes or induction of damage to important 
cellular constituents such as the DNA. Altogether, these assays reveal that 2i ESCs are 
more e¦cient at buering ROS. 
 
Figure 4 | 2i ESCs are characterized by enhanced metabolic buering. A) GO terms 
belonging to the dierential proteins (p < 0.05) in the cytoplasmic fraction as determined 
via the Metaboanalyst 3.0 software. GO terms visualized were enriched in either 2i or serum 
ESCs (p < 0.05). B) Log2 fold change of glycolysis-associated proteins. PDK1 and LDHA 
localize mainly in the cytoplasm, ZIC3 on the chromatin. Thus, data for PDK1 and LDHA was 
obtained from the cytoplasmic fraction, data for ZIC3 from chromatin fraction. * indicates p < 
0.05 in both experiments. C) Top: schematic overview of ROS scavenging. Bottom: heatmap 
representing the log2 fold changes 2i / serum of two independent SILAC experiments. * 
indicates p < 0.05 in both experiments. D) Fluorescence measurement of total glutathione 
levels in 2i and serum ESCs. n.s. = not signicant. E) Fluorescence measurement of ROS 
levels in 2i and serum ESCs. * = p < 0.05 (t-test). F) Distribution of log2 fold changes 2i / 
serum of mono-, di- or trioxidized peptides in the cytoplasmic fraction as determined by 
the dependent peptide search in MaxQuant. Only peptides with an MS/MS count >1 were 
included. n.s. = not signicant. G-H) Top: Survival of 2i and serum ESCs relative to untreated 
control after 20-hour treatment with doxorubicin ( J) or with 5-azacytidine (K). Bottom: 
ROS production after 3-hour exposure to the compounds (500 nM doxorubicin, 1 µM 
5-azacytidine) relative to DMSO treated control cells.  * = p < 0.05 (t-test). I) Intracellular ROS 
levels after treatment of 2i and serum ESCs with 150 µM H2O2 for 3 hours. * = p < 0.05 (t-test). 
J) Gene expression of genes related to ROS scavenging and glycolysis in preimplantation 
cells (E2.5-E4.5) and post implantation cells (E5.5). Row values are normalized using Z-scores. 
Genes indicated in red have a peak expression in preimplantation cells, those in black have 
a peak expression in post-implantation development, genes in gray are similar in expression 
in pre- and postimplantation embryos.
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The conversion of 2i to serum ESCs represents a powerful model for in vivo development31. 
Therefore, we investigated whether the increased abundance of the proteins comprising 
the glutathione pathway is also observed in vivo. To this end, we analyzed RNA-seq data 
generated from morula (E2.5), the Inner Cell Mass (ICM, E3.5), preimplantation epiblast 
(E4.5) and post implantation epiblast (E5.5)134. We observed that the expression of most 
subunits of the glutathione pathway was enriched in the preimplantation stage. These 
included the glutathione peroxidase (GPX1/4) and synthetase (GSS) which are critical for 
the glutathione redox function as well as early embryonic development135,136. On the other 
hand, the glycolysis pathway, which is enriched in serum ESCs, increases dramatically 
in the post implantation stage (Fig 4J)33,134. Taken together, this could implicate that 
enhanced buering against free radicals is a feature important for early embryonic 
development. 
Discussion
SILAC-based work§ows have been rapidly adopted in quantitative proteomics because 
of the robustness and simplicity. A major advantage of SILAC over label free proteomics 
(LFQ) or chemical labeling strategies such as dimethyl labeling is that it allows for early 
mixing of samples. This results in  minimization of variation introduced during sample 
preparation and enhanced precision and reproducibility of quantication116. As such, 
SILAC is typically suited for subcellular proteomics, which allows both studying molecular 
pathways as well as identication of low-abundant proteins (e.g. pluripotency and other 
transcription factors) through reduction of sample complexity, which brings these 
proteins into the dynamic range of the mass spectrometer137. Here, we show that SILAC 
can be adopted for the subcellular comparison of 2i and serum ESCs. This is particularly 
powerful with the use of 2i ESCs as these are grown in chemically dened medium in 
which normal (“light”) lysine and arginine can conveniently be substituted by “heavy” 
lysine and arginine. Here, we mixed 2i and serum ESCs prior to subcellular fractionation, 
which minimizes variations introduced due to sample handling. We observed a slight 
skewing of the non-normalized heavy/light ratios towards the light channel, which is 
resolved upon normalization. For future applications of the SILAC work§ow, comparing 
mixing on cellular level and protein level might be benecial to determine the optimal 
experimental work§ow. 
Signicant eorts have been made to disentangle the proteome of 2i and serum 
ESCs37,138. Here we complement these studies using SILAC-based quantitative subcellular 
proteomics, which improves on the quantication accuracy and simultaneously 
increases the depth of the proteome. This allowed us to provide quantitative insights 
into the subcellular proteome of 2i and serum ESCs. Amongst others, we investigated the 
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pluripotency modules sustaining 2i and serum ESCs. Previous reports demonstrated that 
2i ESCs are characterized by the upregulation of naïve pluripotency factors118,139,140. Here, 
we provide evidence that upregulation of these naïve factors in 2i ESCs is accompanied 
by enrichment of these factors on chromatin. As such, a comprehensive analysis of 
genomic binding sites of naïve factors such as TFCP2L1 and TBX3 in 2i and serum ESCs 
might provide further insights into the maintenance of the ground state of pluripotency. 
Next to factors that characterize 2i ESCs, we identify pluripotency factors that are 
enriched in serum ESCs, such as SALL4 and KLF5. It has been shown that Sall4 and Klf5 
mutant ESCs grown in serum show strong signs of premature dierentiation. Therefore, 
it would be interesting to determine the genomic locations of these factors in 2i and 
serum ESCs, as well as in early dierentiated cell types, to pinpoint the role of these 
factors in pluripotency and the exit thereof. 
The changes as we observe in the pluripotency network between 2i and serum ESCs are 
likely to aect the epigenetic state, as epigenetic changes have been directly linked to 
relocalization of core pluripotency factors141. In addition to the epigenetic environment, 
the pluripotency circuit has been found to orchestrate the metabolic state of pluripotent 
stem cells. For example, ESRRB was shown to enhance oxidative phosphorylation and 
is therefore essential for reprogramming of somatic cells to naïve pluripotency. ZIC3 
promotes reprogramming towards primed pluripotency by enhancing glycolysis.142,143. The 
core pluripotency factor OCT4 was found to be directly involved in regulation of glycolysis 
and the serum ESC specic factor MYC32 has been linked to the glutamine-dependence 
of serum ESCs124,144. Also LIN28A/B, direct targets of FGF signaling, have been shown to 
modulate metabolic pathways towards glycolysis to facilitate priming of ESCs97. Previous 
analyses on the RNA level suggested dierences in metabolism between 2i and serum 
ESCs32. Here we extend these analyses with quantitative information on the cytoplasmic 
proteome. Our analyses of the members of metabolic pathways indicated that serum 
ESCs are enriched for glycolysis. However, previous observations revealed similar use of 
the glycolysis pathway in 2i and serum ESCs124. As such, this indicates that serum ESCs 
are inducing transcriptional networks that are required to switch to exclusively glycolysis 
metabolism as characteristic for the in vivo post implantation epiblast as well as epiblast-
derived stem cells (EpiSCs)127. This further supports the observation that serum ESCs 
represent a more primed version of pluripotency compared to 2i ESCs and suggests that 
the enhancement of glycolysis is readily initiated upon dissolution of the pluripotent 
ground state. 
We show that 2i ESCs contain increased levels of proteins involved in the glutathione 
pathway, as well as enhanced resistance to intracellular ROS generation as compared 
to serum ESCs. As total levels of glutathione itself are similar between 2i and serum 
ESCs, this suggests that the turnover of oxidized and reduced glutathione, during which 
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ROS are scavenged, is more e¦cient in 2i ESCs. This might be required as 2i ESCs are 
metabolically more active and hence are likely to generate more free radicals during 
metabolic processes such as oxidative phosphorylation as stimulated by ESRRB. Whether 
this is also relevant for the preimplantation embryo remains to be investigated, although 
our RNA-seq analysis indicates that the glutathione pathway is mostly active before 
implantation. Interestingly, the formation of ROS, and consequently the enhanced 
buering, have been shown to aect the levels of DNA methylation145. Given that 2i 
ESCs and preimplantation embryos are hallmarked by global DNA hypomethylation, it 
might well be that the enhanced glutathione metabolism in ground state pluripotency 
contributes to epigenetic features such as DNA hypomethylation.
Concluding remarks
In this work we present a SILAC work§ow to reliably generate subcellular proteomes 
of pluripotent states represented by mouse embryonic stem cells (ESCs) maintained 
in distinct culture media. Using SILAC, we show that the pluripotent ground state 
as presented by 2i ESCs is hallmarked by distinct metabolic programs as compared to 
more primed serum ESCs. Future studies using in-depth metabolomics proling will be 
required to further investigate the metabolic programs as identied here and how these 
contribute to ground state pluripotency. Moreover, the application of this SILAC work§ow 
can be used to comprehensively study the molecular pathways sustaining pluripotency, 
for example through combining subcellular fractionation with phospho- or ubiquitin-
proteomics, which could uncover novel signaling cascades. Furthermore, SILAC could be 
applied in proteomic comparisons of 2i and serum ESCs for which early mixing of cells is 
highly benecial, such as organelle enrichment and interactome studies146. 
Acknowledgements
We thank Luan Nguyen, Nina Hubner and Pascal Jansen for technical support with mass 
spectrometry and the MolBio ES cell group, Henk Stunnenberg and Michiel Vermeulen for 
discussion. We thank Lingxiao Xu and Ron Wevers for help with the SILAC quality controls 
and Leonie Kroeze and Joop Jansen for help with DNA methylation mass spectrometry. 
Research in the group of HM is supported by a grant from the Netherlands Organization 
for Scientic Research (NWO-VIDI 864.12.007).
533641-L-bw-Mierlo
Processed on: 23-7-2019 PDF page: 53
Chapter 3
53
3
Experimental procedures
ES Cell culture and SILAC labeling
E14 ESCs (129/Ola background) were maintained in Dulbecco’s Modied Eagle Medium 
(DMEM) containing 15% fetal bovine serum, 5µM beta mercaptoethanol (BME) (Sigma) 
and Leukemia inhibitory factor (LIF; 1000U/ml) (Millipore), referred to as serum ESCs, 
or in serum-free N2B27 (or Ndi) supplemented with PD0325901 (1 µM), CH99021 (3 
µM) and LIF (1000U/ml), referred to as 2i ESCs. The ESCs have been derived in serum 
conditions and were adapted to 2i culture. For SILAC labeling, 2i ESCs were grown in 
customized Ndi (without Arginine and Lysine, Stem Cell Sciences) supplemented with 
13C615N4 L-arginine and 13C615N2 L-lysine (Isotec). The absence of light arginine and lysine in 
the SILAC medium was veried using ion exchange chromatography (Fig S1). Cells were 
grown in SILAC medium for at least 8 population doublings to ensure full incorporation 
of the heavy labeled aminoacids. For ROS induction experiments, cells were allowed to 
attach overnight prior to exposure to the various compounds. H2O2 was used at a range 
of concentrations and 150 µM for ROS induction. Doxorubicin was used at 500 nM and 
1 µM for survival assays and 500 nM for ROS induction. 5-azacytidine was used at 500 
nM and 1 µM for survival assays and 1 µM for ROS induction. MG132 was used at 5 µM 
for both survival and ROS induction assays. For survival assays, inhibitors were added 
for 20 hours (MG132 for 6 hours) and for ROS induction ESCs were exposed for 3 hours. 
When DMSO was used as a control, the nal DMSO concentration was the same as in 
compound-treated cells (compounds were dissolved in DMSO and further diluted in PBS). 
Subcellular fractionation
Extracts were prepared as described in Dignam et al. 1983147. Cells were harvested with 
trypsin and washed with PBS. An equal number of heavy labeled 2i ESCs and non-labeled 
serum ESCs (grown in regular serum medium) were mixed and pelleted at 400g for 5 min 
at 4°C. The resulting cell pellets were incubated for 10 min at 4°C in ve volumes of Buer 
A (10 mM Hepes-KOH, pH 8.0, 1.5 mM MgCl2, 10 mM NaCl) and centrifuged at 400g for 
5 min at 4°C. Cells were resuspended in two volumes of Buer A plus protease inhibitors 
(Roche) and 0.15% NP-40 and transferred to a Dounce homogenizer. After douncing 30-
40 strokes with a Type B pestle, the lysates were centrifuged at 3200g for 15 min at 4°C. 
After centrifugation, the supernatant was taken as the cytoplasmic extract. The nuclear 
pellet was washed twice with PBS and nuclei were pelleted at 3200g for 5 min at 4°C. 
The nuclear pellet was resuspended in 2 volumes Buer C (420 mM NaCl, 20 mM Hepes-
KOH, pH 8.0, 20% v/v glycerol, 2 mM MgCl2, 0.2 mM EDTA, 0.1% NP-40) supplemented 
with protease inhibitors and 0.5 mM DTT. This solution was rotated for 1 h at 4°C, and 
then spun at 20800g for 45 min at 4°C. The supernatant was taken as the nuclear fraction 
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and stored at -80°C until further use. To obtain the chromatin fraction, the insoluble 
chromatin pellet was resuspended in four volumes of Radio Immunoprecipitation buer 
(RIPA) (150 mM NaCl, 1% NP-40, 0.5% NaDOC, 0.1% SDS, 50mM Tris pH=8) and brie§y 
sonicated to solubilize the chromatin fraction and stored at -80 ˚ C until further use. 
RT-qPCR
Total RNA was isolated using a RNeasy mini kit (Invitrogen). cDNA was synthesized using 
random hexamers and RT-qPCR was performed using iQ SYBR Green Supermix (Bio-Rad) 
on a CFX96 Real-Time System C1000 Thermal Cycler (Bio-Rad). 
Western blot
Protein extracts were denatured in 4x SDS loading dye and separated on a 12% SDS-
PAGE gel. Separated proteins were transferred onto a PVDF membrane for staining 
with primary and secondary antibodies. Primary antibodies used were mouse anti-
ACTB (Abcam; #8226), Rabbit anti-Topoisomerase 1 (Abcam; #109374), rabbit anti-
HDAC2 (Abcam; #7029) and Rabbit anti-H3K9me3 (Abcam; #8898). Protein bands were 
visualized using Pierce Western Blotting Substrate (Thermo, #32209) according to the 
manufacturer’s instructions. 
(Hydroxy)methylation measurements of genomic DNA
Genomic DNA was isolated using the Wizard genomic DNA isolation kit (Promega). Mass 
spectrometry analysis of the nucleosides was performed on genomic DNA digested using 
DNA Degradase Plus (Zymo Research). Levels of (hydroxy)methylation were quantied 
via liquid chromatography-tandem mass spectrometry (LC-MS) as described in Kroeze et 
al., 2014148.
Generation of whole cell extracts
Cell pellets were resuspended in RIPA buer supplemented with protease inhibitor at 
a density of 10.000 cells/µl and sonicated for 2 cycles (30 sec ON, 30 sec OFF) on a 
Biorupter (Diagenode) to solubilize the cells. 
Mass spectrometry and data analysis
Whole cell, cytoplasmic, nuclear and chromatin extracts were denatured using Filter 
Aided Sample Preparation (FASP) and digested using Trypsin/LysC. Trypsin digests were 
desalted using Stage Tips prior to mass spectrometry measurements. Mass spectra were 
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recorded on an LTQ-Orbitrap QExactive mass spectrometer (Thermo Fisher Scientic) 
using a 4-hour acetonitrile gradient, selecting the top 10 most intense precursor ions 
for fragmentation. Thermo Raw MS les were analyzed using the MaxQuant software 
version 1.5.1.0 and searched against the curated UniProtKB mouse proteome105,149. Default 
MaxQuant settings were used with the following modications: multiplicity was set to 
2, Arg10 and K8 were selected as heavy labels, match between runs and requantify were 
enabled. Downstream analysis of proteomics data was performed using Perseus106 and 
in-house R scripts. Dierential proteins were calculated using the Signicance B feature 
in Perseus based on the normalized H/L ratios (threshold at p < 0.05)105. For an overview 
of the pathways sustaining 2i and serum ESCs, the main eector proteins were obtained 
from Hackett and Azim Surani, 2014. The cytoplasmic proteomes were used to obtain 
cytoplasmic ratios. As fold changes of the pluripotency factors in the nucleus and the 
chromatin were similar, we used the ratios of the chromatin for the nuclear / chromatin 
compartment. For a complete overview, the levels of important eector proteins that 
were not detected in our MS data were inferred from literature. 
Quantication of intracellular ROS and glutathione
ROS levels were quantied using the DCFDA Cellular ROS Detection Assay Kit (Abcam, 
#ab113851) according the manufacturer’s instructions. Total glutathione levels were 
quantied using the Glutathione Fluorometric Assay Kit (Biovision, #K264-100) according 
the manufacturer’s instructions. 
RNAseq analysis
Gene expression counts of preimplantation embryos (E2.5, E3,5, E4.5) and 
postimplantation embryos (E5.5) were obtained from Boroviak et al., 201530. Counts 
for the genes  (of which the proteins were detected in our SILAC work§ow) that are 
related to ROS scavenging were extracted and Z-score normalized using R3.3.2. Genes 
with a peak expression (=highest Z-score) at E2.5-E4.5 were considered enriched in the 
preimplantation stage and those with a peak expression (=highest Z-score) at E5.5 were 
considered enriched in the postimplantation stage.
Data accessibility
The proteomics datasets are available from the ProteomeXchange Consortium via PRIDE 
submission with the dataset identier PXD009217. 
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Figure S1 | Validation of SILAC medium. Scatter plot of the amino acids measured in 
regular 2i medium and SILAC 2i medium using ion exchange chromatography. Axis represent 
amino acid concentration (µmol).  
Figure S2 | Complementing Figure 4: 2i ESCs are characterized by enhanced metabolic 
buering. A) MG132 inhibits the proteasome resulting in rapid sequestering of all ubiquitin 
chains, including those previously attached to histones. As such, western blot for H2AK119ub 
provides a control for the MG132-treatment e¦ciency. H2AK119ub western blot intensity was 
largely diminished upon treatment of both 2i and serum ESCs, indicating that the MG132 
treatment was eective. B) Top: Survival of 2i and serum ESCs relative to untreated control 
after 6-hour treatment with MG132. Bottom: ROS production after treatment with MG132 
at 5 µM relative to DMSO treated control cells * = p < 0.05 (t-test). C) H2O2 was added in 
the medium of 2i and serum ESCs for 24 hours in the indicated concentrations. Survival is 
indicated as percentage of control (untreated) cells. n.s. = not signicant.
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Abstract
The pluripotent ground state is dened as a basal state free of epigenetic restrictions, 
which in§uence lineage specication. While naive embryonic stem cells (ESCs) can be 
maintained in a hypomethylated state with open chromatin when grown using two small-
molecule inhibitors (2i)/leukemia inhibitory factor (LIF), in contrast to serum/LIF-grown 
ESCs that resemble early post-implantation embryos, broader features of the ground-
state pluripotent epigenome are not well understood. We identied epigenetic features 
of mouse ESCs cultured using 2i/LIF or serum/LIF by proteomic proling of chromatin-
associated complexes and histone modications. Polycomb-repressive complex 2 
(PRC2) and its product H3K27me3 are highly abundant in 2i/LIF ESCs, and H3K27me3 
is distributed genome-wide in a CpG-dependent fashion. Consistently, PRC2-decient 
ESCs showed increased DNA methylation at sites normally occupied by H3K27me3 
and increased H4 acetylation. Inhibiting DNA methylation in PRC2-decient ESCs did 
not aect their viability or transcriptome. Our ndings suggest a unique H3K27me3 
conguration protects naive ESCs from lineage priming, and they reveal widespread 
epigenetic crosstalk in ground-state pluripotency.
Keywords: Chromatin proling, epigenetics, H3K27me3, embryonic stem cells, ground 
state pluripotency, histone modications
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Introduction
Transient pluripotent states of the embryo can be stably captured in vitro in the form 
of embryonic stem cells (ESCs). Traditionally, these ESCs were cultured using serum 
and leukemia-inhibitory factor, here referred to as “serum”17,23. More recently, a dened 
minimal culture condition for ESC culture has been pioneered relying on two small-
molecule inhibitors of the mitogen-activated protein kinase (MEK) and glycogen-
synthase kinase (GSK3), respectively, referred to as “2i”28. Over the last years, important 
dierences in transcriptome and methylome have been uncovered between serum- and 
2i-cultured ESCs. This demonstrated that the hypomethylated 2i ESCs re§ect their peri-
implantation Inner Cell Mass (ICM) origin well (referred to as ‘ground state’ pluripotency), 
whereas the hypermethylated serum ESCs share features with the more primed post-
implantation embryo32,33,134.
Next to DNA hypomethylation, other prominent epigenetic features that discriminate 
2i from serum ESCs include decreased H3K27me3 over bivalent genes, a global decrease 
of H3K9me2 and the absence of extreme long-range chromosomal interactions (ELRIs) 
which are present in serum ESCs32–36,38,63,109. Together with reduced numbers of nucleosome 
clutches, this results in a more open and §exible chromatin structure in the pluripotent 
ground state39,40. Notably, 2i and serum ESCs are interconvertible32,33 indicating that the 
epigenome between these pluripotent states is highly dynamic. Previous hypotheses 
postulated that the pluripotent ground state represents a ‘blank slate’ devoid of any 
epigenetic restrictions, similar to early blastocyst cells21,63. Accordingly, serum ESCs, 
but not 2i ESCs, display signs of early priming, such as the DNA hypermethylation and 
expression of lineage-specifying genes. However, it has remained largely enigmatic 
which features characterize the unrestricted ground state epigenome, which allow 
maximum §exibility for lineage specication32,41.
In this study, we provide a comprehensive overview of the ground state epigenome by 
integrating histone modications and chromatin-associated protein complexes in 2i ESCs 
at unprecedented resolution using mass spectrometry. Unexpectedly, we identify the 
repressive Polycomb Repressive complex 2 (PRC2) and its catalytic product H3K27me3 
being signicantly gained in 2i ESCs as compared to serum ESCs. We show that PRC2 
changes complex conguration, partly relocalizes to pericentric heterochromatin and 
spreads over large euchromatic areas in 2i ESCs, at the expense of classical Polycomb 
targets. In the absence of H3K27me3 and PRC2, 2i ESC largely retain expression of 
pluripotency factors, but acquire early-priming marks such as DNA methylation and H4 
acetylation. Therefore, we propose that the high levels of PRC2 and its mark H3K27me3 
shield the naive epigenome from early-priming events, as such acting as a gatekeeper of 
the ground-state pluripotent epigenome.
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Results
Posttranslational histone modications in 2i and serum ESCs
To get insight into the epigenetic make-up of ground state pluripotency, we performed 
proling of histone post-translational modications (hPTMs) of 2i and serum ESCs 
by bottom-up label-free mass spectrometry (Figure 1A). We identied and quantied 
42 individual hPTMs and 66 hPTM combinations on histone H3 and H4 with high 
reproducibility (R > 0.95) across replicates (Figure 1B, S1A-C). In total, 12 hPTMs were 
dierential between 2i and serum ESCs (p<0.001 and >1.5-fold change) (Figure 1B). 
These include the PRC2-deposited mark H3K27me3, the DOT1L mediated active mark 
H3K79me2 and less studied hPTMs such as H3R26me2 and H4K5me1 all being higher 
in 2i ESCs. The hPTMs that are lower in 2i ESCs include PRC2-dependent H3K27me1, 
which implies a switch from H3K27me1 towards H3K27me3, the elongation-associated 
and PRC2 antagonizing H3K36me2150 and (in general) acetylation of the N-terminal of 
histone H4. To gain insight in overall abundance, we ranked the hPTMs as normalized 
over all histones. This revealed that of the 10 most abundant hPTMs H3K27me3 is the 
only modication that is signicantly higher in 2i ESCs (Figure 1C, S1D). Although we also 
detect H3.3K27me3151,152 being enriched in 2i ESCs, this modication represents a very 
small part (<1%) of the total pool of H3K27me3.
We validated our approach using Western blot (Figure 1D, S1E-F). Interestingly, these 
blots consistently show a clipped version of H3 in 2i ESC extracts (Figure 1D)153. Querying 
of our MS spectra identied three H3 clipping events, at residue 27 (cH3K27), 28 (cH3S28) 
and 39 (cH3H39), which were all signicantly enriched in 2i cultured cells (Figure S1G). 
As histone precedes histone eviction and chromatin remodeling154, the clipped histones 
might have a regulatory role in providing §exibility for chromatin dynamics in 2i ESCs. To 
investigate which of the pathways as targeted by the two kinase inhibitors is responsible 
for the altered histone prole, we added PD (MEK/ERK signaling inhibition) and/or 
Chiron (Wnt hyperactivation) to serum ESCs for 14 days. This revealed that suppression 
of ERK signaling is su¦cient to induce the main epigenetic features characteristic for 2i 
ESCs (Figure 1E, S1H). Altogether, these analyses revealed hPTMs that characterize the 
histone prole of ground state pluripotent ESCs.
Major epigenetic protein complexes are remodeled between 
pluripotent states
To substantiate the dierential histone modication prole between 2i and serum ESCs, 
we analyzed the chromatin-associated proteins by mass spectrometry (Figure 2A). The 
strong enrichment for chromatin-related terms during gene ontology (GO) analysis for 
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the proteins detected highlighted the purity of the chromatin fraction (Figure S2A, S2B). 
Accordingly, we identied various subunits of major epigenetic complexes as dierential 
between 2i and serum ESCs (Figure 2B). We reproducibly identied 2674 chromatin-
associated proteins, of which 113 were higher in 2i and 76 were higher in serum ESCs 
(p<0.05 and >2 fold). GO terms related to the dierential proteins were mainly chromatin 
related as expected (Figure 2C). Only around a quarter of the dierential chromatin 
proteins were also dierential in whole cell proteome proling (Figure S2C), suggesting 
that most of the observed dierences are the result of dierential recruitment to the 
chromatin. Surprisingly, the dierence in chromatin-associated proteins seems to be 
largely independent of the dierence in DNA methylation between 2i and serum ESCs, as 
the abundance of proteins known to be attracted or repelled by DNA methylation155 was 
similar between 2i and serum ESCs (Figure S2D).
Next, we focused on enzymes and transcription factor modules related to hallmarks of 
ground state pluripotency (as described in Hackett and Surani 2014). The chromatin of 
2i ESCs is enriched for naïve pluripotency factors such as NANOG, TFCP2L1, and TBX3 
(Figure 2D), and displays lower abundance of the priming-associated LIN28A97. Further, 
the de novo methyltransferase proteins (DNMTs) and UHRF136 are strongly reduced in 
2i ESCs. Lastly, various components of the SWI/SNF complex are signicantly dierent 
between 2i ESCs and serum ESCs (Figure 2D), which could underlie the more open 
chromatin structure of 2i ESCs.
To integrate the chromatin-associated proteome with the hPTM proling, we focused 
on the major epigenetic protein complexes and their catalytic subunits (Figure 2E). By 
linking epigenetic modiers to their targets, we observe major hubs characterizing 
the epigenome of 2i ESCs (Figure 2F). These include a gain of H3K79me2 and its writer 
DOT1L and a decrease of H4 acetylation and one of its major writers HAT1. However, 
the only feature characterizing the 2i epigenome with a signicant increase of both the 
writer complex and its associated modication are the PRC2-associated EZH1 and EZH2 
together with H3K27me3. Notably, this is associated with a signicant increase of the 
PRC1 catalytic subunit RING1B and its mark H2AUb119 (Figure 1D).
533641-L-bw-Mierlo
Processed on: 23-7-2019 PDF page: 65
4
Figure 1 | Di erences in the landscape of hPTMs between 2i and serum ESCs. 
A) Schematic overview of the work§ ow used to assay hPTMs. B) Relative abundance of 
modi cations expressed as percentage of parent ion (left) and corresponding log2 fold 
changes (right). Of note: the relative abundance of modi cations on H3.3 is in proportion 
to the H3.3 parent ion, which is ~100-fold less abundant than the corresponding H3 parent 
ion. Error bars (left) represent SEM. Dashed lines (right) indicate 1.5-fold change. Statistically 
di erential hPTMs FDR<0.001 (student’s t-test with Benjamini-Hochberg correction) & fold 
change>1.5 are indicated in red with an asterisk. Error bars represent SEM. C) Top10 most 
abundant histone modi cations in 2i ESCs, ranked as fold change 2i over serum. Numbers 
in column 2 and 3 represent percentage of all H3 and H4 modi cations that were identi ed. 
Colors indicate 1.5-fold higher in 2i ESCs (green) or in serum ESCs (blue). *=FDR<0.001. 
D) Western blot validations of prominent histone modi cations. H2AUb119 was not identi ed 
in the mass spectrometer but included to probe for PRC1 activity. Arrows indicate clipped 
variants of histone H3. E) Western blot for hPTMs characteristic for 2i ESCs in serum ESCs 
supplemented with PD and/or Chiron (CH) for 14 days.
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For PRC2, the core subunits EZH2 and SUZ12 are increased in 2i ESCs, whereas enrichment 
of sub-stoichiometric subunits was much more variable, including a (signi cant) reduction 
of JARID2 and EPOP and a gain of MTF2 (Figure 2E). This suggests a change in PRC2 complex 
composition or a shift between the two known PRC2 sub-complexes PRC2.1 and PRC2.2 
(Figure S2F). To explore this, we determined the PRC2 complex composition in 2i and 
serum ESCs by GFP a¦  nity puri cation using ESCs containing an EED-GFP fusion protein 
(Figure 2G). This revealed a reduction of JARID2 and EPOP in the PRC2 complex in 2i ESCs 
(Figure 2H). The reduction of EPOP in the PRC2 complex in 2i ESCs is accompanied by a 
reduction of TCEB1 (Elongin B) and TCEB2 (Elongin C), consistent with the role of EPOP as 
a bridge between core PRC2 and Elongin BC156 (Figure S2G). Interestingly, MTF2 is the only 
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facultative subunit with a relatively high stoichiometry (>0.1) enriched in PRC2 in 2i ESCs 
(Figure 2H). This suggests that MTF2 might be involved in the increased PRC2 occupancy 
in 2i ESCs, in line with the critical role of MTF2 in Polycomb recruitment157,158. Altogether, 
our data does not suggest a shift between PRC2.1 and PRC2.2 between 2i and serum 
ESCs, but rather substoichiometric changes within the individual PRC2.1 and PRC2.2 sub-
complexes. Notably, the stoichiometry of PRC2 as identied in the GFP pulldown re§ects the 
fold changes as observed in the chromatin proteomes, showing that the chromatin-bound 
proteome has strong predictive value for the conguration of epigenetic protein complexes.
Figure 2 | Epigenetic protein complexes present on chromatin in 2i and serum ESCs. 
A) Schematic overview of the work§ow for proling of the chromatin-associated proteome. 
B) Volcano plot of reproducibly quantied proteins in 3 biological replicates. Major 
epigenetic protein complexes, as indicated in the right top corner, are highlighted. Individual 
complex members with p<0.05 are tagged with names. C) Z-score normalized heatmap of 
all dierential proteins as identied in (B). On the right, representative GO terms for the 
proteins signicantly enriched in either 2i or serum ESCs. D) Comprehensive overview of 
fold changes (log2) of the main proteins involved in pluripotency, DNA methylation and 
chromatin remodeling. Asterisks indicate proteins signicantly dierent between 2i and 
serum ESCs. E) Epigenetic complexes as detected in our chromatin proteome of which the 
catalytic subunit is signicantly dierent between 2i and serum ESCs. Error bars represent 
SEM. Dashed lines represent 1.5-fold change. *=p<0.05 (student’s t-test) & fold change>1.5. 
Catalytic subunits are labeled in red. Data on non-signicant additional epigenetic complexes 
is shown in Figure S2E. Error bars represent SEM. F) Integration of the hPTM measurements 
and the chromatin-associated proteome. Edges indicate functional connection between the 
nodes. Highlighted hubs indicate signicantly dierent hPTMs of which the corresponding 
writer(s) exhibit similar changes (black border if showing a trend; red border if statistically 
signicant). Modications or epigenetic modiers in grey nodes were not detected. G) 
Volcano plots of label-free EED-GFP pulldowns on nuclear extracts of 2i or serum ESCs. The 
label-free quantication (LFQ) intensity of the GFP pulldown relative to the control is plotted 
on the x-axis. The -log10-transformed P value of the t-test is shown on the y-axis. Dotted 
gray lines represent statistical cutos. The proteins in the upper-right corner represent the 
bait (EED, green) and its interactors. H) Stoichiometry of PRC2-complex members relative to 
the bait EED. Bars represent average values of three replicates. Error bars represent standard 
deviation. *=p<0.05 (student’s t-test). Error bars represent standard deviation. Grey: core 
subunits, Red: PRC2.1 subunits, Blue: PRC2.2 subunits.
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H3K27me3 is abundantly present on eu- and heterochromatin in 
2i ESCs
Next, we set out to localize the highly abundant H3K27me3 in 2i ESCs by separating 
the accessible euchromatic regions (S1) from heterochromatic regions (S2) using 
partial MNase digestion (Figure 3A). The S1 fraction mainly consisted of DNA of 
mononucleosomal size and the S2 fraction mainly contained DNA of polynucleosomal size, 
indicative for optimal separation of eu- and heterochromatin (Figure S3A). Accordingly, 
the heterochromatin-associated H3K9me3 was mainly present in the S2 fraction, while 
the active mark H3K4me3 was higher in the S1 fraction (Figure 3B, S3B). Interestingly, 
H3K27me3 was increased in both the S1 and S2 fraction in 2i ESCs as compared to 
serum ESCs (Figure 3B, S3B). In line, mass spectrometry analysis of the euchromatic S1 
fractions revealed an increase of the PRC2 core subunits in 2i ESCs (Figure 3C, S3C-D). 
To investigate the gain of H3K27me3 over heterochromatin in 2i ESCs in more detail, 
we interrogated the chromatin content of the pericentric heterochromatin using protein 
isolation of chromatin segments (PICh)159. We observed strong enrichment for PRC2 
subunits over pericentric heterochromatin in 2i ESCs, which was not present in serum 
ESCs (Figure 3D). This was accompanied by decreased levels of DNA methyltransferases 
and the H3K9me3-depositing epigenetic enzyme SUV39H2 in 2i ESCs, which mediate the 
formation of constitutive heterochromatin (Figure 3D, S3E). This suggests that pericentric 
heterochromatin is largely facultative in the pluripotent ground state. The reduction of 
constitutive heterochromatic features in 2i ESCs did not aect transcription, as ncRNA 
expression from the pericentromeres was not signicantly dierent from serum ESCs 
(Figure S3F). Altogether, these analyses show that despite the reduction of H3K27me3 
and PRC2 over bivalent promoters32,141, the total levels of H3K27me3 and PRC2 in 2i ESCs 
are increased on both eu- and heterochromatin as compared to serum ESCs.
To further explore the localization of the increased H3K27me3 at base-pair resolution, 
we performed quantitative H3K27me3 ChIP-Seq proling by the use of Drosophila “spike-
in”. Normalization to the spike-in reads revealed that the H3K27me3 signals were 1.55-
fold higher in 2i ESCs as compared to serum ESCs, in line with the 1.76 fold change as 
measured using hPTM proling (Table S3; Figure 1B, 3E). Next, we performed de novo 
peak calling identifying 8,581 or 9,045 H3K27me3 peaks in 2i or serum ESCs, respectively 
(Figure 3F, 3G; S3G-K). In terms of genomic distribution, peaks present in both 2i and 
serum ESCs and peaks specic for serum ESCs are highly enriched for CpG-island (CGI) 
promoters, suggesting a gene regulatory role. In contrast, the 2i-specic H3K27me3 
peaks were mainly present at non-CGI intergenic regions and the genomic distribution 
of these peaks resembled random distribution (Figure 3G; cf. Figure S5B). Surprisingly, 
the total normalized H3K27me3 read count within all peaks was only slightly higher in 2i 
ESCs (11%; Table S4) as compared to the serum ESCs, not matching the much higher total 
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levels of H3K27me3 as determined by the hPTM proling and the quantitative ChIP-Seq. 
Importantly, in 2i ESCs the enrichment of the peaks was relatively low as compared to the 
very high baseline levels of H3K27me3 surrounding the peaks (represented by 25kb up- or 
downstream of the peaks) (Figure 3F, 3G). We conrmed the increased baseline levels of 
H3K27me3 in 2i ESCs as compared to serum ESCs by plotting the H3K27me3 prole over 
10.000 random regions (Figure S3L). Plotting genome-wide signals over 1kb bins further 
illustrates the distinct H3K27me3 conguration between 2i and serum ESCs, with 2i ESCs 
showing increased H3K27me3 baseline levels and serum ESCs containing relatively high 
H3K27me3 levels in peaks (Figure S3X). Together, these results strongly suggest that the 
largest increase in H3K27me3 in 2i ESCs does not occur within the classical H3K27me3-
enriched Polycomb targets (“peaks”), but rather outside H3K27me3 peaks (illustrated 
in Figure 3H). Notably, the H3K27me3 conguration in 2i ESCs resembles H3K27me3 
patterns as observed in preimplantation embryos, while serum ESCs re§ect H3K27me3 
proles of postimplantation embryos (Figure S3U-S3X).
To extend these observations, we investigated the coverage of ChIP-Seq signal outside 
H3K27me3 peaks in relation to CpGs. This revealed a clear correlation between the 
global increase of H3K27me3 with CpG density in regions with low to medium CpG 
density (Figure 3I, S3M). In line, we observed signicantly higher levels of H3K27me3 
over non-CGI CpGs as compared to other dinucleotides in 2i ESCs, but not in serum ESCs 
(Figure S3N). Notably, H3K27me3 peaks over CpG islands (comprising the majority of the 
common and serum ESC-specic peaks in Figure 3F, G) show reduced levels of H3K27me3 
in 2i ESCs as compared to serum ESCs (Table S4). Next to the euchromatic part of the 
genome, we extended our ChIP-Seq analysis to pericentric heterochromatin (Figure 
S3O), which conrmed previous observations on increased H3K27me3 over satellite 
repeats in 2i ESCs32,109) and match the PICh results (Figure 3D). Finally, as a control for 
the H3K27me3 ChIP-Seq analysis, we performed spike-in ChIP-Seq on H3K36me3, which 
was largely similar between 2i and serum ESCs (Figure 3G-I, S3L-M, S3P). Altogether, our 
quantitative ChIP-Seq data shows that the increase of H3K27me3 in 2i ESCs as compared 
to serum ESCs occurs on both eu- and heterochromatin (satellites), in line with the 
MNase experiments (Figure 3B). As the increase of H3K27me3 mainly occurs at baseline 
levels and is specically correlated with CpG density, this suggests that the increase is 
associated with the CpG hypomethylation in 2i ESCs (Figure S3Q). This is in line with 
recruitment of PRC2 being associated with density of unmethylated CpGs 161. Notably, 
spike-in H3K27me3 ChIP-Seq proles of serum ESCs supplemented with the 2i inhibitors 
resembled the H3K27me3 proles as obtained for 2i ESCs, conrming that the H3K27me3 
conguration of 2i ESCs is caused by the two kinase inhibitors and not by any other 
factors present in 2i culture media (Figure S3O, S3R-T).
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Figure 3 | High levels of H3K27me3 is increased on eu- and heterochromatin in 2i ESCs. 
A) Schematic overview of the MNase work§ow. B) Top: Representative image of western 
blot analysis for histone modications present in fractions S1 and S2. Numbers represent 
ratio to H3 loading control. Bottom: Quantication of western blot signal of two biological 
replicates. Log2 ratio S1/S2 based on relative intensity to H3 is plotted. Error bars represent 
SEM. Asterisk indicates signicant (p<0.05: two-way ANOVA with Bonferroni post-test) 
dierence between fraction S1 and S2 based on H3K4me3 and H3K9me3. C) Scatter plot of 
MS analysis of fraction S1 in 2i and serum ESCs. Dierential PRC2 subunits are highlighted. 
D) LFQ-based fold change of epigenetic modiers signicantly enriched on pericentric 
heterochromatin using PICh. All proteins shown are signicantly enriched over pericentric 
heterochromatin in 2i ESCs. With respect to PRC2 complex members in serum ESCs, only 
Aebp2 was signicantly enriched over pericentric heterochromatin. *=p<0.05 and fold 
change >3 (intensity-dependent t-test). E) Ratio of total amount of H3K27me3 reads in 2i 
and serum ESCs after normalization for spike-in chromatin. *=p<0.05 (student’s t-test). Error 
bars represent standard deviation (2 replicas). F) Average proles of H3K27me3 ChIP-seq 
after spike-in normalization (two replicas per sample). Categories represent common peaks 
(called in both 2i and serum) and serum or 2i-specic peaks. Numbers above the proles 
indicate the number of peaks as present in each category. G) Heatmaps of H3K27me3 and 
H3K36me3 on the categories as shown in panel (F). Pie charts indicate genomic distribution 
of the peaks, with categories subdivided based on the presence of CpG-islands (CGIs). 
H) Representative genome browser views showing increased baseline levels of H3K27me3 
in 2i ESCs (boxed in red), while the signal intensity of serum ESC peaks is reduced in 2i ESCs. 
The right panel represents an active gene decorated with H3K36me3 which shows low, 
background levels of H3K27me3 in 2i and serum ESCs, in line with previous observations that 
H3K27me3 and H3K36me3 are mutually exclusive160. I) Correlation between fold change (2i 
/ serum ESCs) of H3K27me3 and H3K36me3 ChIP-Seq versus CpG density outside H3K27me3 
peaks. Note that the x-axis only represents regions with low to medium CpG density, while 
CGIs have higher CpG contents.
 
2i ESCs gain primed-like features upon H3K27me3 removal
To functionally investigate the unique H3K27me3 conguration in 2i ESCs, we made 
use of Eed-/- ESCs which lack a functional PRC2 complex and consequently H3K27me3. 
First, we investigated whether Eed-/- 2i ESCs maintained their pluripotent state by 
assaying expression of pluripotency and stem cell maintenance genes using RNA-Seq32. 
This revealed that Eed-/- 2i ESCs largely preserve expression of these genes at wildtype 
levels, including factors typical for the naïve state such as Prdm14 and Dazl (Figure S4A, 
S4B). Moreover, Eed-/- 2i ESCs maintain the typical 2i morphology, further conrming 
the undierentiated state of 2i ESCs lacking PRC2 (Figure S4C). To assay the eect of 
PRC2 removal on the epigenome, we performed hPTM proling of Eed-/- 2i ESCs (as in 
Figure 1A; Figure S4D). The hPTMs present in the Eed-/- 2i ESCs are drastically changed 
as compared to wildtype 2i ESCs, with 21 hPTMs of the total of 42 reproducibly quantied 
hPTMs on H3 and H4 being aected (p<0.001 and >1.5-fold change) (Figure 4A). The 
H3K27me1/2/3 histone marks show a signicant reduction, validating the experimental 
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conditions (Figure 4A, 4B, S4E). H3K27ac and H3R26me2, two hPTMS on or adjacent to 
H3K27, are signicantly increased in Eed-/- 2i ESCs, suggesting these sites are normally 
occupied (H3K27ac) or masked (H3R26me2) by H3K27me3 (Figure 4B, 4C). To obtain 
a global overview of the hPTM proling, we performed principal component analysis. 
This shows that that Eed-/- 2i ESCs are more similar to wildtype serum ESCs than to 2i 
ESCs, suggesting that removal of PRC2 results in a serum-like ESC epigenome (Figure 4E). 
Indeed, several of the signicant dierences discriminating 2i from serum ESCs, such as 
H4 hypoacetylation and H3K79me2, were signicantly aected in Eed-/- 2i cells resulting 
in levels similar to serum ESC level (Figure 4B, 4D). Importantly, the change in the hPTMs 
in Eed-/- 2i ESCs are a direct consequence of a perturbed PRC2 function, as these changes 
are phenocopied in wildtype 2i ESCs treated with small molecule inhibitors inhibiting 
PRC2 catalytic activity (Figure 4F; Figure S4G). The epigenetic priming as observed for 
the Eed-/- 2i ESCs is further substantiated by global analysis of the RNA-Seq, which 
showed that the GO terms associated with upregulated genes in Eed-/- 2i ESCs (p<0.05) 
include various dierentiation-linked processes, despite the preserved expression levels 
of core pluripotency genes (Figure S4F).
 
Figure 4 | Eed-/- ESCs in 2i display primed-like characteristics. A) Changes of hPTMs in 
Eed-/- 2i ESCs as compared to changes between wildtype 2i and serum ESCs. Bars represent 
log2 fold changes. hPTMs are ranked by 2i / serum fold change. Boxplots indicate spread of 
abundance between all samples. *=FDR<0.001 & fold change>1.5. B) Abundance of a subset 
of hPTMs. Axes represent percentage of parent ion. Error bars represent SEM. *=FDR<0.001 
& fold change>1.5. n.s. = non-signicant. C) Western blot validation of H3K27Ac and 
H3R26me2. D) Western blot analysis of H3K79me2 and acetylation marks on the N-terminus 
of H4. E) Principal component analysis of the hPTM proling. Two major components, 
explaining most of the variation in the data (x-axis: 81.1% and y-axis: 14.3%) are shown. 
F) Western blot analysis of histone modications in 2i ESCs before or after 3-day treatment 
with PRC2-inhibitor GSK126. Quantication represents fold change normalized to H3 
loading. Error bars represent SEM of 2 biological replicates. *=p<0.05 (student’s t-test). 
G) Volcano plot of chromatin-associated proteome comparison of Eed-/- 2i ESCs with 
wildtype 2i ESCs (n=3 experiments). Dashed lines indicate FDR-cuto of 0.05. DNMT3 
proteins as well as PRC1 and PRC2 complex members with p<0.05 are highlighted. 
H) LFQ-based log2 fold change of all reproducible quantied catalytic epigenetic modiers. 
*=p<0.05 (student’s t-test). Error bars represent SEM. I) DNA (hydroxy)methylation levels 
in wildtype, Eed-/- and Suz12-/- ESCs. Error bars represent SEM. *=p<0.05 (student’s t-test). 
J) DNA methylation levels in 2i ESCs in the presence of DMSO or PRC2 inhibitor GSK126 for 14 
days. Error bars represent SEM from 2 independent experiments.
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To complement the hPTM proles, we interrogated the chromatin-bound proteome in 
Eed-/- 2i ESCs (as in Figure 2A). Compared to wildtype 2i ESCs, we observed a strong 
reduction of many PRC2 components, suggesting their association to chromatin strongly 
relies on the presence of a functional PRC2 complex containing EED (Figure S4H). The 
majority of PRC1 subunits was retained on the chromatin of Eed-/- 2i ESCs (Figure 4G), 
in line with the fact that PRC1 can be recruited independently of PRC2 and H3K27me3. 
Focusing on epigenetic modiers, SUV39H1/2 is increased in Eed-/- 2i ESCs (Figure 4H), 
suggesting restoration of constitutive heterochromatin in 2i ESCs in the absence of PRC2, 
and HAT1 and KAT7 are increased, in line with the increased level of H4 acetylation in Eed-
/- 2i ESCs. However, the most prominent change was an unexpected increase of DNMT3A, 
3B and 3L on the chromatin of Eed-/- 2i ESCs as compared to wildtype 2i ESCs (Figure 4H). 
As DNMT3A, 3B and 3L only show a minor increase at transcript levels141 (between 1.5- and 
2.5-fold; Figure S4I) or total cellular protein levels in Eed-/- 2i ESCs (shown for DNMT3A 
in Figure S4J), the strong increase of the DNMT3 proteins on the chromatin in Eed-/- 2i 
ESCs (between 6- and 28-fold) is likely results from specic recruitment. The increase 
of DNMTs on the chromatin was accompanied by a strong gain of DNA methylation as 
measured via DNA methylation LC-MS (Figure 4I). Comparable results were obtained in 
Suz12-/- 2i ESCs. Notably, treatment of wildtype 2i ESCs with the EZH2-specic inhibitor 
GSK126 also resulted in an increase of DNA methylation, albeit to a lower extent (Figure 
4J). This suggests that next to H3K27me3 also the presence of PRC2 on the chromatin of 
2i ESCs is important to retain the hypomethylated state. This is in line with the protective 
role for PRC2 together with H3K27me3 in maintaining DNA hypomethylation within so-
called “demethylated valleys” in serum ESCs162.
Eed-/- 2i ESCs display genome-wide increase of DNA methylation
To further investigate the increased DNA methylation, we performed whole-genome 
bisulte sequencing (WGBS) of Eed-/- 2i ESCs. This revealed that the majority of CpGs 
have a methylation level between 0.25 to 0.75, while additionally 14% of the CpGs are 
unmethylated (Figure 5A-C). Comparison of the Eed-/- 2i ESCs with wildtype 2i or serum 
ESCs33 shows that Eed-/- 2i ESCs contain intermediate levels of CpG methylation, in line 
with the mass spectrometry results (Figure 5A-C, cf. Figure 4I). The CpG methylation 
prole of Eed-/- 2i ESCs is very similar to an intermediate CpG methylation state between 
2i and serum ESCs (Figure S5A), providing further evidence that PRC2 is important to 
maintain the epigenome in the pluripotent ground state. Next, we plotted the WGBS 
proles over various (functional) genomic elements (Figure 5D). Similar to 2i and serum 
ESCs, CpG islands (which in ESCs largely comprise bivalent promoters occupied by both 
H3K4me3 and H3K27me3) remain unmethylated in Eed-/- 2i ESCs. This ts previous 
reports that CpG islands are protected from DNA methylation by various mechanisms, 
including the presence of H3K4me3163. Outside CpG islands, we observed a consistent 
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increase of CpG methylation in Eed-/- 2i ESCs as compared to 2i ESCs, such as in 
enhancers and up- and downstream of other functional elements (Figure 5D). To classify 
the regions with the highest gain of CpG methylation in Eed-/- 2i ESCs as compared to 2i 
ESCs, we binned the genome in 1kb regions and plotted the genomic location of the 2500 
sites with the highest gain. This showed that the distribution of these sites was close 
to random distribution (Figure S5B). We also assayed non-CpG methylation, which was 
mainly conned to the CpA context for which the levels in Eed-/- 2i ESCs were up to levels 
as present in serum ESCs (Figure S5G).
To further understand the interplay between CpG methylation and H3K27me3, we 
grouped the 1kb bins according to H3K27me3 levels in wildtype 2i ESCs and plotted 
the corresponding levels of CpG methylation (Figure S5C). This revealed that regions 
with very low to no H3K27me3 levels possess the highest CpG methylation in 2i ESCs, 
whereas higher amounts of H3K27me3 signal are associated with lower CpG methylation. 
Focusing on Eed-/- 2i ESCs, we observed that the regions with (near-)absent H3K27me3 
in 2i ESCs display the lowest relative gain of DNA methylation in Eed-/- 2i ESCs, whereas 
all other regions containing medium or high levels of H3K27me3 gained a similar high 
amount of CpG methylation (Figure 5E, S5C). The same dynamics is observed at the 
relatively few regions that are hypermethylated in 2i ESCs, which lack H3K27me333 and 
as such display only a minor increase in CpG methylation in Eed-/- 2i ESCs (Figure S5D). 
Furthermore, we determined CpG methylation at regions harboring H3K27me3 peaks in 
2i ESCs (Figure 3F, 3G), which shows that the H3K27me3 peak regions associated with 
CGIs remain unmethylated in Eed-/- 2i ESCs in line with the general hypomethylation of 
CGIs observed in Eed-/- 2i ESCs (Figure S5E, Figure 5D). On the other hand, the non-CGI 
H3K27me3 peak regions in 2i ESCs (which largely comprised the 2i ESC specic peaks as 
compared to serum ESCs) gained CpG methylation in a similar fashion as the remainder 
of the genome. This further shows that, outside of regions with (near-)absent H3K27me3 
and outside of CGIs, the local gain of CpG methylation is independent of H3K27me3 
levels. WGBS proling of Suz12-/- 2i ESCs yielded similar results as the Eed-/- 2i ESCs, 
although the global levels of CpG methylation in the Suz12-/- 2i ESCs are slightly lower as 
also observed by mass spectrometry (Figure S5F, cf Figure 4I). Collectively, these results 
support a model in which the widespread H3K27me3 and/or PRC2 directly or indirectly 
renders the 2i ESC chromatin less permissive to the acquisition of CpG methylation.
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Figure 5 | Genome-wide increase of DNA methylation in Eed-/- 2i ESCs. A) Distribution 
of 5mC levels in CpG sequence context by WGBS. The boxplot layout is according to 
the Tukey ve-number summary (horizontal line within the box represents median). 
B) Distribution of DNA methylation levels for all individual CpGs covered in WGBS genome-
wide. C) A typical example depicting methylation proles of the various ESCs. Methylation 
levels of individual CpG sites, between 0 (unmethylated) and 1 (fully methylated) after a 
running median of 19 CpGs, are shown by bars. D) Average DNA methylation prole over 
enhancers, CpG islands and bivalent promoters. E) Ratio CpG methylation Eed-/- wt 2i 
ESCs for 1kb bins grouped according to H3K27me3 ChIP-seq signal in 2i ESCs. Signicance 
was calculated using a paired Wilcoxon rank sum test with Holm-Bonferroni multiple 
testing correction. F) DNA (hydroxy)methylation of wildtype 2i and Eed-/- 2i ESCs after 
treatment with 1 µM 5-azacytidine for 6 days. Error bars represent SEM from 2 independent 
experiments. *=p<0.05 (t-test) n.s. = not signicant. G) Boxplot of all genes excluding PRC2 
targets (“no PRC2 targets”; left) and PRC2 targets (right). Y-axis represents gene expression 
values (TPM). *=p<0.001 (Wilcoxon Rank test). 
Increase of DNA methylation in Eed-/- 2i ESCs is redundant for 
transcription or survival
To investigate whether the gain of DNA methylation in the Eed-/- 2i ESCs is functional, 
we treated these cells with 5-azacytidine (5-aza). This enabled rescuing DNA (hydroxy)
methylation to wildtype 2i ESC levels (Figure 5F) without aecting cell survival (data 
not shown). Next, we performed RNA-Seq on the 5-aza-treated Eed-/- 2i ESCs. The 5-aza 
treatment was validated by induction of expression of several direct DNA methylation 
targets known to be induced by 5-aza (Figure S5H). Focusing on PRC2 targets in 2i ESCs 
(as determined in Figure 3F), we observed mild upregulation of PRC2 target genes in 
Eed-/- 2i ESCs, which was similarly present in 5-aza treated Eed-/- ESCs (Figure 5G). This 
suggests that the increase of DNA methylation in Eed-/- 2i ESCs is not aecting gene 
expression of PRC2 targets. At a global level, we observed signicant upregulation (p < 
0.05) of only 40 genes in Eed-/- ESCs treated with 5-aza compared to untreated ESCs, 
including the 5-aza target Dpep3 (Figure S5I). This suggests that the DNA methylation 
present in Eed-/- 2i ESCs is largely unlinked to transcriptional regulation. In line, 5-aza 
treatment did not aect expression of pluripotency genes, suggesting that the DNA 
methylation gained in the Eed-/- 2i ESCs is not essential to maintain the pluripotent state 
(Figure S5J). Altogether, these data demonstrate that the genome-wide increase of DNA 
methylation as observed in the Eed-/- 2i ESCs is largely redundant for survival, growth 
and maintenance of the ESCs. 
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Discussion
The ground state of pluripotency is dened as a developmental state without epigenetic 
restriction or developmental specication164. Although transcriptional events and 
transcription factor modules maintaining the pluripotent ground state have been 
subject of many studies (see Hackett and Surani, 2014 for a comprehensive review), 
the corresponding constitution of the chromatin has remained largely enigmatic. In 
this study, we prole histone PTMs and chromatin-associated proteins that characterize 
the naïve pluripotent epigenome of 2i ESCs. Our ndings conrm the lack of known 
priming-associated features in 2i ESCs, including the near absence of DNMT3 proteins 
and UHRF136. Other features largely reduced in the 2i ESCs include H4 acetylation and the 
previously reported H3K9me236. As it has been shown that the rst days of dierentiation 
of ESCs are accompanied by a wave of H4 hyperacetylation165, it is tempting to speculate 
that H4 acetylation is among the rst events to prime lineage specication genes, 
starting upon dissolution of the pluripotent ground state. On the other hand, we identify 
various hPTMs that characterize 2i ESCs, such as H3K27me3, H3R26me2 and H3K79me2. 
H3R26me2 is promoted by the 2i-specic factor PRDM14 and promotes chromatin 
association of core pluripotency factors including OCT4 and SOX2166. As such, H3R26me2 
might be key to stabilize the core pluripotency network as observed in 2i ESCs. Notably, 
we show that the unique conguration of the epigenetic landscape of 2i ESCs is directly 
linked to suppression of ERK signaling, in line with recent ndings that PD and not Chiron 
aects the methylome of ESCs167,168.
Ground state pluripotent ESCs maintained in 2i are largely devoid of DNA methylation, 
which we hypothesized to aect the chromatin landscape. However, only the prominent 
gain of H3K27me3 and PRC2 in 2i ESCs seems to be directly linked to the hypomethylated 
state. PRC2 is preferably attracted towards non-methylated DNA, in line with studies 
showing that H3K27me3 and DNA methylation are largely mutual exclusive at a genome-
wide level159,169. Global increases and/or redistribution of H3K27me3 have been observed in 
DNA-methylation decient mouse embryonic broblasts and serum ESCs151,170,171. Together 
with the current observations including the high correlation between the increase of 
H3K27me3 and CpG-density in 2i ESCs, this strongly suggests that DNA hypomethylation 
in 2i ESCs results in accumulation of H3K27me3 at a genome-wide scale. Recently, 
genome instability has been observed after prolonged culture of 2i ESCs167,168, which is 
likely associated with the lack of DNA methylation in 2i ESCs. Apparently, the increased 
H3K27me3 as we observe in 2i ESCs cannot compensate for the lack of DNA methylation 
in maintaining genome integrity. Notably, our chromatin proling did not signicantly 
enrich for proteins involved in DNA repair in (Eed-/-) 2i ESCs as compared to serum ESCs, 
suggesting that short-term adaptation of serum ESCs to 2i (up to 28 days) as performed 
here does not largely aect genome integrity.
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Although compensation of DNA hypomethylation by an increase of H3K27me3 has 
been reported151,170, here we observe the reciprocal relationship. This increase of DNA 
methylation occurs at a global level at the majority of CpGs, predominantly at locations 
previously covered by H3K27me3 except for CpG islands. Our data suggest that the highly 
abundant and widespread H3K27me3 and PRC2 that we observe in 2i ESCs creates a 
chromatin environment that is largely refractory to the deposition of DNA methylation, 
which is generally considered as a very early event preparatory for lineage priming. 
Notably, the total DNA methylation levels in PRC2-decient 2i ESCs (~2%) are not as high 
as the levels observed in serum ESCs (~4%). This is likely in part due to the reduced levels 
of UHRF1 and the DNMT3 proteins (involved in meC deposition) in 2i ESCs (Table S1). 
In vivo, H3K27me3 is prominently present in inner cell mass cells172. Immuno§uorescent 
analysis shows the presence of punctuate H3K27me3 nuclear spots during mouse 
preimplantation stages in vivo, suggesting coverage of H3K27me3 over heterochromatin173. 
Recent ChIP-Seq analysis further showed that the H3K27me3 prole from late 
preimplantation embryos is characterized by larger domains of H3K27me3 in the genome 
and little enrichment at the promoters of most canonical Polycomb targets174. Together, this 
suggests that the H3K27me3 conguration in 2i ESCs is very similar to H3K27me3 patterns 
observed in pre-implantation stage embryos. Therefore, it is tempting to speculate that 
H3K27me3 and/or PRC2 have a protective role in early blastocyst cells as well, shielding 
the DNA from acquiring features associated with priming. This could well underlie the 
high tendency of Eed mutant embryos to commit towards dierentiation rather than 
expand in the inner cell mass175. Notably, post-implantation developmental stages display 
a H3K27me3-signature that is mainly conned to developmental promoters174, re§ecting 
the dierence between 2i and serum ESCs and thereby further suggesting that 2i ESCs 
represent an earlier developmental stage than serum ESCs.
Previous reports have shown that ESCs lacking either H3K27me3 or DNA methylation 
are viable, although the absence of either epigenetic mark is associated with severe 
dierentiation defects. Whereas the phenotype or transcriptome of PRC2-decient 
ESCs is hardly compromised141,176,177, we here provide evidence that a functional PRC2 
complex is required to maintain epigenomic features characteristic for ground state 
pluripotency. Whether maintenance of ESCs is compatible with the simultaneous lack of 
both epigenetic marks H3K27me3 and DNA methylation has remained obscure thus far. 
Eed-/- 2i ESCs were assumed to lack both H3K27me3 and DNA methylation141, but we nd 
that the absence of PRC2 results in increased DNA methylation in 2i ESCs. Interestingly, 
induction of DNA hypomethylation in PRC2-decient 2i ESCs or removal of H3K27me3 in 
DNMT TKO ESCs does not aect cell viability, cell growth and/or gene expression (Figure 
S5K-M). Together, this suggests that maintenance of ESCs is independent of both major 
silencing marks H3K27me3 and DNA methylation.
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Collectively, the observations reported here yield insight in the epigenetic features 
underlying ground state pluripotency. This includes an unanticipated role for PRC2 
and H3K27me3 as shielding the epigenome from acquisition of primed-like features. 
Hence, we propose that H3K27me3 acts as a gatekeeper of the ground state pluripotent 
epigenome. Recently, various studies have reported on the derivation of human 
pluripotent stem cells in a naïve state (overviewed in63,178. One of the main hallmarks 
for claims towards the naïve pluripotent state in human is the presence of global DNA 
hypomethylation. Most other features previously reported to characterize the pluripotent 
ground state as compared to more primed states, such as the lower expression of 
lineage-a¦liated genes or fewer bivalent domains, are often relatively di¦cult to assay 
or not relevant to human178. Given the stability of hPTMs and their conservation between 
species179, the epigenomic features as characterized in the current study may therefore 
add to further evaluation and characterization of the pluripotent ground state of human 
ESCs or other species.
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STAR methods
Contact for Reagent and Resource Sharing
Further information and requests for resources and reagents should be directed to and 
will be fullled by the Lead Contact, Hendrik Marks (H.Marks@ncmls.ru.nl).
Experimental Model and Subject Details
Cell lines
E14 ESCs (129/Ola background) were purchases from ATCC. All knockout cell lines have 
been described elsewhere. Specically: Eed-/- ESCs180, Suz12-/- ESCs181, EED-GFP ESCs79 and 
Dnmt TKO ESCs182. All ESC lines were regularly screened for the absence of mycoplasm.
Cell culture conditions
Wildtype and knockout ESCs were maintained in Dulbecco’s Modied Eagle Medium 
(DMEM) containing 15% fetal bovine serum, 5 µM beta mercaptoethanol (Sigma) and 
Leukemia inhibitory factor (LIF: 1000 U/ml; Millipore), referred to as serum ESCs, or in 
serum-free N2B27 (also known as Ndi) supplemented with PD0325901 (1 µM), CH99021 
(3 µM) and LIF (1000 U/ml), referred to as 2i ESCs. Wildtype and knockout ESCs have been 
derived in serum conditions and were adapted to 2i culture conditions. To determine the 
eect of the individual 2i inhibitors on serum ESCs, serum ESCs were grown in serum 
medium supplemented with PD0325901 (1 µM), CH99021 (3 µM) or both for 14 days 
(used in Fig 1E, S1H, S3O, S3R-T).
Method Details
Experimental Design
All experiments were replicated. For the specic number of replicates done see either 
the gure legends or the specic section below. No aspect of the study was performed 
blinded.
Chromatin Immunoprecipitation followed by Sequencing (ChIP-Seq)
Chromatin extracts were prepared by on-plate cell crosslinking in 1% PFA for 8 minutes. 
Crosslinking was quenched using freshly dissolved glycine (125 mM nal concentration). 
Fixed cells were washed in PBS and collected by scraping. Pellets were lysed and sonicated 
in 50 mM Tris pH 8.0, 1% SDS and fresh protease inhibitor cocktail (Roche) at a density of 
15 million cells per ml. The cells were sonicated ( Diagenode Bioruptor Pico) for eight to 
ten 30-second cycles. A small quantity of sonicated chromatin was eluted and DNA was 
quantied using Qubit HS. 25 µg DNA equivalent mouse chromatin was ChIPped using 
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4 µg H3K27me3 (Millipore 07-449) or 2 µg H3K36me3 (Diagenode C15410192) antibody. 
In view of the dierential levels of H3K27me3, we added Drosophila “spike-in” to the 2i 
and serum ESC-chromatin to allow for quantitative comparisons. Spike-in was performed 
by adding 50ng Drosophila Melanogaster chromatin (Active Motif 53083) and 2 µg 
Drosophila-specic H2Av antibody (Active Motif 61686) to the mouse chromatin. ChIPs 
were diluted 9-fold using IP buer (1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris pH 8.0, 
167 mM NaCl) and incubated overnight at 4°C while rotating. Subsequently, a mixture of 
10 µl Protein A and 10 µl Protein G beads (Thermo) was blocked twice in IP buer with 
0.15% SDS and added to the ChIP. ChIPs with beads were incubated for 1 hour at 4˚C and 
precipitated using a magnetic rack. Chromatin was washed once in a buer containing 
2 mM EDTA, 20 mM Tris pH 8.0, 1% Triton, 0.1% SDS, 150 mM NaCl, twice in a buer 
containing 2 mM EDTA, 20 mM Tris pH 8.0, 1% Triton, 0.1% SDS, 500 mM NaCl and twice 
in a buer containing 1 mM EDTA, 10 mM Tris pH8.0. ChIPped DNA was eluted using a 
buer consisting of 200 mM NaCl, 1%SDS, 20 mM Tris pH 8.0 by shaking at 65°C for one 
hour, followed by the addition of Proteinase K and shaking at 55°C for one hour, then 
shaking at 65°C for four hours. The DNA was puried using Qiagen Minelute columns 
according to the manufacturer’s instructions. Libraries were generated using Kapa Hyper 
prep kit (KAPA Biosystems) using 5 ng DNA according to the manufacturer’s instructions 
and size selected using Ampure XP beads (Beckman Coulter). DNA was quantied using 
Qubit HS and DNA fragment sizes were checked using Agilent Bioanalyzer HS. The DNA 
was sequenced on an Illumina NextSeq 500 using 42-bp paired-end sequencing. Next 
to the ChIPped material, DNA obtained from 2i, serum or 2i+serum ESC input chromatin 
(containing both mouse and Drosophila chromatin) was sequenced to correct for the 
relative ratio in the starting input chromatin for the spike-in ChIP-Seq and for background 
correction during peak calling.
Immuno­uorescence
Cells were xed in 4% paraformaldehyde and permeabilized with 0.2% Tween-20 and 
0.2% NP-40. Blocking of non-specic sites and incubation with primary and secondary 
antibodies was performed in permeabilization buer supplemented with 3% BSA. 
Primary antibodies used in this study are Rabbit anti H3K27me3 from Millipore (07-449; 
1:100), rabbit anti Suz12 from Abcam (Cat# 12073; 1:200) and rabbit anti-H3S10P from 
Abcam (Cat# 5819; 1:100). Secondary antibodies were goat anti-rabbit Alexa Fluor 488 
from Thermo (Cat# A11008; 1:1500). DAPI (Sigma, Cat# D9542) was added together with 
the secondary antibody incubation (1:500). Slides were mounted in Fluoromount G from 
eBioscience (#00-4958-02). Images were acquired using an Olympus FV1000 confocal 
microscope and processed with ImageJ.
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Inhibitor Treatment of ESCs
Treatment with GSK126 (Cayman Chemicals), a potent inhibitor of EZH2 methyltransferase 
function and EED226 (Selleckchem), an inhibitor that binds the EED WD-40 domain and 
thereby inhibits methyltransferase activity, was performed at a nal concentration of 10 
µM. The PRC2 inhibitors were refreshed every other day. Treatment with 5-azacytidine 
(Sigma) was performed for 6 days at a nal concentration of 1 µM. 5-aza was refreshed 
every day. All inhibitors were dissolved in DMSO and further diluted in PBS.
Histone extraction, propionylation, digestion and LC-MS
Nuclei were isolated from frozen cell pellets by resuspension in hypotonic lysis buer (10 
mM Tris-HCl pH 8.0, 1 mM KCl, 1.5 mM MgCl2), supplemented with 1 mM dithiothreitol 
(DTT) and complete protease inhibitors (Roche) at 5*106 cells per ml. The lysed cells were 
rotated for 30 minutes at 4˚C followed by centrifugation for 10 min at 16000 g. Nuclei 
were resuspended in 0.4N HCl at a cell density of 8*103 cells/µl. Samples were rotated for 
30 minutes at 4˚C and centrifuged (10 min, 16000 g). Histones were precipitated using 
trichloroacetic acid in Protein LoBind Eppendorf tubes. Histone extracts were dissolved 
in MS-grade mQ and stored at -80˚C until further use. For histone quantication and 
normalization, a fraction of each extract corresponding to 3.5*105 cells was loaded onto 
1D-PAGE with 1 µg bovine histone standard. 5 µg of each sample was vacuum dried and 
propionylated. Specically, histones were resuspended in 20 µl TEAB (1M), supplemented 
with 20µl propionylation reagent (isopropanol:propionic anhydride (158:2)) and 
incubated at room temperature for 30min. 20 µl mQ was added and the mixture 
was incubated for 30min at 37°C, followed by vacuum drying. For the tryptic digest, 
histones were resuspended in 50 µl 500 mM TEAB, 1 mM CaCl2, 5% ACN and trypsin 
was added at a 1:20 ratio followed by incubation overnight at 37°C. A second round of 
propionylation was performed like the rst round and over-propionylation was reversed 
by resuspending the vacuum dried sample in 50 µl 0.5 M NH2OH and 15 µl NH4OH at pH 
12 for 20 minutes at room temperature, after which 30 µl 100% formic acid was added. 9 
µl injection on-column contained 1.5 µg histones and 50 fmol beta galactosidase (Sciex) 
/ MPDS (Waters) internal digest standards in 0.1% FA. Quality control samples (QC) were 
performed using a mix of 5 µl of each sample. Peptides were separated using low pH 
reverse phase gradient on the NanoLC™ 425 system operating in micro§ow mode. A 
Triart C18 150 x 0.3mm column (YMC) was used at 5 µl/min §ow rate (0.1% FA with 3% 
DMSO) with a 60 min gradient from 3-55% ACN in 0.1% formic acid for a total run time 
of 75 minutes per sample. The sample list was randomized and interspersed with QC 
injections. Each cycle consisted in one full MS1 scan (m/z 400-1250) of 250 ms followed 
by MS2 data-dependent trigger events (m/z 65-2000, high sensitivity mode). A maximum 
of 10 candidate ions (charge state +2 to +5) exceeding 300 cps were monitored per cycle 
and excluded for 10s, with an accumulation time of 200 ms and using a rolling collision 
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energy (CE) with a spread of 15V. Cycle time was 2.3 s, in order to have 10 to 12 data points 
per LC peak.
Whole cell proteome measurements
Cell pellets were resuspended in RIPA buer supplemented with protease inhibitor at 
a density of 10.000 cells/µl and sonicated for 2 cycles (30 sec ON, 30 sec OFF) on a 
Biorupter (Diagenode) to lyse the cells. 10 µg of whole cell protein extract was denatured 
using Filter Aided Sample Preparation (FASP) and digested using Trypsin/LysC.
EED-GFP anity purication
Triplicate GFP pulldowns were performed as described in Kloet et al. 201679. In brief, per 
individual pulldown, 2 mg nuclear extract was incubated with 7.5 µl GFP Nano trap beads 
(Chromotek) and 50 µg / ml Ethidium Bromide in buer C (300 mM NaCl, 20 mM HEPES-
KOH pH 7.9, 20% (v/v) glycerol, 2 mM MgCl2 and 0.2 mM EDTA) supplemented with 0.1% 
NP-40, complete protease inhibitors (Roche), and 0.5 mM DTT in a total volume of 400 
µl. After incubation, beads were washed six times: First two washes with buer C with 
0.1% NP-40, next two washes with PBS 0.1% NP-40 and nally two washes with PBS. 
Non-GFP containing beads were used as control. A¦nity puried proteins were subjected 
to on-bead digestion. Beads were resuspended in 50 µl elution buer (2M Urea, 100 mM 
Tris pH 7.5 and 10 mM DTT) and incubated in a shaker, 20 min, room temperature (RT). 
After incubation, the supernatant was collected and iodoacetamide (IAA) was added to 
a nal concentration of 50 mM. Next, the beads were resuspended in 50 µl incubation 
buer supplemented with 50 mM IAA (without DTT) and incubated for 5 min at RT. 
Remaining proteins attached to the beads were partially digested by addition of 0.25 µg 
Trypsin (Promega) for 1hr at RT. The resulting supernatant was combined with the rst 
supernatant. 0.1 µg Trypsin was added to the solution and incubated overnight at RT. The 
next day, peptides was acidied using TFA and desalted using Stagetips183.
RT-qPCR
Total RNA was isolated using the RNeasy mini kit (Qiagen). cDNA synthesis was 
synthesized using random hexamers and RT-qPCR was performed using iQ SYBR Green 
Supermix (Bio-Rad) on a CFX96 Real-Time System C1000 Thermal Cycler (Bio-Rad). 
Primer sequences are present in Table S5.
Proteomics of Isolated Chromatin segments (PICh)
PICh was performed according to159. 5*108 cells were grown and crosslinked in 3% 
formaldehyde for 30 minutes. Nuclei were isolated using mechanical douncing in sucrose 
buer (0.3 M Sucrose, 10 mM HEPES-NaOH pH 7.9, 1% Triton X-100, 3 mM CaCl2, 2 mM 
MgOAc). Nuclei were digested o/n with RNase A (100 µg/ml) and sonicated in LB3JD 
buer (10 mM HEPES-NaOH pH 7.9, 100 mM NaCl, 2 mM EDTA pH 8, 1 mM EGTA pH 8, 
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0.2% SDS, 0.1% Sarkosyl, protease inhibitors) using a microtip sonicator (Misonix 4000) 
for total 7 minutes (15 sec ON, 45 sec OFF). After overnight preclearing with streptavidin 
beads (GE Healthcare), the chromatin was desalted using Sephacryl S-400-High 
Resolution beads according to the manufacturer’s guidelines (GE Healthcare). 0.5% SDS 
was added together with 0.5 µM LNA probes and probes were hybridized to the DNA at 
25°C for 3 min, 70°C for 9 min, 38°C for 60 min, 60°C for 2 min, 38°C for 60 min, 60°C for 2 
min, 38°C for 30 min, 25°C nal temperature. Biotin-LNA-DNA complexes were captured 
using MyONE C1 beads for 2 hrs at RT and eluted using 1ml elution buer (12.5 mM Biotin 
(Invitrogen), 7.5 mM HEPES-NaOH pH 7.9, 75 mM NaCl, 1.5 mM EDTA pH 8, 0.75 mM EGTA 
pH 8, 0.15% SDS, 0.075% Sarkosyl). The eluate was precipitated using trichloracetic acid 
and decrosslinked using 250 mM Tris pH 8.8, 2% SDS, 0.5 M 2-mercaptoethanol and 1 
X loading buer for 30 min at 95°C. Puried proteins were separated on SDS-PAGE and 
sliced into equal fractions. Proteins in each fraction were in-gel digested with Trypsin and 
subjected to LC-MS analysis.
Nuclear extraction and chromatin isolation
ESCs were harvested with trypsin, washed with PBS and pelleted at 400g for 5 min at 
4°C. Cell pellets were incubated for 10 min at 4°C in ve volumes of Buer A (10 mM 
HEPES-KOH pH 8.0, 1.5 mM MgCl2, 10 mM NaCl) and centrifuged at 400g for 5 min at 4°C. 
Cells were resuspended in two volumes of Buer A plus protease inhibitors (Roche) and 
0.15% NP-40 and transferred to a Dounce homogenizer. After douncing 30-40 strokes 
with a Type B pestle, the lysates were centrifuged at 3200g for 15 min at 4°C. After 
centrifugation, the supernatant was taken as the cytoplasmic extract. The nuclear pellet 
was washed twice with PBS and nuclei were pelleted at 3200g for 5 min at 4°C. The nuclear 
pellet was resuspended in 2 volumes Buer C (420 mM NaCl, 20 mM HEPES-KOH pH 8.0, 
20% v/v glycerol, 2 mM MgCl2, 0.2 mM EDTA, 0.1% NP-40) supplemented with protease 
inhibitors and 0.5 mM DTT. This solution was rotated for 1h at 4°C, and centrifuged at 
20800g for 45 min at 4°C. The supernatant was taken as the nuclear fraction and stored 
at -80°C until further use. For mass spectrometry of the chromatin fraction, the insoluble 
chromatin pellet was resuspended in four volumes of Radio Immunoprecipitation buer 
(RIPA) (150 mM NaCl, 1% NP-40, 0.5% NaDOC, 0.1% SDS, 50mM Tris pH 8) and brie§y 
sonicated to solubilize the chromatin fraction and stored at -80 ˚C until further use. For 
the generation of chromatin proteomes, 30 µg of chromatin extract was denatured using 
Filter Aided Sample Preparation (FASP) and digested using Trypsin/LysC.
Separation of euchromatin and heterochromatin using partial MNase digestion
Serum and 2i ESCs were grown to a density of 2 x 106 cells/ml, harvested by trypsinization 
and lysed in Nuclear Isolation Buer (15 mM Tris pH 7.5, 15 mM NaCl, 60 mM KCl, 5 mM 
MgCl2, 1 mM CaCl2, 250 mM sucrose, 5 mM natrium butyrate, Protease Inhibitor Cocktail) 
with 0.3% NP-40. Nuclei were pelleted by centrifugation at 600g for 5 minutes at 4°C. 
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After two washes with Nuclear Isolation Buer, the nuclei were resuspended at a density 
of 107 cells/ml in nuclear isolation buer. Following preincubation at 37°C for 10 min, 
nuclei were digested with MNase (New England Biolabs) for 5 min at 37°C. The amount 
of MNase was titrated to obtain optimal separation of mono-nucleosomes and poly-
nucleosomes (as displayed in Figure S3A). The reaction was terminated by addition of 1 
mM EGTA for 10 min on ice. The samples were centrifuged at 1000g for 5 min at 4°C and 
the resulting supernatant was taken as rst fraction (S1 = euchromatic fraction). The pellet 
was resuspended in 2 mM EDTA with PMSF for 10 min on ice and centrifuged at 12000g 
for 10 min at 4°C. The supernatant was taken as second fraction (S2 = heterochromatic 
fraction).
RNA-sequencing
Total RNA was isolated using a RNeasy mini kit (Invitrogen) according to manufacturer’s 
instructions with on-column DNAseI treatment. Ribosomal RNA was depleted using 
Ribo-Zero Gold rRNA Removal Kit (Illumina) according to manufacturer protocol starting 
from 5µg RNA. The resulting 180uL of rRNA-depleted RNA was puried by mixing 18 µl 
3 M Sodium Acetate and 2 µl of 20 mg/mL glycogen, then adding 3x volumes of ice-cold 
100% ethanol and incubation at -20°C for 1 hour. Samples were centrifuged at 10.000g 
for 30 minutes. After removal of supernatant, RNA pellet was washed in 500 µl ice-
cold 70% ethanol and centrifuged at 10.000g. Supernatant was removed and RNA was 
eluted in 40 µl nuclease free H2O. rRNA depleted RNA was fragmented to ~200 bp size 
using 10 µl of a 5x buer consisting of 200 mM Tris-acetate, 500 mM Potassium Acetate, 
150 mM Magnesium Acetate (pH 8.2) at 95°C for 200 seconds, then incubated on ice 
for 10 minutes before repeating the ethanol purication procedure. First strand cDNA 
synthesis was performed using SuperScript III Reverse Transcriptase (Life Technologies), 
puried using Qiaquick MinElute Column (Qiagen) followed by second strand synthesis 
using dUNTPs. Libraries were generated using Kapa Hyper Prep kit (KAPA Biosystems) 
according to manufacturer’s protocol with UNTP cleavage before amplication. Libraries 
were size selected using Agencourt Ampure XP beads (Beckman Coulter) and sequenced 
42bp paired-end on a NextSeq 500 (Illumina).
(Hydroxy)methylation measurements of genomic DNA
Genomic DNA was isolated using the Wizard genomic DNA isolation kit (Promega). Mass 
spectrometry analysis of the nucleosides was performed on genomic DNA digested using 
DNA Degradase Plus (Zymo Research). The individual nucleosides were measured using 
a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) 
system consisting of an Acquity UPLC (Waters, Milford, MA) containing a Waters Atlantis 
Hilic column (2.1 mm × 100 mm 3 µm) connected to a Micromass Quattro Premier XE 
(Waters). 
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Whole genome bisulte sequencing (WGBS)
Genomic DNA was extracted using the Wizard genomic DNA isolation kit (Promega). 
200 ng of puried genomic DNA was digested with Proteinase K before proceeding with 
sample processing for WGBS. Libraries for next-generation sequencing were prepared 
using the EpiGnome Methyl-Seq kit (Epicenter, EGMK81312) with the following critical 
steps: bisulte-converted genomic DNA was transcribed using tagged random hexamer 
primers, excess random hexamer primers were digested by the addition of Exonuclease I, 
terminal tagging was performed to extend the synthesized DNA strand on its 3′ side using 
elongation blocked and tagged random hexamers, and Illumina-compatible sequencing 
adapters were introduced through enrichment PCR using primers corresponding to the 
tagged sequences §anking the random hexamers. The nal library was puried twice 
using Agencourt AMPure XP beads (Beckman Coulter). Quality control for the nal 
library was performed by measuring the DNA concentration with the Qubit HS and by 
determining library fragment sizes. Sequencing was performed on Illumina HiSeq 2000 
and 2500 machines.
Mass spectrometry
Tryptic peptides were acidied and desalted using StageTips183 prior to mass spec 
analyses. Mass spectra were recorded on a LTQ-Orbitrap QExactive mass spectrometer 
(Thermo Fisher Scientic) or an Orbitrap Fusion Tribrid (Thermo Fisher Scientic) mass 
spectrometer using a 240-minute acetonitrile gradient.
Western blot
Whole cell extracts or histone acid extracts were denatured in 4x SDS loading dye and 
separated on a 12% SDS-PAGE gel. Separated proteins were transferred onto a PVDF 
membrane for staining with primary and secondary antibodies. A list of antibodies used 
in this study can be found in the Key Resources list. Protein bands were visualized using 
either Pierce Western Blotting Substrate (Thermo, #32209) or Amersham ECL Western 
Blotting Detection Reagent (GE Healthcare, #RPN2109), according to the manufacturer’s 
instructions. When dierent lanes on a western blot were stitched together for visual 
purposes, a line indicates where lanes were removed (as in Fig S4E). 
Quantication and statistical analysis
Analysis of spike-in ChIP-sequencing data
Bowtie2 v2.0.2 was used to map the data to a merged mm9 and dm3 genome. Mapped 
reads were indexed and sorted with Samtools. To allow for quantitative comparisons 
using the spike-in, the mapped data was split into les containing the species-specic 
reads. Drosophila and mouse reads were counted to determine the relative genomic 
occupancy of H3K27me3 and H3K36me3. In summary, after determining the species-
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specic read counts, we divided these to obtain the mouse / Drosophila ratio. Next, 
the mouse / Drosophila ratio of the ChIP-Seq samples was divided over the ratio of 
corresponding input samples which gives the percentage ChIP-Seq e¦ciency (the counts 
used in this manuscript are present in Table S3). The ChIP-Seq e¦ciency of 2i ESCs was 
divided over that of serum ESCs to obtain the normalization factor (1.55 in the case of 
H3K27me3). To generate the nal ChIP-Seq BAM les used for further analysis (counts 
are shown in Table S4), duplicate and low quality (mapq<30) reads were removed, after 
which we normalized the number of reads by down-sampling based on the spike-in 
normalization factor (for example: in case of H3K27me3, the serum ChIP-Seq proles 
were down-sampled).
For H3K27me3 peak calling, we used SICER which is specically designed for the 
detection of broad ChIP-Seq marks like H3K27me3. SICER was using the following 
settings: window size 200, gap size 600, E-value 0.00001, background correction using 
input and excluding signals from the Encode mm9 blacklist. Overlap of peaks between 
replicates/MACS2 was determined using Bedtools v2.20.1 (peaks showing  1bp overlap 
were considered common peaks). Replicate consistent peak calls (using an overlap 
of  1bp) were determined using Bedtools v2.20.1, after which peaks within 3kb were 
merged to obtain the nal peak set. For comparison between 2i and serum ESCs, peaks 
were divided in common peaks (showing  1bp overlap between 2i and serum ESCs) and 
2i-unique or serum-unique peaks. For comparison of peak calling algorithms, SICER peak 
calls were compared to MACS2 (used with the parameter –broad and a p-value cuto of 
0.01; Figure S3I). Tag counting and selection of random genomic regions was performed 
using Bedtools v2.20.1. Heatmaps and average proles were created using ngsplot v2.61. 
The reference-adjusted read counts per million mapped reads (“Reference adjusted 
RPM or in short RRPM”) are based on the samples with the highest chip e¦ciency. For 
the correlation plot of the change in H3K27me3 and CpG density, bins overlapping with 
either CpG islands (which are largely unmethylated in both 2i and serum ESCs) or peaks 
as present in serum ESCs were excluded from the analysis. For calculation of H3K27me3 
over dinucleotides outside peaks, random dinucleotides were selected from an mm9 
genome using bedtools random (setting: –seed 1). Dinucleotides overlapping with either 
CpG islands or peaks as present in serum ESCs were excluded from the analysis, similar to 
the correlation plot. Per dinucleotide context, H3K27me3 reads from 50000 random sites 
were counted. To plot average proles over random regions, 10k random sites of 20kb 
width each were selected using bedtools random. 
To determine the ratio of reads within peaks as compared to the reads outside peaks 
(Figure S3W), 5k random regions of 10kb width each were generated using bedtools 
random. Reads within the peaks and the random regions were counted using bedtools 
multicov, after which the ratio was determined. For the average proles of the peaks in 
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the embryo datasets, read normalization was performed between 2i ESCs and the in vivo 
ICM samples, as well as between serum ESCs and the in vivo E5.5 or E6.5 samples.
For 1kb binning approaches, the mm9 genome was extracted using mysql and binned 
using bedtools makewindows. Counting of H3K27me3 tags in these bins was performed 
using bedtools multicov. Dierential bins were determined using DESeq2 (p<0.01). Bins 
containing <20 reads on average per prole were removed. Density proles of H3K27me3 
reads within the 1kb bins were generated using R3.3.2 (ggplot2 package). 
RNA-seq analysis
Strand specic RNA-seq reads were aligned to the mm9 reference genome and indexed 
and sorted with Samtools. Gene quantication was performed using STAR v2.5.2b with 
parameters --quantMode GeneCounts --outSAMmapqUnique 255 --outSAMmultNmax 1 
--outFilterMismatchNoverLmax 0.05 --outFilterMatchNmin 16. Dierential genes were 
determined using DESeq2 (p<0.05).
Histone PTM analysis
To perform untargeted screening of all relevant hPTMs and overcome ambiguity of 
annotation, we performed data analysis using an established method described in184. 
Brie§y, raw data from all runs were imported and aligned in Progenesis QIP 3.0 (Nonlinear 
Dynamics, Waters) for feature detection. Feature detection was manually validated for 
all annotated histone features to resolve isobaric near-coelution. For identication, per 
feature three MSMS spectra closest to the elution apex were selected and exported for 
searches using Mascot (Matrix Science). To ensure untargeted screening, six searches were 
performed, each using six dierent PTM sets. The searched PTM sets were determined as 
follows: all selected MSMS spectra were merged in a single *.mgf le. A standard search 
without biological modications was performed using a complete mouse Swissprot 
database (downloaded from Uniprot on 01/17/17 and supplemented with contaminants 
from the cRAP database (http://www.thegpm.org/crap/)) to identify the proteins present 
in the sample (assuming at least a single non-modied peptide can be detected for each 
protein). From these proteins a FASTA database was generated and all curated PTMs were 
retrieved from SwissProt and the Cell Snapshot from10. For each feature, all candidate 
modied peptides in this database were determined based on their MS1 mass. Based 
on the frequency of each PTM (combination) with respect to the features and modied 
peptide candidates, the most abundant candidate sets of PTM combinations were 
selected sequentially. With the inclusion of more sequential searches, the percentage 
(comprehensiveness) of all considered modied peptide candidates increases. The six 
sequential searches performed here have a comprehensiveness of 68% of all possible 
explanations for the MS1 precursor masses found in the combined experiment. 
Searched PTMs included Acetylation (Ac), Crotonylation (Cr), Monomethylation (me1), 
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Dimethylation(me2), Trimethylation (me3), Citrullination(Ci), Phosphorylation (Ph), 
Formylation (Fo), ubiquitination (Ub), Sumoylation (Su) and Hydroxyisobutyrylation 
(Hib). Search one: K-Ac, K-Cr, K-Bu, K-Me2, R-Cit and S-Ph. Search two: K-Ac, K-Cr, K-Hib, 
K-Me3, R-Me and R-Me2. Search three: K-Ac, K-Fo, K-Me2, K-Su, R-Cit and T-Ph. Search 
four: K-Ac, K-Bu, K-Me3, R-Cit, R-Me2 and S-Ph. Search ve: K-Ac, K-Cr, K-Fo, K-Hib, 
K-Me2 and R-Cit. Search six: K-Hib, K-Me3, K-Ub, R-Cit, R-Me and S-Ac. Per search, the 
top 10 highest scoring (above-threshold) annotations per MSMS were reimported into 
Progenesis QIP. For each feature, all identications from all searches from all MSMS 
spectra were exported with Progesis' "Export all Identications" option. All annotations 
were analyzed using python to determine per individual modied peptide isoform if a) 
it is biologically modied, b) these biological modications are curated (i.e. are known 
to exist in curated literature/databases), c) this annotation was made on more than one 
MSMS spectrum (belonging to the same feature) and thus is reproducible. Finally, all 
labeled annotations were linked back to their respective features and classied based 
on their reproducibility and ambiguity (more than one curated annotation above score 
threshold) and in rare cases manually curated by an expert. Importantly, only previously 
reported PTMs were retained in this work§ow. Notably, modications on H3K4 could 
not be identied in our work§ow, as the peptide harboring any of these modications 
is very short (TKQTAR) and therefore ionizes ine¦ciently in the mass spectrometer. 
Percentages of individual PTMs were calculated by summing the intensity of the peptides 
containing the same modication and were normalized by dividing it by the sum of all 
the peptides containing that Lysine (K) or Arginine (R) Notably, single unmodied amino 
acid positions on the histone tails were not included in downstream analysis for the 
individual modications. These resulting numbers (the relative abundance) are plotted 
in Figure 1B. Signicantly dierent histone PTMs were determined using a t-test with 
Benjamini Hochberg correction (FDR<0.05) and an additional fold change cut-o of 1.5-
fold as determined using Perseus 1.5.0.0.
WGBS analysis
Unmethylated CG-rich DNA sequences were spiked in prior to sample prep to enable 
correction for bisulte conversion e¦ciencies. Sequence reads of the paired-end 
sequencing were mapped as mate-pairs by RMAPBS-PE. Reads mapping equally well on 
multiple positions on the genome were excluded from further analysis. Mates mapping 
within a maximum distance of 500 bp were merged and other reads were excluded 
from further analysis. If multiple mated reads mapped on exactly the same genomic 
coordinates (duplicates), all but one were discarded. Within a CpG context, symmetric 
cytosines on both forward and reverse strands were combined. Cytosine methylation 
level was called per individual C as #C/(#C + #T). For histograms, CpGs with a minimal 
coverage of 15 were used (as in Fig 5B). Screenshots were made using the R package 
Gviz for which CpGs with a minimal coverage of 4 were used. Smoothing was done 
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using a running median (as in Fig 5C). For average plots (Fig 5D, Fig S5D-E), weighted 
methylation means185 were calculated in non-overlapping 100 bp bins. These bins were 
grouped according to distance to the elements of interest, after which cross-group means 
were calculated. Annotation of genomic regions was done by overlapping these with 
all elements of interest (transcription start sites [-0.5 to +0.5 kb relative to TSS], exons, 
introns, intergenic regions), while distinguishing between inside and outside of CpG 
islands. A non-redundant set of overlaps was obtained using hierarchy among element 
types element types (i.e. TSSs > exons > introns > intergenic regions) (as in Fig S5B). For 
1kb binning approaches, the mm9 genome was extracted using mysql and binned using 
bedtools makewindows. DNA methylation counts (and corresponding H3K27me3 tags 
from the spike-in ChIP sequencing experiments) in bins were calculated using bedtools. 
For calculation of non-CpG methylation, a weighted methylation mean (see above) of 
all non-CpG cytosines was calculated for each context (CpA, CpC, CpT). Downstream 
analysis was performed using R3.3.2. 
LFQ protein identication and analysis
Thermo Raw MS les were analyzed using the MaxQuant software version 1.5.1.0 and 
searched against the curated UniProtKB mouse proteome using default MaxQuant 
settings including match between runs105,149. LFQ and IBAQ values were generated for 
all les. Identied proteins were searched against a decoy database from MaxQuant. 
Proteins §agged as ‘reverse’ or ‘contaminant’ were ltered from the nal protein list. 
Biological triplicates were grouped to calculate dierential proteins. Regarding the 
chromatin-associated proteomes: for comparison between wildtype samples, the 
protein list was ltered for proteins that were not reproducibly quantied in three 
replicates of either 2i or serum. For the comparison including Eed-/- cells, proteins that 
were detected in less than half of the datasets were excluded. Next, missing values 
were imputed from a normal distribution using the default settings (Width=0.3, Down 
shift=1.8). Dierential proteins between triplicates were calculated using a student’s 
t-test (p<0.05) and a fold-change of >1.5 fold, following previous recommendations186. An 
additional ltering was included for proteins annotated with GO terms for mitochondria, 
ribosomes and cytoskeleton, which were removed as these are known contaminants 
of chromatin-enrichment procedures86. For an overview of major protein complexes, 
individual complex members of complexes associated with OCT4 (hence potentially 
involved in pluripotency) were selected187. For data integration of the hPTMs and the 
chromatin proteome, writers and erasers were selected from the HIstome database 188. 
The reproducibly quantied epigenetic modiers and their target modication were 
integrated using Cytoscape version 2.8.2189. Volcano plots and downstream analysis of 
proteomics data was performed using Perseus106 and in-house R scripts.
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Analysis of DNA methylation mass spectrometry
Quantication was performed using area-based linear regression curves derived from 
calibration standards containing internal standard solutions corresponding to 0.025, 
0.05, 0.1, 0.2, 0.5, 1 and 2 µg of DNA. The 5mC and 5hmC levels were calculated as a 
concentration percentage ratio of % 5-methyl-2′-deoxycytidine/2′-deoxyguanosine 
(%mdC/dG) and % 5-hydroxymethyl-2′-deoxycytidine / 2′deoxyguanosine (%hmdC/dG), 
respectively. 
Analysis of EED-GFP anity purication mass spectrometry
Triplicate pulldowns were grouped in GFP and control and the protein list was ltered for 
proteins that were quantied in all replicates of at least one group. Missing values in the 
resulting dataset were imputed using Perseus 1.5.0.0 using default settings (Width=0.3, 
Down shift=1.8). Statistically enriched proteins in the GFP group were identied using 
a permutation-based false discovery rate (FDR)-corrected two-sided t-test. To calculate 
the stoichiometry, IBAQ values of the control (non-GFP beads) were subtracted from the 
IBAQ values in the pulldown samples. The resulting numbers were divided by the IBAQ 
value of the bait.
PICh analysis
PICh puried samples and input chromatin extracts corresponding to comparable 
amounts of input chromatin were analyzed in parallel using mass spectrometry. Thermo 
Raw MS les were analyzed using the MaxQuant software version 1.5.1.0 and searched 
against the curated UniProtKB mouse proteome using default MaxQuant settings 
including match between runs105,149. LFQ and IBAQ values were generated for all les. 
Proteins were considered enriched over input when the IBAQ values of PICH preparations 
were at least two-fold higher than in input material. Statistically dierentially enriched 
proteins between 2i and serum ESCs were determined using an intensity-dependent 
t-test using the Signicance B feature in Perseus 1.5.0.0.
Data and Software Availability
Data availability
The proteomics datasets are available from the ProteomeXchange Consortium via 
PRIDE submission with the dataset identier PXD007154. RNA-Sequencing and ChIP-
Sequencing datasets generated in this study have been submitted to the Gene Expression 
Omnibus (GEO accession code: SuperSeries GSE101675). 
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Published datasets used in this study
H3K27me3 ChIP-sequencing proles of in vivo developing embryos have been obtained 
from GEO: GSE GSE76687174 and GEO: GSE73952190. WGBS proles for serum and 2i 
wildtype ESCs were obtained from GEO: GSE4192333. 
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Figure S1 | Supplementary data complementing Figure 1. A) Representative sample 
validation of the 2i and serum ESC samples that were measured using (hPTM) mass 
spectrometry. Top: DNA (hydroxy)methylation levels are signicantly reduced in 2i ESCs. 
Bottom: RT-qPCR of genes known to be similar between 2i and serum ESCs (Oct4), higher 
in 2i ESCs (Nanog) or higher serum in serum ESCs (cMyc, Dnmt3a and Dnmt3b). B) Pearson 
correlation matrix of individual replicates of hPTM mass spectrometry runs. C) Heatmap for 
average values of hPTM combinations as detected by mass spectrometry. Colors represent 
log2 values of % of parent ion. Peptides not containing any modication were not included 
for the analysis in this clustering. Unmod indicates peptides that were modied on a 
single position. D) Top10 most abundant histone modications in serum ESCs, ranked as 
fold change 2i over serum. Numbers in column 2 and 3 represent percentages relative to 
all H3 and H4 modications that were identied. Colors indicate 1.5-fold higher in 2i ESCs 
(green) or in serum ESCs (blue). *=FDR<0.001. E) Western blot for H3K4me3 using GAPDH 
as loading control. Notably, H3K4me3 (a hPTM associated with active promoters) was not 
detected using mass spectrometry (see methods). F) Western blot for the PTM combination 
H3K9K14Ac. Numbers represent relative ratio compared to the H3 loading control with 
serum ESCs set at 1.00. G) Normalized abundance of several histone clipping events on the 
tail of H3 as identied by mass spec. p-values were calculated using a student’s t-test. Of 
note: the most studied clipping event cH3A21 is not included here, as this peptide is too 
short and cannot be identied using our mass spectrometry work§ow. H) DNA (hydroxy)
methylation levels of ESCs grown in the same conditions as shown in Figure 1E, as measured 
by mass spectrometry. 
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Figure S2 | Supplementary data complementing Figure 2. A) Western blot validation 
of cell fractions. Visualized proteins are mainly cytoplasmic (ACTB), Nuclear (TOPO I), 
both nuclear and chromatin-associated (HDAC2) and chromatin only (H3K9me3). CE = 
cytoplasm. NE = nuclear extract. CH = chromatin. B)  Representative GO terms associated 
with proteins identied in the chromatin-associated proteomes in 2i (light grey) and serum 
ESCs (dark grey). C) Circle chart of proteins that were called dierential in the chromatin 
proteomes of 2i and serum ESCs. The smaller circle indicates proteins also dierential (>2 
fold) in whole cell proteomes. D) Left: log2 LFQ values of chromatin-associated methyl-C 
and hydroxymethyl-C readers as identied in155. Right columns indicate log2 fold change 
of LFQ values in the chromatin-associated proteome or whole cell proteome. Grey = not 
detected. E) Subset of major epigenetic complexes and individual subunits, as detected in 
our chromatin proteome. Error bars represent SEM. Dashed lines represent 1.5-fold change. 
Asterisks indicate signicance based on a student’s t-test (p<0.05, FC>1.5). Catalytic subunits 
are shown in red. F) Schematic representation of PRC2.1 and PRC2.2. G) Log2 fold changes 
corresponding to the stoichiometric values in Figure 2H. Error bars represent SEM. 
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Figure S3 | Supplementary data complementing Figure 3. A) Agarose gel electrophoresis 
of titration of MNase units for partial digestion in 2i and serum ESCs. Red numbers 
indicate the optimal conditions used in Figure 3B (1000U/ml). NC = no MNase control. 
B) Left: Western blot of two independent MNase digestion experiments. Right: average 
of quantication of the Western blots. *=p<0.05 (two-way ANOVA with Bonferroni post-
testing). n.s. = not signicant. Error bars represent SEM. C) Fold change of PRC2 subunits 
based on mass spectrometry analysis of fraction S1 as in Figure 3C. D) Western blot analysis 
of core PRC2 subunits in fractions S1 and S2 from MNase experiments, as in Figure 3B. E) 
Immuno§uorescence for histone marks associated with pericentric heterochromatin in 2i and 
serum ESCs, as exemplied by specic enrichment over DAPI-dense regions (representing 
pericentric heterochromatin). Scale bar represents 5 µM. Boxplots represent quantication 
of the §uorescent signal at DAPI-dense regions relative to DAPI (n = at least 75 pericentric 
heterochromatin foci measured in 3 independent experiments). *indicates signicance 
(Mann Whitney U test, p<0.05). n.s. = not signicant. F) qPCR and RNA-seq identication of 
transcripts originating from the pericentric heterochromatin in 2i and serum ESCs. Error bars 
represent SEM. G) Scatter plots of log2 transformed H3K27me3 reads between replicates in 
common, 2i unique and serum unique peaks, showing high reproducibility. R values indicate 
Pearson correlation. H) Combined violin and boxplots of the H3K27me3 reads in the dierent 
peak sets. rep=replicate. I) (top) Overlap of H3K27me3 peaks between replicates as called 
using SICER; (middle and bottom) Overlap of H3K27me3 peaks called using SICER (used for 
the main paper) and MACS2. All overlaps are shown prior to merging of peaks (methods). 
Note that SICER is specically designed for the detection of broad ChIP-Seq marks like 
H3K27me3. Venn sizes are proportional to the number of peaks. J) Number of dierential 
peaks within the 2i and serum unique peak set used in the main manuscript (“Total”; blue) 
as determined using the Dibind R package (purple)191. This shows that the majority of 
dierential peaks as determined using SICER are also dierential using DiBind, validating 
our peak calling. K) The genome was divided into 1kb bins and the number of reads of the 
2i and serum H3K27me3 ChIP-Seq was determined for each bin. Dierential bins (p<0.01) as 
determined by DESeq2 were intersected with the 2i and serum unique peak set used in the 
main manuscript (“Total”; grey). Light blue bars indicate the number of peaks that contain 
at least one dierential 1kb bin within the peaks. This shows that the majority of dierential 
peaks as determined using SICER are also dierential using a combined 1kb-binning/DE-
Seq2 approach, further validating our peak calling. L) Average prole of H3K27me3 and 
H3K36me3 ChIP-Seq over 10.000 random genomic regions (excluding H3K27me3 and 
H3K36me3 peaks in 2i and serum ESCs). *=p<0.05 (Wilcoxon test). n.s.=not signicant. M) 
Representative genome browser view of the H3K27me3 ChIP-seq tracks and the relation 
to CpG density. N) Genome quantication of H3K27me3 ChIP-seq tags per DNA doublet 
outside H3K27me3 peaks. * indicates signicance (Kruskall Wallis test with Dunn’s posttest, 
p<0.05). Note that the dierences between doublets are partly masked by the resolution of 
ChIP-seq which comprises at least one nucleosome. O) H3K27me3 ChIP-seq reads on major 
satellites repeats after spike in normalization (two replicas per sample) *=p<0.05 (t-test)192. 
P) Average proles of H3K36me3 ChIP-seq at the H3K27me3 peaks as identied in Figure 3F. 
Q) Correlation of CpG methylation in 2i ESCs and CpG density. R) Pearson correlation matrix 
of H3K27me3 spike-in ChIP-seq in serum ESCs, 2i ESCs or ESCs grown in serum plus both 2i 
inhibitors (two replicas per sample) for 14 days. S) Representative genome browser view 
of the H3K27me3 ChIP-Seq tracks in the same samples as in (R). T) Heatmap of H3K27me3 
signal after spike-in normalization of the same samples as in (R). Categories as dened in 
Figure 3F / Figure 3G are shown. 
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U) Representative genome browser view of H3K27me3 proles in 2i and serum ESCs, the 
preimplantation inner cell mass (ICM174,190) and the postimplantation epiblast (E.5.5 and 
E6.5174). 2i ESCs and ICM samples both have high baseline levels of H3K27me3 and relatively 
low levels of H3K27me3 in peaks, whereas serum ESCs and postimplantation samples 
mainly contain high H3K27me3 signals in peaks. V) Average proles of H3K27me3 peaks of 
the samples in (U). 2i ESCs and ICM samples both have high baseline levels of H3K27me3 
and relatively low levels of H3K27me3 in peaks, whereas serum ESCs and postimplantation 
samples mainly contain high H3K27me3 signals in peaks. W) Quantication of H3K27me3 in 
peaks relative to baseline levels. Red dashed line indicates 1.5-fold over baseline levels. This 
gure further illustrates the relatively low levels of H3K27me3 in peaks in 2i ESCs and ICM 
samples as compared to serum ESCs and postimplantation samples. X) The genome was 
divided into 1kb bins and the number of H3K27me3 reads of the H3K27me3 ChIP-Seq proles 
were determined for each bin. The graphs represent a kernel density estimate of the number 
of bins relative to the H3K27me3 signal. The shift in the mean of the distribution illustrates a 
global increase of H3K27me3 at baseline levels in 2i ESCs and preimplantation embryos (ICM) 
as compared to serum ESCs and postimplantation embryos (E6.5), respectively. As compared 
to 2i ESCs and preimplantation embryos (ICM), serum ESCs and postimplantation embryos 
(E6.5) contain a substantial number of bins with relatively high H3K27me3 signal (located 
right of the red line and representing peaks for these proles). The dierent distribution 
between 2i and serum as well as between ICM and E6.5 is statistically signicant (Wilcoxon 
test, p<0.0001). 
Figure S4 | Supplementary data complementing Figure 4. A) Gene expression values 
(TPM) for pluripotency and stem cell maintenance genes in 2i, Eed-/- 2i and serum ESCs. B) 
qPCR validation of a subset of genes as shown in panel (A). Error bars represent SEM.  C) 
Morphology of wildtype 2i and Eed-/- 2i ESCs. D) Pearson correlation matrix of hPTMs of 
individual measurements in wildtype serum and 2i ESCs and Eed-/- 2i ESCs. E) Western blot 
analysis of PRC2-deposited histone modications. The grey line indicates that lanes on this 
western blot were removed for visual purposes. F) GO terms related to genes upregulated 
in Eed-/- 2i ESCs compared to wildtype 2i ESCs. Numbers in brackets indicate the number of 
genes per GO term. G) Western blot analysis of histone modications in 2i ESCs before or 
after 3-day treatment with PRC2-inhibitor EED226. Quantication represents fold change 
normalized to H3 loading. Error bars represent SEM of 3 biological replicates. *=p<0.05 
(student’s t-test). H) Log2 fold change of PRC2 subunits of Eed-/- 2i ESCs compared to wt 
2i ESCs on the chromatin. Orange indicates core subunits, blue indicates substoichiometric 
subunits. Error bars represent SEM. *=p<0.05. I) Gene expression values (TPM) of DNA 
methylation-associated genes. J) Western blot analysis of DNMT3A and EED. GAPDH was 
used as loading control. 
533641-L-bw-Mierlo
Processed on: 23-7-2019 PDF page: 101
4
EE
D
EZ
H
1
EZ
H
2
SU
Z1
2
M
TF
2
JA
R
ID
2
A
EB
P2
EP
O
P
+E
E
D
22
6
co
nt
ro
l
Chapter 4
101
A
E
Figure S4
noitalerr o
C 0.8
0.9
1
Eed-/- 2i wt 2i wt serum
E
ed
E
ed
-
E
ed
-
E
ed
//-/--/-/
2i2i
w
t 2
i
w
t 2
i
w
t s
er
um
w
t s
er
um
wt 2i Eed-/- 2i
B
Eed-/- 2iwt 2i wt serum
0.01 0.1 1 10 100 1000
Prdm14
Spi1
Fgf10
Bmp7
Tert
Dazl
Kit
Tcl1a
0.01 0.1 1 10 100 1000 10000
Myc
Mycn
Id1
Id2
Eras
Sox4
Sall4
Lin28a
Lin28b
Crebbp
Dppa2
Wnt7a
Utf1
Pluripotency Stem cell maintenance
higher 2i
Stem cell maintenance
higher serum
C
0.01
0.1
1
10
Sox2 Oct4 Prdm14Nanog cMyc Fgf10
%
 A
ct
in
F
D
0 1 2 3 4
animal organ development (46)
neurogenesis (25)
nervous system development (31)
cell morphogenesis (20)
axon guidance (7)
-log10 (p-value)
TPM
TPM
TPM
1 10 100 1000 10000
Nanog
Oct4
Sox2
Esrrb
Klf4
Tbx3
Tcfcp2l1
Klf2
Stat3
Gbx2
Sall4
Tcf3
Klf5
Nr0b1
Mbd3
Chd4
Zfp42
17 -
(kDa)
17 -
17 -
17 -
H3K27me1
H3K27me3 
H3
H3K27me2
w
t 2
i
E
ed
-/-
 2
i 
E
ed
-/-
 2
i 
E
ed
w
t s
er
um
EE
D
EZ
H
1
EZ
H
2
SU
Z1
2
M
TF
2
JA
R
ID
2
A
EB
P2
EP
O
P
-10
-8
-6
-4
-2
0
lolol
g2
(E
ed
-
(E
ed
-
(
/
E
ed
-/
E
ed
--/-/
/w
t)t)t
H I
*
* *
* * * * *
J
TP
M
1
10
100
1000
Dnmt1 Dnmt3a Dnmt3b Dnmt3l Uhrf1 Tet1 Tet2 Tet3
wt 2i
wt serum
Eed-/- 2i w
t 2
i
w
t s
er
um
E
ed
-/-
 2
i
E
ed
-/-
 2
i
E
ed
36 -
100 -
70 -
50 -
- GAPDH
- DNMT3A
- EED
(kDa)
Total cell
G
H3
GAPDH
H3K27Ac
H3K27me3
H4K16Ac
H4K8Ac
35 -
17 -
17 -
(kDa)
12 -
12 -
17 -
H3K79me217 -
+E
E
D
22
6
co
nt
ro
l
control
EED226
Quantification
0.0 1.0 2.0
Fold over control
*
*
*
*
*
533641-L-bw-Mierlo
Processed on: 23-7-2019 PDF page: 102
2i CGI
2i nonCGI
up down
2i hypermethylated regions
Eed-/- 2i rep2 Suz12-/- 2i rep1 Suz12-/- 2i rep2Eed-/- 2i rep1
Serum rep1 Serum rep2 2i rep1 2i rep2
intergenic
enhancers
genebodies
promoters
PRC2-dependent crosstalk in ground state pluripotency
102
K
D
M
S
O
G
S
K
12
6
D
M
S
O
G
S
K
12
6
H3K27me317 -
(kDa)
12 - Histone H4
M
1
10
100
1000
Fkbp6 Dazl Dpep3 Rhox13
wt 2i
wt 2i +Aza
Eed-/-2i
Eed-/-2i + aza
TP
M
JI
w
t 2
i
w
t 2
i +
 A
za
E
ed
-/-
 2
i
E
ed
-/-
 2
i
E
ed
E
ed
-/-
 2
i +
 A
za
E
ed
-/-
 2
i +
 A
za
E
ed
0.01
0.1
1
10
100
1000 *
n.s.
n.s. *
TP
M
(lo
g1
0
sc
al
e)
1 10 100 1000 10000
0.01 0.1 1 10 100 1000
0.01 0.1 1 10 100 1000
Myc
Mycn
Id1
Id2
Eras
Sox4
Sall4
Lin28a
Lin28b
Crebbp
Dppa2
Wnt7a
Utf1
Prdm14
Spi1
Fgf10
Bmp7
Tert
Dazl
Kit
Tcl1a
Esrrb
Klf2
Klf4
Nanog
Pou5f1
Tbx3
Tfcp2l1
Stat3
Gbx2
Sall4
Tcf3
Sox2
Klf5
Nr0b1
Mbd3
Chd4
Zfp42
wt 2i
wt 2i + aza
Eed-/- 2i
Eed-/- 2i + aza
TPM
TPM
TPM
0.00
0.25
0.50
0.75
1.00
S
er
um 2
i
E
ed
-/-
 2
i
E
ed
-/-
 2
i
E
ed
S
uz
12
-/-
 2
i
C
pG
 m
et
hy
la
tio
n
le
ve
l
I
F
0.00
0.25
0.50
0.75
H3K27me3 tags / kb in wt 2i
C
pG
 m
et
hy
la
tio
n
le
ve
0
(1
69
77
)
1-
5
(1
25
59
2)
5-
10
(3
15
57
7)
l1
0-
15
(4
05
56
9)
15
-2
0
(2
88
10
6)
20
-2
5
(1
55
13
6)
25
-3
0
(7
46
71
)
30
-5
0
(6
29
30
)
>5
0
(3
77
6)
A B
C ED
0 1
0
wildtype 2i
EeEeE
d-d-d
/-
2i
1
wildtype 2i
w
t s
er
um
0 1
0
1
wildtype 2i
se
ru
m
 to
 2
i (
p3
)
0 1
0
1
serum to 2i (p3)
EeEeE
d-d-d
/-
2i
0 1
0
1
Whole genometop 2.5k Eed-/- vs wt 2i
TSS
TSS CGI
exons
exons CGI
intergenic
intergenic CG
introns
introns CGI
1% 0.7%
7.3%
28%
62.8%
1.00
el
wt 2i Eed-/- 2i
0
0.05
0.10 CpG density
Figure S5
0.0
0.2
0.4
0.6
0.8
distance to center
−5
 k
b
−2
.5
 k
b 0
2.
5 
kb
5 
kb
0.0
0.2
0.4
0.6
0.8
C
pG
 m
et
hy
la
tio
n 
le
ve
l
C
pG
 m
et
hy
la
tio
n 
le
ve
l
H
2i Serum
distance to the center
C
pG
 m
et
hy
la
tio
n 
le
ve
l
C
pG
 m
et
hy
la
tio
n 
le
ve
l
Serum rep1
Serum rep2
2i rep1
2i rep2
Eed-/- 2i rep1
Eed-/- 2i rep2
-1
5 
kb
−1
0 
kb
−5
kb
5 
kb
10
 k
b
15
 k
b
0.0
0.2
0.4
0.6
0.8
1%
8%
61%
30%
d0 d2 d5 d8 d11
0
50
100
150
wt 2i
wt serum
TKO 2i
TKO serum
Time (days)
pr
ol
ife
ra
tio
n
(%
of
DM
SO
)
H3K27me3
Histone H3
17 -
17 -
D
M
S
O
G
S
K
12
6
D
M
S
O
G
S
K
12
6
(kDa)
TKO 2i TKO Serum
0
1
2
3
4 5mC
0
0.1
w
t 2
i
w
t 2
i
TK
O
 
K
O
 2
i
w
t s
er
um
w
t s
er
um
TK
O
 s
er
um
se
ru
m
5hmC
TK
O
 s
er
um
se
ru
m
+ 
G
S
K
12
6
+ 
G
S
K
12
6
%
 5
m
C
%
 5
hm
C
L
G
To
ta
lD
N
A 
m
et
hy
la
tio
n
CpA
CpC
CpT
D
N
A 
m
et
hy
la
tio
n 
pe
r e
le
m
en
t
D
N
A 
m
et
hy
la
tio
n 
pe
r e
le
m
en
t
D
N
A
0.000
0.010
0.020
0.000
0.010
0.020
S
er
um
 re
p1
S
er
um
 re
p2
2i
 re
p1
2i
 re
p2
E
ed
-/-
 2
i r
ep
1
E
ed
-/-
 2
i r
ep
1
E
ed
-/-
E
ed
-/-
 2
i r
ep
2
E
ed
-/-
 2
i r
ep
2
E
ed
-/-
S
uz
12
-/-
 2
i r
ep
1
S
uz
12
-/-
 2
i r
ep
1
S
uz
12
-/-
S
uz
12
-/-
 2
i r
ep
2
S
uz
12
-/-
 2
i r
ep
2
S
uz
12
-/-
0.00
0.02
0.04
0.06
0.08
0.00
0.02
0.04
0.06
0.08
S
er
um
 re
p1
S
er
um
 re
p2
2i
 re
p1
2i
 re
p2
E
ed
-/-
 2
i r
ep
1
E
ed
-/-
 2
i r
ep
1
E
ed
-/-
E
ed
-/-
 2
i r
ep
2
S
uz
12
-/-
 2
i r
ep
1
S
uz
12
-/-
 2
i r
ep
1
S
uz
12
-/-
S
uz
12
-/-
 2
i r
ep
2
S
uz
12
-/-
 2
i r
ep
2
S
uz
12
-/-
533641-L-bw-Mierlo
Processed on: 23-7-2019 PDF page: 103
Chapter 4
103
4
Figure S5 | Supplementary data complementing Figure 5. A) Smoothed scatter plot for 
average CpG methylation in 1kb bins for ESCs grown in various conditions. Serum to 2i (p3) 
indicates serum ESCs adapted to 2i culture for 3 passages (7 days). Interestingly, Eed-/- 2i 
ESCs resemble serum ESCs that are halfway through adaptation to 2i (bottom right panel). 
Full conversion of a serum ESC methylome to a 2i ESC methylome takes 14 days of culturing 
serum ESCs in 2i culture media33. B) Genomic annotation of top 2500 1kb bins with the 
highest gain of DNA methylation in Eed-/- 2i ESCs relative to 2i ESCs (left) as compared to 
the total genomic distribution of 1kb bins (right). C) DNA methylation (1kb bins) sorted by 
the H3K27me3 ChIP-seq signal in wt 2i ESCs. Grey boxplot in the top panel presents CpG 
density in the same categories. Numbers between brackets indicate the number of bins 
per category. Notably, the far-right category (highest level of H3K27me3) mainly consist of 
H3K27me3 peaks in 2i ESCs. A subset of these peaks is associated with CGIs and therefore are 
hypomethylated in all conditions, while the H3K27me3 peaks that are not associated with 
CGIs show dynamics similar to the remainder of the genome (Figure S5E), explaining the CpG 
methylation values and boxplots in this category. D) CpG methylation over regions that are 
hypermethylated in 2i ESCs (average CpG methylation level of 0.63) as determined in Habibi 
et al.33. E) CpG methylation over regions containing H3K27me3 peaks in wt 2i ESCs (Figure 
3F, 3G), subdivided over CGI (2418 peaks) and non-CGI containing peaks (6163 peaks). F) 
Distribution of 5mC levels in CpG sequence context by WGBS as in Figure 5A, including Suz12-
/- 2i ESCs. The boxplot layout is according to the Tukey ve-number summary (horizontal 
line within the box represents median). G) (top) Total DNA methylation levels in non-CpG 
context. (bottom) Presence of non-CpG methylation over various genomic elements. H) 
Gene expression values (TPM) of genes that are known to be upregulated upon treatment 
with 5-azacytidine. I) Boxplot of gene expression values of genes upregulated after 5-aza 
treatment of Eed-/- 2i ESCs. *=p<0.05 (Kruskal-Wallis test). n.s. = not signicant. J) Gene 
expression values (TPM) for pluripotency and stem cell maintenance genes (as in Figure 
S4A). K) Western blot after treatment of various ESC lines with GSK126 for 14 days. DMSO 
was included as a carrier control. L) DNA (hydroxy)methylation levels as determined using 
mass spectrometry showing the absence of 5(h)mC in DNMT TKO ESCs. Error bars represent 
SEM. M) Growth curve of wildtype and Dnmt TKO 2i and serum ESCs during treatment with 
GSK126 for the indicated time frame. Cell proliferation is expressed as percentage of control 
(DMSO treated) cells.
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Supplementary Tables
Table S3 | Spike-in ChIP e¨ciencies relative to H2Av Drosophila spike-in and 
normalized to input, related to Figure 3 and S3
Table S4 | Tag counts (in +/- 1kb from the center of the peaks) in the various categories 
of H3K27me3 peaks, related to Figure 3
Sample H2Av reads H3K27me3  
reads
H3K27me3 /  
H2Av
% ChIP e¨ciency over 
H2Av chip (relative to in-
put which is set at 100%)
2i ESCs
2i H3K27me3 rep1 983923 44778848 45.51 6.27
2i H3K27me3 rep2 1032044 48694916 47.18 6.50
2i H3K36me3 496682 24711461 49.75 6.86
2i input 81074 58831043 725.65 100.00
2i+serum ESCs
2i + serum 
H3K27me3 rep1
468838 27255510 58.13 5.53
2i + serum 
H3K27me3 rep2
518278 25901032 49.98 4.76
2i + serum input 17886 18794447 1050.79 100.00
Serum ESCs
Serum H3K27me3 
rep1
1334064 55227559 41.4 4.12
Serum H3K27me3 
rep2
1197378 50145534 41.88 4.16
Serum H3K36me3 437760 25997618 59.39 5.90
Serum input 62061 62436932 1006.06 100.00
Counts in peaks 2i ESC_rep1 2i ESC_rep2 Serum ESC_rep1 Serum ESC_rep2
2i and serum common 
peaks
124173 114780 139195 138418
Serum peaks 133855 128251 173777 173528
2i peaks 166860 162481 62704 63550
Total counts in peaks 424888 405512 375676 375496
Normalized total reads 
based on spike-in
30501427 31618613 20009199 20248980
% of tags present in peaks 
in 2i 
ESCs as compared to serum 
ESCs
Rep1
113
Rep2 
108
Average 
Rep1/Rep2 
111
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Table S5 | Primer sequences used in this study, related to STAR methods.
Gene Sequence
Nanog FW AGCAGAAGATGCGGACTGTGTT
Nanog RV CCTTGAGTGCACACAGCTGG
cMyc FW CCCCAAGGTAGTGATCCTCA
cMyc RV TCGTCTGCTTGAATGGACAG
Sox2 FW GACCGTTTTCGTGGTCTTGT
Sox2 RV ACGATATCAACCTGCATGGAC
Dnmt3a FW ACCAGGCCACCTACAACAAG
Dnmt3a RV TGCTTGTTCTGCACTTCCAC
Dnmt3b FW GCGTCAGTACCCCATCAGTT
Dnmt3b RV TGTGCTGTCTCCATCTCTGC
Gapdh FW TTCACCACCATGGAGAAGGC
Gapdh RV CCCTTTTGGCTCCACCCT
Oct4 FW TTGAGAACCGTGTGAGGTGG
Oct4 RV TCGGGCACTTCAGAAACATG
Prdm14 FW CAGCCAAGCAATTTGCACTA
Prdm14 RV ACCTGGCATTTTCATTGCTC
Fgf10 FW GTCACAATGGCAAATGATGC
Fgf10 RV GGATTCTGTGGGCCTTACAA
MajSat FW GACGACTTGAAAAATGACGAAATC
MajSat RV CATATTCCAGGTCCTTCAGTGTGC
b-actin FW AGTGTGACGTTGACATCCGT
b-actin RV TGCTAGGAGCCAGAGCAGTA
533641-L-bw-Mierlo
Processed on: 23-7-2019 PDF page: 106
533641-L-bw-Mierlo
Processed on: 23-7-2019 PDF page: 107
5
Chapter 5
Cooperative recruitment and 
interactions of PRC2 
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Abstract
The Polycomb Repressive Complex 2 (PRC2) and its catalytic repressive histone mark 
H3K27me3 are essential for mammalian development. The core PRC2 complex consists of 
EED, EZH2 and SUZ12 and it is often associated with accessory subunits, resulting in two 
main sub-complexes PRC2.1 and PRC2.2. MTF2 (in PRC2.1) and JARID2 (in PRC2.2) were 
shown to recruit PRC2 to target genes in ESCs. Currently, it remains unclear if and how 
these sub-complexes cooperate. Here, we combine a range of Polycomb mutant ESCs 
with chemical inhibition of PRC2 catalytic activity and ChIP-Seq to address the complex 
interactions of the Polycomb system. Our results uncover that PRC2.1 and PRC2.2 are 
mutually dependent on each other for recruitment. In addition, the EED-H3K27me3 
interaction is important for recruitment of both PRC2 sub-complexes and in part conveys 
their interdependence, but it is not the sole mediator. Strikingly, removal of either JARID2 
or H3K27me3 only has a minor eect on PRC2 recruitment, while their combined ablation 
largely attenuates PRC2 recruitment, suggesting redundancy between JARID2 and EED-
H3K27me3 mediated recruitment of PRC2. Finally, we demonstrate that all core PRC2 
recruitment occurs through the combined action of MTF2, the EED-H3K27me3 interaction 
and PRC1-mediated recruitment of JARID2-containing PRC2.2. The data presented here 
demonstrate interactions between PRC2 sub-complexes which are important to establish 
PRC2 at target sites. 
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Introduction
Cell fate specication during embryonic development requires tightly controlled 
epigenetic programs. A key component safeguarding these processes is Polycomb 
Repressive Complex 2 (PRC2) that catalyses the histone modication H3K27me3, playing 
an essential role in the establishment of cellular identity by ensuring proper gene 
silencing193. The critical role of PRC2 during developmental processes is underscored 
by the embryonic lethality observed in mice lacking a functional PRC2 complex175,181,194. 
PRC2 consists of the core subunits EED, SUZ12 and the catalytic subunit EZH2. Next to 
these core subunits, PRC2 contains multiple ancillary subunits exerting functions such 
as guiding PRC2 to target genes and modulation of its enzymatic activity. These include 
PCL proteins (PHF1, MTF2 and PHF19), EPOP and GM340 (also called C10ORF12), which 
together with the core subunits comprise PRC2.1, and JARID2 and AEBP2, which are part 
of PRC2.2195. 
Within Embryonic Stem Cells (ESCs), a key model to study Polycomb biology, PRC2 core 
is mainly associated with MTF2 and EPOP, or AEBP2 and JARID2, whereas alternative 
PRC2.1 complexes containing PHF1, PHF19 and/or GM340 are very lowly abundant, 
due to the low expression of these subunits. Intriguingly, exit of the pluripotent state 
is accompanied by rapid downregulation of MTF2 and EPOP, and an upregulation of 
PHF1, PHF19 and GM340, suggesting that these factors are mainly important for lineage 
specication or during dissolution of the pluripotent state79,196. In recent years, our 
understanding of Polycomb regulation in terms of recruitment and enzymatic activity 
has signicantly increased. In ESCs, it has been shown that both MTF2 and JARID2 are 
important for PRC2 recruitment, whereas ablation of either AEBP2 or EPOP does not aect 
PRC2 localization156,157,197–201. Another important player in the recruitment of PRC2 is PRC1, 
which binds to non-methylated DNA via its subunit KDM2B. PRC1 deposits H2AK119ub 
which can be bound by JARID2, resulting in PRC2 recruitment202–204. Furthermore, after 
establishment of primary PRC2 recruitment, the complex can self-reinforce and spread 
from its target sites through an allosteric feedforward loop by binding of EED WD40 
domain to the PRC2 catalytic product, H3K27me3205,206. Interestingly, this mechanism is 
not su¦cient for H3K27me3 maintenance207, indicating the constant requirement of de 
novo recruitment of core PRC2 by its ancillary subunits, which likely includes MTF2 and/or 
JARID2. Conversely, the H3K27me3 mark can also be bound by canonical PRC1 complexes 
via the CBX7 subunit208 resulting in PRC2-mediated PRC1 recruitment and H2AK119ub 
deposition. Thus, while PRC1 and PRC2 can be recruited independently, they mutually 
enhance the recruitment of one another. Finally, both PRC1 and PRC2 recruitment can be 
ne-tuned by long non-coding RNAs, as well as through promiscuous binding to nascent 
RNA209–211. 
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As MTF2 and JARID2 together mediate primary PRC2 recruitment in ESCs, ESCs lacking 
either or both MTF2 and JARID2 show severe PRC2 recruitment phenotypes212. This 
depends to a large extent on MTF2-mediated DNA binding with a relatively minor 
contribution of JARID2157,158,198. Interestingly, PRC2 recruitment is partially retained in both 
Mtf2 and Jarid2 mutant ESCs. As MTF2 and JARID2 are mutually exclusive in the PRC2 
complex, this suggests that PRC2.1 and PRC2.2 synergize in establishing Polycomb at 
target genes213, but how such a synergy would materialize currently eludes explanation. 
To investigate the interactions between PRC2.1 and PRC2.2, we combine a range of 
Polycomb mutant ESCs with chemical inhibition of PRC1 and PRC2 catalytic activity to 
address the complex interactions of the Polycomb system using ChIP-sequencing. We 
demonstrate the individual attribution of primary recruitment mechanisms established 
by JARID2, MTF2 and H3K27me3. Our data strongly implicates that PRC2.1 and PRC2.2 
act synergistically for PRC2 recruitment, which is in part mediated through H3K27me3. 
Furthermore, our data reveals a redundancy between JARID2-mediated recruitment and 
recruitment via the H3K27me3-EED axis. Finally, we show that core PRC2 recruitment 
requires the concerted action of MTF2 and JARID2, as well as EED binding to H3K27me3. 
These data indicate that PRC2 recruitment can be divided into two major axes, of which 
one relies more on MTF2-mediated DNA binding, and the other to a larger extent on 
JARID2-H3K27me3-PRC1 mediated recruitment. Moreover, these dierent recruitment 
axes seem to be dierentially balanced at dierent sets of target sites. The data presented 
here demonstrate interactions between PRC2 sub-complexes and highlight that these 
interactions are important to establish PRC2 at target sites. 
Results
PRC2 recruitment mainly depends on MTF2
Recent advances have pinpointed three main recruitment mechanisms of PRC2: I) 
DNA-mediated recruitment via MTF2, II) recruitment via JARID2, and III) H3K27me3-
mediated recruitment via EED (Fig 1A)157,158,204,205,212,214. Currently, it remains 
unclear if and how these dierent recruiters cooperate in establishing PRC2 at target 
genes. To investigate this, we rst evaluated whether these mechanisms act at the same 
genomic sites by performing chromatin immunoprecipitation followed by massive 
parallel sequencing (ChIP-seq) using antibodies against endogenous EZH2, H3K27me3, 
MTF2 and JARID2. We performed peak calling for EZH2 and determined the occupancy of 
H3K27me3, MTF2 and JARID2 on these peak sites, which revealed a near-perfect overlap 
(Fig 1B). The same scenario was evident for peaks called for H3K27me3 or MTF2 (Fig 
S1A-B). By contrast, we observed a large number of sharp JARID2 peaks with little or 
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no occupancy of the other PRC2 subunits (Fig S1C; cluster 3). This could indicate that 
JARID2 exerts functions independent of the PRC2 complex as previously suggested in 
Drosophila215, but, as these sites do not overlap with other PRC2 subunits, they were 
excluded from further analysis, and only peaks overlapping H3K27me3 regions (Fig S1D, 
S1E) were used for subsequent analysis. 
Knowing that EZH2, H3K27me3, JARID2 and MTF2 largely co-localize on the genome, 
we aimed to understand how these factors are involved in recruitment of PRC2. First, 
we focused on MTF2 and JARID2 and used knockout ESCs for these subunits (Mtf2GT/GT 
and Jarid2-/-, respectively). These ESCs lack MTF2 or JARID2, respectively, but globally 
retain wildtype levels of core PRC2 subunits (Fig S1F). ChIP-sequencing revealed a 
major reduction for EZH2 and H3K27me3 at target sites in MTF2 mutants, whereas the 
reduction in Jarid2-/- ESCs is minor (Fig 1C,1D). These observations are in line with previous 
reports attributing a prime role for MTF2 in PRC2 recruitment157,158,212. To investigate 
whether PRC2.1 and PRC2.2 mediate recruitment of each other, we proled the genomic 
locations bound by MTF2 and JARID2 in the knockout cells, which revealed that MTF2 
and JARID2 mutually aect their recruitment, with the most profound eect of MTF2 
knockout on JARID2 recruitment (Fig 1E, 1F). This suggests that the PRC2 sub-complexes 
directly or indirectly modulate their mutual recruitment. Next, to investigate the role of 
the allosteric EED feedforward loop, we extended our analysis to wildtype ESCs treated 
with EED226. By binding the EED WD40 domain, EED226 hampers the binding of EED 
to H3K27me3 while simultaneously inducing a conformational change that impedes 
stimulation of the EZH2 catalytic activity by EED216. Importantly, EED226 does not disturb 
physical associations between core PRC2 subunits216. After conrming the complete 
absence of H3K27me3 in EED226-treated ES cells (Fig S1G), we performed ChIP-seq for 
EZH2, MTF2 and JARID2. This revealed that in the absence of H3K27me3, EZH2 and MTF2 
were retained on target sites at near-control levels (Fig 1c,e). JARID2 binding, instead, is 
>50% reduced by EED226 treatment (Fig 1F), suggesting JARID2 recruitment to target 
sites partly relies on H3K27me3. Typical examples of these observations above are 
visualized in Fig 1g. Also, we conrmed the most relevant observations by ChIP-qPCR (Fig 
S2). Taken together, these analyses are in line with previous observations that primary 
PRC2 recruitment in the absence of H3K27me3 occurs largely through MTF2157,158. 
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Figure 1 | PRC2.1 and PRC2.2 binding and interdependency. A) Schematic representation 
of the recruitment of PRC2.1 and PRC2.2. MTF2 binds to DNA and the EED subunit of core 
PRC2 (orange) binds to H3K27me3 as part of an allosteric feedback loop. The EZH2 subunit of 
core PRC2 catalyzes H3K27 methylation. The PRC2.2 complex contains JARID2 but not MTF2. 
Both  contain the core PRC2 subunits, however the interactions of the PRC2.1 and PRC2.2-
specic subunits with chromatin are dierent. The arrow from JARID2 to DNA is dashed as 
DNA binding has been shown in vitro but not in vivo217 B) PRC2.1 (MTF2) and PRC2.2 ( JARID2) 
co-localize to all EZH2 targets. C-F) Heatmap and  rpkm quantication (boxplots) of PRC2 
subunits and the catalytic product H3K27me3. EZH2 recruitment is heavily aected by the 
absence of MTF2, while JARID2 and H3K27me3 absence have minor eects (C). The eect 
of MTF2 and JARID2 on EZH2 recruitment is re§ected on H3K27me3 deposition. D) MTF2 
is marginally aected by H3K27me3 removal, but its binding is reduced to approximately 
half the WT level in the absence of JARID2 (E). JARID2 recruitment is strongly reduced in the 
absence of either H3K27me3 or MTF2 (F). G) Genome browser examples of PRC2 binding 
to classical Polycomb targets. Box plots represent median and interquartile range (IQR; 
whiskers, 1.5 IQR).
Stratication of Polycomb target sites reveals two major types of 
targets
We noticed that several of the clusters observed in Figure 1 showed distinct characteristics, 
such as the strength of binding or the width of the peaks (for example cluster 4 and 5 of 
the EZH2 ChIP-seq, Fig 1C). Moreover, the consequences of removal of MTF2 or JARID2 
seems dierent per cluster (compare cluster 2 and 4 in Fig 1C, and cluster 3 and 5  in 
Fig 1F for the Mtf2GT/GT line, or cluster 2 and 5 in Fig1e for the Jarid2-/- ESCs). Furthermore, 
recent work implied that recruitment of MTF2 relies on the physical presence of EED only 
in a subset of PRC2 targets158, which already provides cues supporting distinct modes 
of recruitment to dierent genomic regions. To understand how PRC2 recruitment 
might be distinct depending on the genomic loci analyzed, we included the public 
MTF2 ChIP-seq in ESCs lacking EED (and consequently the PRC2 core), BioCap data to 
identify regions free of DNA methylation218 (which is common for Polycomb targets 
and required for MTF2 binding to DNA158) and H3K4me3 ChIP-seq in wildtype ESCs (to 
identify bivalent promoter elements), that comprise the majority of Polycomb targets 
in ESCs219. We combined these data with those shown in Figure 1 and clustered them to 
identify dynamic changes among dierent conditions. Clustering of these data with the 
ChIP-seq tracks shown in Figure 1 on the common set of PRC2-bound regions revealed 
six major clusters (Fig 2A). Clusters 1-4 display strong BioCap and H3K4me3 signals and 
are likely bivalent promoters74, whereas clusters 5-6 show lower BioCap and H3K4me3 
signals and could comprise silenced genes. We observed that the consequences of the 
perturbations for PRC2 recruitment varied per cluster (Fig 2B, S3A). A notable example 
includes the H3K27me3 signal, which is aected more in clusters 1-4 compared to cluster 
5-6 in Mtf2GT/GT ESCs (Fig 2B, right top). Similar patterns hold true for EZH2 and JARID2 
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recruitment (Fig 2B, left top and right bottom). In addition, removal of EED results in very 
strong reduction of MTF2 recruitment in all clusters, although this seems slightly more 
profound in clusters 5-6 compared to cluster 1-4. As recent work revealed that MTF2 is 
recruited to CpGs in the context of a specic shape of the DNA158, we also analysed the 
DNA shape contents of each cluster. This revealed shape-matching GCG trinucleotides, 
characterized by a helix twist (HelT) and propeller twist (ProT) with values within the 
permissive ranges, are enriched in cluster 1-4 (Fig 2C), conrming previous ndings158. 
Together, these analyses suggest that cluster 1-4 rely relatively more on MTF2-mediated 
recruitment compared to cluster 5-6. 
Previous reports have suggested that Polycomb target sites contain distinct gene sets219. 
To attest whether cluster 1-4 and 5-6 also contain dierent sets of genes, we analyzed 
the genomic elements underlying these clusters. We calculated enrichment (against all 
genes) of body structure whose development is in§uenced by the genes of every cluster 
and found that all clusters show strong enrichments for classical Polycomb targets, as 
expected from the strong binding of all PRC2 subunits to these regions (Fig S3B). Next, 
we stratied the clusters by calculating the enrichment only among PRC2 targeted 
genes, and found that cluster 5 and 6 contain genes prevalently related to body plan, 
limb, mesenchyme and branchial arches development, including all the Hox genes, while 
cluster 2 and 4 show a stronger enrichment for neural structures (Fig 2D). Collectively, 
these analyses identify at least two distinct Polycomb target regions, which could rely on 
dierent mechanisms of PRC2 recruitment. 
Figure 2 | Stratication of PRC2 targets based on recruitment mechanisms. A) 
Clustering of all PRC2 targets using ChIPseq data in multiple PRC2 mutants. Cluster 1-4 are 
unmethylated CpG islands (strong BioCap) signal, showing bivalent marks in WT (H3K4me3 
and H3K27me3). These regions display heavy reduction of EZH2 recruitment in the MTF2 
mutant, milder eects of H3K27me3 absence (EED226 treatment), and little eect of JARID2 
absence. The intensity of MTF2 binding depends on both H3K27me3 and JARID2 but binding 
is still clearly detectable even in the absence of PRC2 core (Eed-/-) indicating a primary 
binding to DNA, reinforced by other mechanisms, such as JARID2-mediated recruitment, 
which in turn also depends on both H3K27me3 and MTF2. Cluster 5 and 6 have lower BioCap 
and H3K4me3 signal, and, while still aected by the absence of MTF2, this has a much less 
marked eect on recruitment of both EZH2 and JARID2, and on H3K27me3 deposition. B) WT-
normalized, input-subtracted RPKM quantication of signal shown in (a). C) Quantication 
of GCG trinucleotides matching DNA shape requirement for MTF2 recruitment as dened in 
Perino et al, 2018158. Cluster 1-4 are strongly enriched in shape-matching GCGs, indicating 
potential for strong DNA-mediated MTF2 recruitment. D) Enrichment of anatomical terms 
in the genes associated with peaks in the six clusters. Cluster 4 shows strong enrichment for 
CNS structures, cluster 5 and 6 for limb and branchial arches tissues and mesenchyme. See 
Fig S3B for the full overview.
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Figure 3 | The H3K27me3 feedback loop and JARID2 are mutual backups for PRC2 
recruitment. A) Heatmap showing the e ect of H3K27me3 depletion on the binding of EZH2. 
WT and MTF2GT/GT show mild reduction of EZH2 binding when treated with EED226 inhibitor, 
while the treatment is highly synergistic with the depletion of JARID2. B) Bootstrapping-based 
RPKM quanti cation (methods) of the signal in (A). Each colored dot represents the median 
of one round of bootstrapping, grey bars represent 99.9% con dence interval for the mean of 
bootstrapped values in each condition and cluster. C) Treatment with EED226 further a ected 
MTF2 recruitment in Jarid2  and JARID2 recruitment in Mtf2 , with the former leading to 
a recruitment pattern closely resembling the Eed line (cf. Fig2a). D) Bootstrapping-based 
RPKM quanti cation of the signal in (C) similar as in 3B. E) Genome browser view of example 
Polycomb targets. For each genotype two tracks are overlaid: the darker color represents 
EED226 treated samples, the lighter color untreated cells.
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JARID2 and H3K27me3 are mutually redundant for PRC2 recruitment
Our analyses allowed us to investigate the individual attributions of MTF2, JARID2 and 
H3K27me3 for PRC2 recruitment. However, ablation of single subunits individually 
does not exclude the possibility of compensation by other factors. Thus, we combined 
knockouts of MTF2 and JARID2 with chemical removal of H3K27me3. We treated MTF2GT/GT 
ESCs with EED226 to remove H3K27me3, which leaves only JARID2-mediated recruitment 
intact. Similarly, we combined removal of JARID2 knock-out with EED226 treatment, 
which would leave only the attribution of MTF2-mediated recruitment (cf. Fig 1A). In both 
situations, treatment with EED226 resulted in the complete removal of H3K27me3 (Fig 
S4). Next, we examined the eect on core PRC2 recruitment to target genes by performing 
ChIP-sequencing of EZH2 in Mtf2GT/GT+EED226 ESCs and Jarid2-/-+EED226 ESCs. Inspection 
of the EZH2 signal revealed a minor decrease of EZH2 recruitment in MTF2+EED226 
ESCs, when compared with the already severe phenotype caused by MTF2 depletion 
alone (Fig 3A,B). However, some EZH2 binding persisted, which suggests that additional 
recruitment mechanisms exist besides those mediated by PRC2.1. Interestingly, although 
the absence of H3K27me3 or JARID2 alone has only marginal eect on EZH2 recruitment, 
their combined ablation resulted in a major decrease of EZH2 recruitment, as shown both 
genome-wide (Fig 3A,B) and at specic locations (Fig 3E). These observations indicate 
that JARID2 and H3K27me3 are mutually redundant for PRC2 recruitment. In addition, 
this demonstrates that MTF2-mediated recruitment by itself is not su¦cient to establish 
a Polycomb domain but requires PRC2.2 and/or the EED feedforward loop. We extended 
our analyses by performing ChIP-sequencing for JARID2 in Mtf2GT/GT+EED226 ESCs and for 
MTF2 in Jarid2-/-+EED226 ESCs. Removal of both JARID2 and H3K27me3 further reduced 
MTF2 recruitment, and especially in cluster 5-6 MTF2 recruitment was near-zero (Fig 3C-
E). Interestingly, these are the same clusters in which Eed-/- ESCs display near-absence 
of MTF2 recruitment and where the GCG trinucleotides matching MTF2 DNA-shape 
requirements are not enriched (Fig 2a,d). When focusing on JARID2 in Mtf2GT/GT+EED226 
ESCs, we observed a reduction of recruitment in all clusters although the decrease was 
marginally stronger in cluster 5-6 (Fig 3D). Together, these data uncover an important 
contribution of the EED-H3K27me3 interaction to PRC2 recruitment, in particular for 
PRC2.2, and show that the relative importance of PRC2.1 and PRC2.2 diers across the 
genome. 
JARID2 recruitment is largely dependent on PRC1
Our analyses indicate that both PRC2.1 and PRC2.2 are required to establish PRC2 
recruitment to target genes. In this process, the allosteric feedforward loop mediated by 
EED seems to buer the absence of JARID2 and vice versa. We hypothesized this could be 
mediated through PRC1, as the catalytic subunit RING1B can deposit H2AK119ub which 
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can in turn mediate JARID2 recruitment204,220. As PRC1-mediated PRC2 recruitment was 
shown to be mediated exclusively through H2AK119ub and JARID2, a scenario in which 
H3K27me3 and H2AK119ub are absent simultaneously might phenocopy the eect of 
Jarid2-/-+EED226 ESCs. To test this, we used RING1A/B double mutant ESCs treated with 
EED226 (Ring1a/b-/-+EED226) and performed ChIP-sequencing of EZH2, MTF2 and JARID2 
in these ESCs. Interestingly, we observed that the EZH2 and MTF2 proles as obtained in 
Jarid2-/-+EED226 and Ring1a/b-/-+EED226 were nearly identical (Fig 4A, B). Also, JARID2 
binding was aected in Ring1a/b-/-+EED226, especially in cluster 5 and 6, which are less 
dependent on MTF2 (Fig 4A,B). These observations indicate that JARID2 and PRC1 act in 
the same recruitment axis. As JARID2 recruitment seems to be retained to some extent in 
the RING1a/b+EED226 condition, additional mechanisms might attract JARID2 to target 
sites, for example binding of JARID2 to DNA217 or RNA211,221. To extend our analysis on PRC1/
PRC2 interdependencies and disentangle the roles of H3K27me3 versus PRC2 subunits 
in PRC1 recruitment, we performed RING1B ChIP-seq in WT, MTF2GT/GT, and Jarid2-/- in the 
presence of EED226. Interestingly, removal of H3K27me3 in wildtype ESCs had only limited 
eect on RING1B recruitment  (Fig 4C-E, Fig S5), which is in line with the observation 
that PRC1 can be recruited independent of PRC2202. Surprisingly, however, the combined 
absence of H3K27me3 and either MTF2 or JARID2 results in strong reduction of RING1B 
binding (Fig 4C-E). While the Polycomb dogma posits that PRC1 and PRC2 mutually aect 
each other only via their catalytic products (respectively H2AK119ub and H3K27me3), 
these data suggest that other H3K27me3-independent mechanisms exist that mediate 
PRC1 recruitment. As direct physical interaction between the two complexes has never 
been documented, this would require alternative explanations, such as scaolding eects 
of RNA molecules. Alternatively, it is possible that the physical presence of PRC2 (which is 
strongly reduced in  MTF2GT/GT+EED226 and Jarid2-/-+EED226 ESCs) stabilizes PRC1 binding 
to chromatin, which could shift the balance of a competition with additional factors or by 
building a generally more favorable chromatin context for PRC1 recruitment. 
Figure 4 | PRC1-PRC2 crosstalk in the absence of H3K27me3. A) Heatmap showing EZH2, 
MTF2 and JARID2 binding in the absence of H3K27me3 in PRC2 and PRC1 mutant lines. In the 
absence of H3K27me3, JARID2 and RING1A/B mutant phenocopy each other with regard to 
EZH2 and MTF2 binding, suggesting JARID2 and RING1B act in the same PRC2 recruitment 
mechanism. JARID2 recruitment is also strongly aected by the absence of RING1A/B, in line 
with the JARID2-mediated PRC2 recruitment via binding to PRC1-deposited H2AK119ub. B) 
Average plot of the ChIP signal shown in (A), centered on called peaks. C) Heatmap showing 
Ring1b binding in several conditions. Ring1b is only mildly aected by removing H3K27me3 
using EED226 (~40%). Binding is further attenuated in MTF2 and JARID2 mutant ESCs. D) 
Examples of loci of the data as shown in (C). E) Average plot of the ChIP signal shown in (C), 
centered on called peaks.
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Finally, we investigated whether the residual EZH2 recruitment observed in Ring1a/b-/-
+EED226 and Jarid2-/-+EED226 ESCs was mediated through MTF2. To do so, we used 
Mtf2GT/GT ESCs in which we removed H3K27me3 using EED226 and additionally H2AK119ub 
using MG132 (MTF2GT/GT + d.i.), a drug that can is known to remove H2AK119ub202, and 
performed ChIP-sequencing for EZH2 in these ESCs. In this ‘triple ablation’ condition, the 
recruitment of EZH2 to target genes was completely abrogated (input levels, Fig 5, Figure 
S6). Collectively, these analyses demonstrate that the combined action of MTF2, the 
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Figure 5 | EZH2 recruitment depends on MTF2, H3K27me3 and H2AK119ub. A) 
Heatmap of ChIP-seq signal for EZH2 in multiple conditions including Mtf2 cells double 
inhibited (d.i.) with EED226 (to remove H3K27me3) and MG132 (to remove H2AK119ub). 
B) Example loci of the data shown in (A). C) Average pro les of the ChIP signal shown in (A), 
centered on called peaks. The lower row is a zoom in of the area in the black box.
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allosteric EED feedforward loop and PRC1-mediated recruitment of JARID2-containing 
PRC2 sub-complexes are required for PRC2 recruitment in ESC.
GT/GT
The mechanisms guiding PRC2 to target sites have long remained enigmatic. Clear 
evidence demonstrated that the allosteric feedforward loop mediated by EED is 
important for spreading of PRC2 away from its initial nucleation site205. However, the 
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mere presence of H3K27me3 is not su¦cient to maintain PRC2 at its target genes, which 
indicated that continuous DNA-mediated sequence-specic recruitment is required 
to attract PRC2 to newly synthesized chromatin strands222. The recent discovery of 
facultative PRC2 subunits and the presence of functionally distinct sub-complexes has 
greatly advanced our understanding of PRC2 recruitment213,223. In particular, individual 
ablation of all prime facultative subunits in ESCs revealed a major role for MTF2 in PRC2 
recruitment, which together with JARID2 mediates the initial PRC2 recruitment to the 
initiation sites (‘nucleation sites’)157,158,212,217.  However, MTF2 and JARID2 occupy distinct 
mutually-exclusive PRC2 sub-complexes and it has remained unclear how these sub-
complexes cooperate224. 
In this study, we aimed to unify the role of each prime constituent that mediates primary 
PRC2 recruitment. Our analyses further conrm previous observations that MTF2 is 
required for a signicant proportion of PRC2 recruitment157,158 and extend on recent work 
highlighting that the remaining recruitment is mediated via JARID2212. We show that MTF2 
and JARID2 modulate their mutual recruitment, which in part is mediated through the 
EED feedforward loop and in part through PRC1. It remains in question how JARID2 aects 
MTF2 recruitment mechanistically, as absence of JARID2 does not aect EZH2 (and hence 
core PRC2223) recruitment but does result in a ~50% reduction of MTF2 recruitment. A 
potential explanation would be that hybrid PRC2.1/2.2 complexes containing AEBP2 
and MTF2 form that show altered functioning, such as for example JARID2-MTF2 hybrid 
complexes in AEBP2 mutant ESCs201. The formation of hybrid complexes could sequester 
the complex or inhibit MTF2-mediated recruitment. Alternatively, RNA-mediated 
scaolding could be inhibited in the mutants, resulting in a reduced recruitment of the 
residual subunits.
Combining MTF2 or JARID2 absence with removal of H3K27me3 allowed us to gain 
additional insights into the establishment of Polycomb domains. A notable example 
includes the redundancy of JARID2 and H3K27me3 as observed in the current study, 
which indicates that these factors can substitute for each other, at least to a large extent. 
Notably, our results have been obtained in a steady state situation and assessing such a 
redundancy mechanistically would require conditional removal of both factors followed 
by time-course ChIP-seq experiments. However, it is tempting to speculate that initiation 
of the formation of a Polycomb domain only requires initial recruitment to target sites 
to establish a su¦cient amount of PRC2 molecules that catalyze H3K27me3. This might 
su¦ce to  kick-start an allosteric feedforward loop. As primary recruitment is mainly 
mediated via MTF2, such a loop can still exist in the absence JARID2 (when the allosteric 
loop can occur through EED). In addition, when H3K27me3 is absent, we speculate that 
an alternative route could take over that requires JARID2 binding to H2AK119ub. As such, 
only combined ablation of both JARID2 and H3K27me3 would attenuate all possible 
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feedforward loops, leaving only DNA-mediated recruitment intact, as observed here. 
This hypothesis is further substantiated by our analysis of ESCs lacking MTF2, H3K27me3 
and H2AK119ub in which all core PRC2 recruitment is absent. 
In line, the observations in the current study further substantiate previous work 
that demonstrated that the role of PRC1 and PRC2 are large intertwined, as both 
complexes can be recruited independently but simultaneously modulate their mutual 
recruitment202,220,225. Our analyses of EED226 treated ESCs reveals that ~40% of PRC1 
recruitment depends on the presence of H3K27me3 (Fig 4e), which would be mediated 
through canonical complexes containing CBX7208,225. The remainder of PRC2-independent 
PRC1 is likely recruited via KDM2B-mediated DNA binding, which is in line with previous 
observations showing that ~60% of RING1B recruitment is mediated by KDM2B226,227. 
Surprisingly, our analyses reveal that MTF2 and JARID2 decient ESCs treated with 
EED226 show a more profound decrease (than ~40%) of RING1B occupancy at target 
genes. This could indicate either a so far unknown link between PRC1 and PRC2, or 
alternatively, a stabilization of KDM2B-mediated recruitment to DNA by the physical 
presence of core PRC2, that would extend the residence time of PRC1 on chromatin212. 
Together, these observations further corroborate the dogma that PRC1 and PRC2 can be 
recruited autonomously, but are synergistic for their reciprocal recruitment. 
In addition to the insights into specic recruitment mechanisms, we provide evidence 
that Polycomb target regions can be sub-divided into (at least) two major clusters. The 
largest group (in this study cluster 1-4) contains mainly bivalent genes which rely more 
on PRC2.1-mediated recruitment. The smaller group (in this study cluster 5-6) seems 
to rely more on PRC1 and PRC2.2. Notably, cluster 5-6 contains very lowly expressed 
and developmentally relevant genes such as all the Hox genes (Table S1). As the two 
major target groups harbour functionally dierent genes, it is tempting to speculate 
that distinct recruitment mechanisms are in play. This is supported by the observation 
that MTF2 is strongly downregulated upon dierentiation while the paralogues PHF1 
and PHF19 are upregulated and start occupying the PRC2.1 complex79. Although these 
paralogues share many genomic targets in ESCs, they might have dierent genomic 
targets upon ESC dierentiation as MTF2 is recruited by shape-specic DNA binding and 
PHF1 and PHF19 via binding to H3K36me3 and potentially sequence non-specic DNA 
binding157,228,229. As such, it is possible that the bivalency of cluster 1-4 is resolved resulting 
in expression of these genes in early dierentiation. Cluster 5-6, however, comprise the 
genes required for later dierentiation (such as limb formation) and as PRC2.2 is stable 
during early dierentiation, these genes will remain silenced79,89. 
Interestingly, inhibition of PRC2 catalytic activity using EED226 which results in the 
absence of H3K27me2/3 has only limited implications for core PRC2 recruitment, whereas 
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mutating the WD40 domain of EED has major consequences212. On the one hand, this 
could indicate that inhibition by EED226, while preventing binding to H3K27me3 and 
allosteric activation of EZH2, still allows binding to potential other substrates for which 
EED has only limited a¦nity such as other (tri)methylated histone lysines, unmodied 
histone tails, RNA or DNA interactions. On the other hand, it is possible to conceive that 
mutations in the highly hydrophobic aromatic cage of the WD40 domain could induce 
additional conformational changes on EED itself or other PRC2 subunits, resulting in 
molecular phenotypes more severe than the one attributable to the WD40 domain alone. 
Further structural studies will be required to clarify this question. 
Collectively, the observations here provide novel insights into Polycomb recruitment in 
ESCs and provide a model in which PRC2 recruitment can be initiated solely through 
direct recruitment via DNA, after which PRC2.1/PRC2.2 and PRC2/PRC1 functional 
interactions are required to achieve the establishment of a complete Polycomb domain 
through self- and mutual reinforcement and spreading to neighboring nucleosomes. 
Methods
Embryonic stem cell culture
Wildtype E14 ESCs (129/Ola background) and knockout ESCs were maintained in 
Dulbecco’s Modied Eagle Medium (DMEM) containing 15% fetal bovine serum, 10 
mM Sodium Pyruvate (Gibco), 5 µM beta mercaptoethanol (BME; Sigma) and Leukemia 
inhibitory factor (LIF: 1000U/ml; Millipore). Eed-/- ESCs have been described by Schoeftner 
et al180., Jarid2-/- ESCs have been described in Landeira et al197. Mtf2 knockout (Mtf2GT/GT)230 
and Ring1a-/-/ Ring1b+/- ESCs231 were a kind gift from Haruhiko Koseki. Ring1b ESCs are 
knockout for Ring1a and heterozygous for Ring1b. Full knockout of Ring1b was induced 
through treatment with Tamoxifen (OHT) for 2 days. To inhibit EED function, ESCs were 
treated with 10 µM EED226216 for 4 days. Complete removal of H3K27me3 was validated 
using western blot.  
Western blot
Cell pellets were dissolved in RIPA buer at a density of 104 cells per µl and brie§y 
sonicated to ensure proper cell lysis. Proteins denatured in SDS-PAGE gels were 
transferred onto PVDF membranes. Primary antibodies used were rabbit anti-MTF2 
(ProteinTech; 16208-1-AP), rabbit anti-JARID2 (Novus Bio; NB100-2214), rabbit anti-
H3K27me3 (Millipore; 07-449), rabbit anti-H3 (Abcam;1791). Secondary antibodies were 
HRP-conjugated anti-rabbit (Dako; P0217) and anti-mouse (Dako; P0161). Protein bands 
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were visualized using Pierce ECL western blotting substrate (Thermo). Images were 
analysed using ImageJ. 
ChIP-sequencing
Cells were crosslinked in 1% PFA at room temperature for 10 min. The crosslinking 
reaction was halted using 1.25M glycine and cells were harvested by scraping in buer 
B (0.25% Triton X-100, 10 mM EDTA, 0.5 mM EGTA, 20 mM HEPES). The suspension was 
centrifuged for 5 min at 1600 rpm, 4 ˚C and the pellet was resuspended in 30 ml buer 
C (150 mM, 1 mM EDTA, 0.5 mM EGTA, 50 mM HEPES) and rotated for 10 min at 4 ˚C. 
The nuclei were centrifuged 5 min at 1600 rpm, 4 ˚C and resuspended in incubation 
buer (0.15% SDS, 1% Triton X-100, 150 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 20 mM 
HEPES) supplemented with Protease inhibitor. Nuclei were sonicated using a Biorupter 
Pico to obtain chromatin with an average DNA length of 300 bp. The chromatin was snap 
frozen and stored at -80 ˚C until further use. The sonicated chromatin was incubated 
overnight with the required antibody and pulled down using protein A/G magnetic 
beads. After washes, eluted chromatin was de-crosslinked overnight and puried 
with MinElute PCR Purication columns (Qiagen). After qPCR quality check for target 
enrichment, up to 5 ng/sample of ChIP was prepared for sequencing using the Kapa 
Hyper-prep Kit (Kapa Biosystems) using NEXT§ex adapters (Bio Scientic), followed by 
8-11 cycles amplication by PCR. After size-selection using E-gel (Invitrogen) to enrich 
for 300bp fragments, libraries were sequenced paired-end on an Illumina NextSeq500. 
qPCR analysis of ChIP DNA was performed with iQ SYBR Green Supermix (Bio-Rad) on a 
CFX96 Real-Time System C1000 Thermal Cycler (Bio-Rad). All the ChIPs in this study were 
performed at least in duplicate.
Antibodies
ChIP was performed using 3ul/sample of the following antibodies: MTF2 (Aviva System 
Biology ARP34292, lot QC49692-42166), H3K27me3 (Millipore 07-449, lot 2717675), EZH2 
(Diagenode C15410039, lot 003), JARID2 (Novus Biologicals NB100-2214, Lot E2), RING1B 
(Abcam, AB3832 lot GR86503-25).
Bioinformatic analysis
Data from Perino et al.,158 were reprocessed in parallel with those of this study. To ensure 
maximum comparability (75bp single-end, 42bp paired-end) and accurate quantication, 
all fastq les were trimmed to 42bp using fastx_trimmer (version 0.0.13.2), and in 
case of paired-end sequencing only read_1 was used for mapping. All fastq les were 
mapped using bwa (version 0.7.10-r789), ltered to retain only uniquely mapping reads 
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using mapping quality of 30 and samtools (version 1.7, §ag -F 1024), and normalized for 
sequencing depth to produce bigwig. Peaks were called with MACS2-2.7232 with qvalue 
0.0001 using --call-summits for transcription factors and --broad for H3K27me3. Only 
peaks independently called in both replicates were used for downstream analysis. 
High-condence peaks for each mark were obtained by merging peaks called in both 
replicates and overlapping by at least 50% of their length, and combined to obtain the 
list of all PRC2 peaks. Heatmaps of ChIPseq signal were generated using §u v3.0.2233, 
and clustered for dynamics using the “–g” option. ChIP metaplots were obtained with 
deeptools v 3.1.3234. Anatomy term enrichment was calculated using MouseMine235. 
RPKM bootstrapping analysis was performed using scipy (v 1.1.0). RPKM from the two 
independent ChIPseq replicates were combined into a single pool. Values were drawn 
from this pool, recorded, and returned, such that every value could be drawn multiple 
times. For each bootstrapping round a number of value matching the total number of 
PRC2 peaks was drawn, and the median plotted as one dot in the swarmplot. Condence 
intervals (99.9%) were calculated from 100 bootstrapping events.
Whole cell proteomes
Cell pellets were dissolved in RIPA buer at a density of 104 cells per µl and brie§y 
sonicated to ensure proper cell lysis. Protein extracts (10 µg) were processed using Filter 
Aided Sample Preparation (FASP) and digested overnight with Trypsin. Peptide mixtures 
were desalted prior to LC-MS analysis. 
533641-L-bw-Mierlo
Processed on: 23-7-2019 PDF page: 126
Supplementary Figure 1 | A-D) Heatmap of WT ChIP-seq signal on the indicated peak set. 
H3K27me3-negative JARID2 peaks were excluded from further analysis. E) Venn diagram 
showing the overlap of peaks called for the ChIP-Seq of each protein independently. F) Mass 
spectrometry quanti cation of PRC2 subunits in the di erent cell lines. Detection of JARID2 
and MTF2 in the respective mutants (asterisks) are due to value imputation in Perseus. G) 
Western blot validation of EED226 depletion of H3K27me3, for the ChIPs shown in Figs 1 and 
2. H) Scatterplots of peak RPKM values showing high reproducibility of ChIP replicates.
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Supplementary Figure 2 | ChIP-qPCR validation of the ChIP-Seq data shown in Figure 2A. 
Each dot represents the enrichment value in one replicate.
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Supplementary Figure 3 | A) Average plot of the ChIP signal shown in Fig 2a, centered on 
called peaks. B) Enrichment of anatomical terms in the genes associated with peaks in the 
six clusters shown in Fig 2A, relative to all genes.
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Supplementary Figure 4 | Western blot validation of EED226-mediated depletion of 
H3K27me3 for the ChIP data shown in Figure 3 and 4.
Supplementary Figure 5 | Examples loci of the data shown in Fig 4C, two for each cluster.
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Supplementary Figure 6 | Examples loci of the data shown in Fig 5, two for each cluster.
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Abstract
The Polycomb Repressive Complex 2 (PRC2) is a multi-subunit protein complex essential 
for development of multicellular organisms by means of its gene-regulatory function. 
Recruitment of PRC2 to target genes followed by deposition and propagation of its 
catalytic product trimethylation of histone H3 lysine 27 in a spatio-temporally controlled 
manner are key to PRC2 function. A compendium of recent breakthrough studies has 
uncovered unexpected roles for substoichiometric PRC2 subunits in these processes. 
Here, we elaborate on how facultative PRC2 subunits regulate catalytic activity, targeting 
and propagation of PRC2, and how this aects chromatin structure, gene expression and 
cell fate.
533641-L-bw-Mierlo
Processed on: 23-7-2019 PDF page: 135
Chapter 6
135
6
Introduction
Tight control of gene expression, achieved through the concerted action of transcription 
factors and epigenetic modiers, is critical for embryonic development. The Polycomb 
Repressive Complex 2 (PRC2) is a major epigenetic complex that is key to this process. 
Through deposition of one or more methyl groups on Lysine 27 of Histone H3 (H3K27me1, 
H3K27me2 or H3K27me3, respectively), PRC2 safeguards cellular identity by ensuring 
proper gene silencing236. The regulatory role of PRC2 during development is underscored 
by embryonic lethality of mice lacking a functional PRC2 complex175,181,194.
The PRC2 complex consists of core subunits EZH1/2, EED, SUZ12 and RBBP4/7, together 
with a wide range of substoichiometric subunits237–239. EZH2, the main catalytic subunit 
of PRC2 depositing the bulk of methylation on H3K27, requires the physical presence of 
both EED and SUZ12 for catalytic activity, as in their absence EZH2 is auto-inhibited240,241. 
After trimethylation of H3K27 by EZH2, binding of EED to H3K27me3 through its WD40 
domains results in a conformational change of EZH2 which enhances its catalytic activity, 
referred to as allosteric activation242–244. By binding its own product via EED, PRC2 can 
spread to neighbouring nucleosomes to deposit H3K27me3205,206,245. Although SUZ12 was 
thought to mainly serve as a stabilizing factor for PRC2, recent work highlighted a role 
for the VEFS domain of SUZ12 in guiding PRC2 to target loci, thus identifying SUZ12 as 
essential for PRC2 recruitment246. RBBP4 and RBBP7 stabilize PRC2 binding to unmodied 
nucleosomes247.
The mechanism of PRC2 recruitment to target genes is an intense area of study. In 
mammals, PRC2 was shown to have a strong tendency to bind CpG islands promoters of 
lowly transcribed and inactive genes248,249. Although the feedback loop through binding 
of EED to H3K27me3 was shown to assist in sustaining PRC2 at these CpG-rich target 
sites205, the mere presence of H3K27me3 is not su¦cient to maintain PRC2 at target sites 
during cellular divisions in Drosophila and likely in mammals222,246. Thus, it is apparent 
that continuous sequence-specic de novo recruitment of PRC2 is required to maintain 
Polycomb and H3K27me3. As the core of PRC2 does not possess such ability, PRC2 
facultative subunits could serve such purpose. Here, we highlight recent insights on how 
PRC2 facultative subunits contribute to PRC2 localization at target genes and regulation 
of the catalytic activity of PRC2. Furthermore, we discuss how PRC2 individual sub-
complexes might cooperate to regulate PRC2 function. We will mainly focus on PRC2 in 
mouse embryonic stem cells (mESCs), as these have yielded key insights into Polycomb 
regulation.
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Figure 1 | Top: the core of PRC2 consists of EED, SUZ12 and EZH1 or EZH2 (EZH1/2; only one 
is present in a complex). EZH1/2 is the catalytic subunit of PRC2 that deposits methylation on 
H3K27. EED binds H3K27me3, which results in allosteric activation of EZH1/2. SUZ12 mainly 
serves as stabilizer of the complex. Bottom: The left graph indicates the stoichiometry of 
the facultative PRC2 subunits relative to core PRC2 based on AP-MS. In practice, there are 
two major sub-complexes which contain the core subunits and several distinct facultative 
subunits (right). Note that RBBP4/7 are not displayed here as these factors associate with a 
multiple epigenetic protein complexes as stabilizing factors.
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PRC2 consists of two dierent functional sub-
complexes: PRC2.1 and PRC2.2
In search for proteins that modulate PRC2 function, various groups have taken an 
unbiased approach by performing PRC2 a¦nity purications coupled to tandem mass 
spectrometry (AP-MS; Figure 1). These experiments convincingly showed that the core 
of PRC2 is associated with a number of subunits that are present at substoichiometric 
levels, including PHF1, MTF2, PHF19 (these three proteins are homologs of Drosophila 
Polycomblike), PALI1 (also referred to as C10ORF12), EPOP (also known as C17ORF96), 
JARID2 and AEBP288,195,223. Further AP-MS studies using individual PRC2 subunits as 
baits revealed that not all facultative subunits are simultaneously engaged in the PRC2 
complex, but that PRC2 exists in at least two distinct multimeric protein complexes, 
referred to as PRC2.1 and PRC2.2 213. Both sub-complexes contain the PRC2 core subunits, 
while the facultative subunits are mutually exclusive to either complex: PRC2.1 includes 
one of the Polycomblike (PCL) proteins (PHF1, MTF2 or PHF19) together with EPOP or 
PALI1, and PRC2.2 further includes AEBP2 and JARID2200,201,213,250 (Figure 1).
PRC2.1
PCL proteins are important for primary PRC2 recruitment
Genetic knockout studies of the individual PCL proteins have revealed a central role for PCL 
proteins in primary recruitment of PRC2. In particular, MTF2 is critical for recruitment of 
PRC2 to unmethylated CpG islands in mESCs157,158,198. Within MTF2, the extended homology 
region forms a winged-helix structure that specically binds to unmethylated CG-dense 
DNA sequences157,251. Further specicity of MTF2 binding relies on the underlying shape 
of the DNA helix. This shape is determined by the stacking interactions of nucleotides, 
which aect rotational parameters (helix twist, propeller twist and roll) and minor groove 
width of the DNA252. MTF2 preferentially recognizes unmethylated DNA with an unwound 
helix relative to canonical B-DNA158. From the MTF2-DNA co-crystal structure it appears 
that the DNA backbone of the locally unwound helix is optimally spaced for contacts 
with the MTF2 winged-helix structure157. Notably, the DNA shape-requirements of MTF2 
binding likely prevents PRC2 recruitment to unmethylated DNA at non-target genes, 
which contain a lower density of CpG dinucleotides in a sequence context of more tightly-
wound DNA158. These sequence signatures required for PRC2 recruitment as identied 
in mESCs are conserved between human, mouse, frog and sh genomes251. In contrast, 
it has long been known that PRC2 recruitment in Drosophila relies on a specic DNA 
sequence referred to as the Polycomb Response Element (PRE)253. It is therefore tempting 
to speculate that the unwound helix containing unmethylated CpGs comprises the 
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vertebrate version of the PRE (Figure 2). Inserting or mutating specic DNA shapes and 
sequences in vivo using CRISPR-Cas9 will provide further insights into DNA sequence- 
and shape-specicity of MTF2 in mammalian systems. Such experiments could further 
reveal the structural DNA requirements to recruit PRC2 to a putative mammalian PRE.
PHF1 and PHF19 are close homologues of MTF2, which all contain one Tudor domain, 
two PHD ngers, an extended homology domain and a conserved C-terminal domain. 
All PCL proteins can modulate the catalytic activity of PRC2 in vitro and in vivo through 
promoting deposition of H3K27me3 by EZH2. In addition, PHF1 can associate with 
H3K36me3 and bind DNA, thereby increasing PRC2 residence time on the chromatin and 
stimulating H3K27me3 deposition (Key Figure X, top)254,255. Similar to PHF1, PHF19 has the 
ability to bind H3K36me3, while PHF19 additionally regulates total protein levels of PRC2 
and H3K27me3228,256. In mESCs, PHF1 and PHF19 are expressed ~10-fold lower relative to 
MTF2. As each PRC2.1 complex can contain only one PCL subunit213, the amount of PRC2.1 
complexes with either PHF1 and PHF19 is minimal compared to MTF2-containing PRC2.1 
(Figure 1)79,89,223. This might explain the mild eect on PRC2 recruitment upon ablation of 
PHF1 or PHF19 as compared to removal of MTF2. Neuronal dierentiation of mESCs is 
accompanied by a very strong downregulation of MTF2, resulting in PRC2.1 complexes 
which mainly contain either PHF1 or PHF1979,89. The downregulation of MTF2 ts with the 
essential role for MTF2 to maintain H3K27me3 patterns at lineage-specic genes in mESCs. 
The (relative) increase of both PHF1-PRC2 and PHF19-PRC2 during NPC dierentiation is 
required to recruit PRC2 to stem cell genes that were previously marked by H3K36me3 
(which is mutually exclusive with H3K27me3257), mediated via the Tudor domain of PHF1/ 
PHF19229,254,258. The subsequent recruitment of the H3K36me3 demethylase NO66 by 
PHF19-PRC2 results in removal of H3K36me3 and deposition of H3K27me3259. Together, 
these observations suggest a model in which PHF1 and PHF19 are required to silence 
stem cell genes during dierentiation, whereas MTF2 is required during pluripotency for 
maintaining H3K27me3 patterns at lineage-specic genes. Although it is now known that 
MTF2 recruits PRC2 through direct sequence- and shape-specic DNA binding, it remains 
unclear how PHF1 and PHF19 control specic binding of PRC2.1 to stem cell genes as 
compared to other genes. Altogether, current data suggest a functional role for the PCL 
proteins in relation to cell identity, with MTF2 being dominant in mESCs and PHF1/ PHF19 
in NPCs. Further support for this hypothesis could be obtained by systematic mutual 
substitution of the PCL proteins in pluripotent mESCs and during dierentiation towards 
the dierent germ layers.
533641-L-bw-Mierlo
Processed on: 23-7-2019 PDF page: 139
6
 
Figure 2 | Top: the Polycomb Response Element (PRE) was rst identied in Drosophila as a 
DNA sequence that has the potential to recruit PRC2 via the accessory factor PHO. The PRE 
sequence is not conserved in mammals and whether a mammalian analogue exists has long 
remained elusive. Bottom: recent work highlighted an exclusive role for MTF2 in directly 
associating PRC2 with unmethylated CpG-rich DNA in mouse ESCs, relying on the extended 
homology domain (EH) within MTF2. This association only occurs when the DNA helix is 
unwound, as such allowing specicity for Polycomb target genes based on DNA shape as 
well as methylation status.
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Despite their dierent functions and abundance, recent observations showed that 
PHF1, MTF2 and PHF19 co-occupy similar genomic regions in mESCs157,260. The functional 
relevance of this co-localization, which might be mediated through PRC2 core subunit 
EED (which is present in all PRC2 complexes) binding to H3K27me3, requires further study. 
However, it should be noted that these results might be explained by the heterogeneity 
of mESCs cultured in serum and LIF, in which a small population of the mESCs show signs 
of dierentiation28. This is supported by observations from single cell RNA-sequencing, 
which show that PHF1 and PHF19 are expressed in a small subset of mESCs only261,262. 
To further address whether the observed co-localization of PHF1, MTF2 and PHF19 is 
related to heterogeneity of mESCs, it would be highly informative to assay binding of 
the various PCL subunits in (more) homogeneous populations, such as mESCs that are 
FACS-sorted for the pluripotency marker REX or mESCs cultured in the presence of 2 
kinase inhibitors, which results in relative homogeneity of mESC cultures32. In addition, 
ChIP-reChIP approaches can provide insights into whether the dierent PCL proteins are 
simultaneously engaged on one genomic locus.
 
Key Figure X | Function of the individual PRC2.1- and PRC2.2-specic subunits. Top: All 
PCL proteins stimulate the catalytic activity of PRC2. PHF1 can associate with H3K36me3 and 
recruits PRC2.1 to genomic regions containing high H3K36me3 during ESC dierentiation. In 
addition, PHF1 increases the residence time of PRC2.1 on chromatin. MTF2 recruits PRC2.1 
to unmethylated CpG islands. PHF19 associates with H3K36me3 and recruits NO66, which 
demethylates H3K36me3 allowing H3K27me3 deposition and further PRC2 recruitment. 
EPOP associates with EloB/C, which maintains low levels of transcription. PALI1/2 promotes 
the catalytic activity of EHZ2. As such, EPOP and PALI1/2 ne-tune the function of PRC2 
at target genes. Bottom: JARID2 stimulates the catalytic activity of EZH2 and can recruit 
PRC2.2 by binding H2AK119ub. JARID2 can bind DNA in vitro, but whether this is important 
for PRC2.2 recruitment in vivo remains in question. Finally, JARID2 can be methylated at K116 
by EZH2, which serves as a binding scaold for EED resulting in stimulation of EZH2 catalytic 
activity. AEBP2 can also stimulate the catalytic activity of EZH2 after binding to H2AK119ub. 
AEBP2 is a stabilizing component of PRC2.2.
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EPOP links PRC2 to gene transcription
Next to the PCL proteins, EPOP has been identied as a PRC2 subunit exclusively 
associating with PRC2.1. EPOP is not essential for establishing H3K27me3 levels at target 
genes, but ablation of EPOP results in abrogation of the interaction of PRC2.1 with 
Elongin B/C (EloB/C)156. As such, EPOP functions as a scaolding protein that bridges 
PRC2.1 and EloB/C. Notably, EloB/C is well known to interact with Elogin A (EloA) in 
the canonical Elongin complex263, which is a positive regulator of elongation by RNA 
polymerase II. As the EloB/C-PRC2 interaction facilitates RNA Polymerase II elongation 
by promoting H3K4me3 and H2Bub1200,264, thereby sustaining low levels of permissive 
transcription at bivalent genes 156, this provides a surprising direct link between PRC2 
and transcription263. EPOP-EloB/C acts by ne-tuning PRC2 and H3K27me3 levels at target 
genes, as removal of either EPOP or EloB/C results in increased PRC2 and H3K27me3 
occupancy156. In addition to EloB/C, recent studies uncovered a link between PRC2 and 
EloA. Specically, PRC2 monomethylates EloA at lysine 754 in vitro and in vivo265. This 
modication of EloA represses transcription at a subset of PRC2 target genes, providing 
a direct mechanism for gene silencing by PRC2. It remains unclear what unies the 
seemingly opposite actions of PRC2 on transcription via EloB/C (low level activation) on 
one hand and EloA (repression) on the other hand. Although it has been shown that the 
EloB/C interaction with either EloA or PRC2 is mutual exclusive156, important questions 
are (i) whether there is any connectivity between PRC2-EloB/C and EloA/B/C on the 
chromatin by genomic co-localisation, possibly dependent on methylation of EloA; 
and (ii) how the balance between PRC2-EloB/C and EloA/B/C modulates transcription. 
Assessing the genomic localization of PRC2.1 and (un)methylated EloA, together with 
analysis of the interactomes of EloA and EloA-K754me, might shed further light on the 
mechanisms by which the Elongin proteins cooperate with PRC2.1 to modulate gene 
expression.
C10ORF12 (PALI1) ne-tunes PRC2 sub-complexes
After C10ORF12 was identied as part of the PRC2 complex using interaction proteomics, 
it turned out that its presence was restricted to PRC2.1223,250. The presence of C10ORF12 
and EPOP in the PRC2.1 complex is mutually exclusive, which is in line with observations 
that dierentiation of mESCs is accompanied by remodeling of the PRC2.1 complex in 
which EPOP is strongly decreased and C10ORF12 is increased79,250. Recently, it became 
evident that C10orf12 is not an independent gene, but part of a larger locus extending 
to the Lcor1 gene on the genome, encoding a protein dubbed PRC2-associated LCOR 
isoform 1 (PALI1)266. In addition, a protein similar to PALI1 was identied that originates 
from the Lcorl1 locus. This gene, being a paralogue of PALI1 and therefore referred to as 
PALI2, also interacts with PRC2.1266. mESCs lacking PALI1 show a dramatic decrease in 
H3K27me3 deposition, which suggests that PALI1 is a critical regulator of EZH2. However, 
since the stoichiometry of PALI1 relative to other PRC2.1 protein members is very low 
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(Figure 1)223,266, an alternative explanation is that the observed eects on H3K27me3 after 
PALI1 ablation are indirect, for example mediated through the interactions of PALI1 with 
EHMT1/2 that deposit H3K9me2250.
PRC2.2
AEBP2 and JARID2 enhance PRC2 function
In contrast to PRC2.1, PRC2.2 shows a uniform stoichiometry in which the core PRC2 
complex members associate with AEBP2 and JARID2, both in mESCs as well as during 
their dierentiation towards NPCs79,89. AEPB2 and JARID2 synergistically enhance the 
catalytic activity of EZH2 by approximately 25-fold203. Recent studies showed that the 
catalytic stimulation of EZH2 by JARID2 is in part mediated by methylation of JARID2 
at lysine 116 (K116me)267. Analysis of PRC2.2 crystal structures revealed that JARID2-
mediated activation of EZH2 parallels H3K27me3-mediated activation of PRC2: JARID2-
K116me acts as a binding scaold for the WD40 domain of EED inducing a PRC2.2 
conformational change resulting in increased EZH2 catalytic activity (Key Figure X, 
bottom)268. Stimulation of EZH2 catalytic activity by AEBP2 remains less-well understood, 
but several mechanisms have been suggested, which might act in parallel. AEBP2 
has three C2H2-type zinc ngers which, when bound to PRC2, are localized near the 
catalytic domain of EZH2269,270. This could potentially stabilize EZH2 and thereby enhance 
its catalytic activity. In addition, the crystal structure of PRC2.2 suggests that AEBP2 
structurally mimics an unmodied histone tail which interacts with RBBP4/7 and may 
contribute to the stability of PRC2.2268. AEBP2 stimulates PRC2 binding to nucleosomes, 
thereby potentially promoting PRC2 residence time on chromatin which in turn enhances 
H3K27me3 deposition by EZH2271. Furthermore, it has been shown that AEBP2 stimulates 
EZH2 through association with nucleosomes carrying ubiquitination on Lysine 119 
of H2A (H2AK119ub)203,244. Clearly, additional insights are required to determine the 
contribution of each of these mechanisms by which AEBP2 can stimulate H3K27me3 
deposition. In particular, it will be informative to determine the crystal structures 
of PRC2.2 either in solution or bound to H2AK119ub, as the increase in EZH2 catalytic 
activity might well depend on conformational changes. Notably, in seemingly contrast 
to the PRC2.2 activating role of AEBP2, AEBP2-null mESCs display a minor increase in 
PRC2 and H3K27me3 at target genes as compared to wild type ESCs201. However, this is 
likely the result from articial PRC2.1/PRC2.2 hybrid complexes harbouring both MTF2 
and JARID2 as a result of the absence of the centrally-localized AEBP2 within PRC2.2269. 
As such, AEBP2 seems important for the structural integrity and distinction of the PRC2 
sub-complexes.
Next to enhancing the catalytic activity of PRC2.2, JARID2 is involved in recruitment of 
PRC2.2 to target genes as mESCs lacking JARID2 show impaired PRC2.2 recruitment214,272. 
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Recent evidence suggests that JARID2 targeting is largely mediated by H2AK119ub as: 
(i) JARID2 can dock to H2AK119ub via its positively charged TR domain273; (ii) PRC2.2 
recruitment towards pericentric heterochromatin regions in DNA methylation-decient 
mESCs and mouse embryonic broblasts is critically dependent on the interaction 
between JARID2 and H2AK119ub171,204; and (iii) JARID2 plays a pivotal role in recruiting 
PRC2 to H2AK119ub domains during X-chromosome inactivation204,274,275. JARID2 possesses 
weak a¦nity for unmethylated DNA in vitro without apparent sequence specicity217,276, 
but whether this has a functional role for JARID2 recruitment in vivo remains to be 
determined. In view of the apparent redundancies in PRC2 recruitment to target genes, it 
will be important to determine the relative contribution of H2AK119ub-mediated PRC2.2 
recruitment as compared to other PRC2 recruitment mechanisms, the specic conditions 
in which this recruitment is essential in vivo, and whether and how DNA binding of JARID2 
is important in this process. An interesting experimental approach to tackle these open 
questions would be to perform genome-wide ChIP-Seq proling of full length JARID2 and 
truncated versions of JARID2 lacking DNA- and/or histone-binding domains.
PRC2.1 and PRC2.2 show a high level of cooperativity
As outlined in the previous sections, it has recently become clear that there are at least 
two dierent PRC2 sub-complexes (PRC2.1 and PRC2.2), which are dierentially regulated, 
exhibit dierent interactions and are recruited to DNA by independent mechanisms 
(Figure 4). However, the high similarity between both sub-complexes, and their near 
complete co-localization on the genome, suggest a high level of cooperativity towards 
establishment of Polycomb domains in mESCs157,158,201,260. In line, while PRC2 and H3K27me3 
are decreased but present in JARID2- or MTF2-null mESCs, the recently generated JARID2-
MTF2 double-null mESCs show a complete lack of PRC2 recruitment to target genes 
and absence of H3K27me3245. These experiments further conrm that MTF2 is the main 
recruiter of PRC2.1, while JARID2 is of PRC2.2, and that their combined action comprises 
the total recruitment of PRC2 in mESCs. Compelling evidence for actual synergy between 
PRC2.1 and PRC2.2 comes from ChIP-Seq experiments, in which MTF2-null mESCs display 
reduced JARID2 binding at target genes and JARID2-null mESCs show reduced MTF2 
binding158. An important mechanism that could convey the interdependence between 
PRC2.1 and PRC2.2 consists of EED binding to H3K27me3, which would allow mutual 
PRC2.1 and PRC2.2 recruitment after initial targeting and deposition of H3K27me.
The schematic overview in Figure 4 summarizes the role of the dierent sub-complexes 
in PRC2 recruitment. The “initiation phase” mainly involves MTF2-mediated recruitment 
of PRC2 and KDM2B-mediated recruitment of PRC1 by means of binding to non-
methylated CpG-rich DNA, with both mechanisms likely acting in parallel. This initial 
recruitment kick-starts several downstream events (“amplication”), during which PRC2 
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can propagate from the initial nucleation site by H3K27me3-mediated binding of EED to 
methylate adjacent H3K27 residues, allowing spreading towards neighbouring regions 
and to distal regions by means of long-range 3D contacts205,206,245. In view of the enhanced 
PRC2.2 catalytic activity as compared to PRC2.1 due to the presence of JARID2 and/or 
AEBP2203,277, PRC2.2 might have a dominant role in the amplication phase. Additional 
feedback occurs by H2AK119ub-mediated recruitment of PRC2.2 via JARID2, suggesting a 
primary role for PRC2.2 as compared to PRC2.1 in the functional interplay between PRC1 
and PRC2171,204,220, and by H3K27me3-mediated recruitment of PRC1 via the CBX proteins208. 
During these activities, PRC2 (and PRC1) can be modulated through association with 
lncRNAs (although it is currently unclear how this aects Polycomb recruitment) or 
inhibited by binding to nascent RNAs produced by RNA polymerase II (extensively 
reviewed in278). Collectively, these mechanisms cooperate to establish Polycomb domains 
in mESCs. Notably, PHF1 and PHF19 are not required for initial PRC2.1 recruitment, as 
combined removal of MTF2 and JARID2 cannot be compensated by either PHF1 or PHF19 
in mESCs245. However, PHF1-PRC2.1 and PHF19-PRC2.1 might assist in amplication 
of H3K27me3 through EED binding to H3K27me modications. During dierentiation 
of mESCs, PRC2.1 containing PHF1 or PHF19 becomes more abundant and these sub-
complexes might add to silencing of stem cell genes covered by H3K36me3259.
Collectively, PRC2.1 and PRC2.2, in concert with PRC1, act cooperatively to establish 
Polycomb domain formation to induce gene silencing (Box 1). Precise recruitment of 
either sub-complex is critical for PRC2 function and therefore required for embryonic 
development. This is highlighted by the observation that removal MTF2/ JARID2 or 
KDM2B, involved in recruitment of PRC2 or PRC1, respectively, results in embryonic 
lethality or severely compromised ospring after birth230,279,280. Moreover, ablation of other 
facultative subunits without apparent recruiting functions, such as AEBP2 and PALI1, 
also results in embryonic lethality201,266. This indicates that an intricate balance between 
the multiple sub-complexes is essential for the (gene) regulatory role of Polycomb. 
Although the critical role of the mechanisms as depicted in Figure 4 has become evident 
in recent years, the relative contributions of each of the individual events towards 
proper Polycomb domain formation is only starting to be uncovered245. Given the large 
amount of ChIP-Seq data for the PRC-associated proteins and hPTMs in mESCs, both in 
the wildtype situation as well as after ablation of individual PRC2 subunits, an important 
next step in our understanding of Polycomb function will be to apply quantitative 
mathematical modeling to explain current observations on genome-wide recruitment 
and localization of PRC2. This might unite complementary observations and generate 
new testable hypotheses on unexpected synergistic events during PRC2 recruitment 
and spreading. Furthermore, it might provide a quantitative framework for the interplay 
between PRC2.1, PRC2.2 and the various PRC1 sub-complexes.
533641-L-bw-Mierlo
Processed on: 23-7-2019 PDF page: 146
The complexity of PRC2 sub-complexes
146
MTF2
PRC2.1 PRC1
KDM2B
Amplification
PRC1
CBX7
PRC2.2
JARID2
H3K27me3
H2AK119ub
PRC2.1/
PRC2.2
CpG-mediated recruitment
PRC2.1 and PRC2.2 spreading 
via H3K27me3 
Initiation phase
Unmethylated CpG
PRC1 / PRC2.2 agonism 
Binding
PRC2.2
PRC1
CBX7
Catalysis
ncRNA and nascent RNA effects
PRC1
Pol II
PRC2.1/
PRC2.2
Nascent RNA
Inhibition
recruitment to active genes
(in differentiation)
H3K36me3
PRC2.1
PHF19
PRC2.1
PHF1
No66
Removal
Intrusion of PRC1 and PRC2
PRC2.1
PHF19
PRC2.1
PHF1
No66
PRC2.1
PRC1
CBX7
Included upon ESC differentiation
PRC2 recruitment to silent genes in pluripotency
lncRNA
PRC2.1/
PRC2.2
PRC2.1/
PRC2.2
PRC2.2
533641-L-bw-Mierlo
Processed on: 23-7-2019 PDF page: 147
Chapter 6
147
6
Figure 4 | An overview of the main mechanisms by which PRC2 (and PRC1) can be recruited 
to target genes. In pluripotency, PRC2.1 recruitment is initiated by MTF2-mediated binding 
to DNA. PRC2.2 recruitment is likely to occur through either EED binding to H3K27me3 as 
deposited by PRC2.1 or JARID2 binding to H2AK119ub as deposited by PRC1. PRC1 can be 
recruited through KDM2B-mediated binding to unmethylated DNA, or through CBX7-
mediated binding to H3K27me3. Together, these recruitment mechanisms will result in 
establishment of a Polycomb domain. As JARID2 binding to DNA has only been shown in 
vitro, this is indicated with a dashed line. Upon dierentiation of ESCs (bottom panel), 
PHF1- or PFH19-containing PRC2.1 complexes become more prevalent on the chromatin 
which allows recruitment of PRC2.1 to H3K36me3-decorated regions, thereby initiating the 
formation of Polycomb domains to silence stem cell genes. 
Box 1: The road towards gene silencing after PRC recruitment
PRC1 and PRC2 cooperate to establish Polycomb domains and gene silencing. Yet, 
how gene silencing is established after initial recruitment of the PRC complexes 
has long remained elusive. Several models have proposed that the Polycomb 
complexes and/or their associated PTMs, H3K27me3 and H2AK119Ub, establish 
chromatin compaction which directly or indirectly inhibits RNA Polymerase II, 
resulting in gene repression281,282. In line with this hypothesis, PRC2 target genes 
display reduced chromatin accessibility in vivo compared to non-Polycomb 
targets283. However, the observation that removal of core PRC2 and consequently the 
H3K27me3 modication has no eect on the chromatin structure or accessibility at 
target genes challenges the role of PRC2 in chromatin compaction284. Interestingly, 
recent work highlighted an exclusive role for PRC1, but not PRC2, in directly 
mediating compaction of the chromatin in Polycomb domains284,285. Specically, 
PRC1 increases the nucleosome occupancy and reduces the nucleosome spacing 
at target genes. Together, these observations support a model in which PRC1 is 
the sole eector molecule in Polycomb silencing. It remains in question how PRC1 
achieves chromatin compaction, whether this is directly mediated by its catalytic 
product H2AK119ub or if co-factors are required in this process.
Concluding remarks and future perspectives
New insight into novel substoichiometric subunits of PRC2 has signicantly enhanced our 
knowledge on Polycomb recruitment and function in mESCs, including the identication 
of two long-sought prime recruiters of PRC2: MTF2 and JARID2. It has become clear that 
distinct sub-complexes exist, which are recruited via partly independent axes and are 
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together required to establish PRC2 recruitment. Recruitment of PRC2.1 and PRC2.2 
has recently been shown to be synergistic and ablation of substoichiometric PRC2 
subunits aects the balance between PRC2.1 and PRC2.2, resulting in aberrant PRC2 
recruitment, H3K27me3 deposition and/ or gene expression. Yet, how a correct balance 
between PRC2.1 and PRC2.2 is achieved, whether and how this is altered upon changes of 
cellular state and the functional role of this balance in embryonic development are open 
questions. In particular, important aspects regarding molecular interactions, recruitment 
synergisms, lineage specicity and potential antagonistic links between the facultative 
subunits require further study. Furthermore, it will be important to extend observations 
on PRC2 sub-complexes to other cellular systems such as somatic cells and potentially 
cancer in which the balance between PRC2.1 and PRC2.2 might be shifted, such as in 
HeLa cells where all PCL proteins are equally present in PRC2.1223. Altogether, we believe 
that addressing the outstanding questions as summarized below will yield critical 
information to obtain a better view on the biology of PRC2 sub-complexes. 
Outstanding questions
How do PRC2.1 and PRC2.2 cooperate to establish Polycomb domains in mESCs? 
Given that PRC2.1 is highly remodeled during dierentiation, but PRC2.2 is stable, 
how are such Polycomb domains established during early lineage dierentiation? 
To what extend are PRC2.1 and PRC2.2 functionally distinct?
As several PRC2 facultative subunits such as PHF1, PHF19 and PALI1 are present 
in only a small fraction of all PRC2 complexes present in mESCs: what are the 
mechanisms by which their removal has a dramatic impact on PRC2 recruitment 
and/or H3K27me3 catalysis? Could there be secondary eects at play?
Given the prime role of the PCL proteins in PRC2.1 recruitment and their 
dierential abundance in various lineages: are the PCL proteins MTF2, PHF1 and 
PHF19 associated with lineage commitment, and are they possible drivers of 
development? 
What is the relative contribution of each (facultative) PRC2 subunit for 
PRC2 recruitment? Is su¦cient data available to generate a robust, in silico 
computational model explaining current observations on genome-wide 
recruitment and localization of PRC2?
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PRC2.1-PRC2.2 hybrid complexes exist in knockout ESCs. How dynamic are PRC2.1 
and PRC2.2 in the wildtype situation in terms of subunits exchange or loss of 
substoichiometric subunits, for example after recruitment to chromatin?
Are facultative PRC2 subunits important for PRC1 recruitment or function? And is 
PRC1 important for recruitment of PRC2.1?
How does the knowledge obtained for PRC2 recruitment and function in mESCs 
extend to other cellular systems, including cancer? 
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The human body consists of over 200 cell types. As all cells contain the same genetic 
information, it has been a long-standing questin how cells acquire specication during 
early embryogenesis to dierentiate into these specic cell types.  During the rst days 
of early embryonic development, all cells are able to dierentiate into every cell type, 
a capacity referred to as pluripotency. A groundbreaking discovery has been that the 
pluripotent early epiblast of the developing mouse embryo, the part that will give rise 
to the three primary germ layers, could be maintained in vitro in the form of Embryonic 
Stem Cells (ESCs) using serum and Leukemia inhibitory factor (LIF). Under permissive 
conditions, ESCs exhibit unlimited self-renewal capacity while retaining features of the 
preimplantation epiblast identity and potency. The indenite pluripotent state of ESCs 
is underlined by the ability to repopulate the epiblast and contribute to all somatic cell 
lineages upon in vivo injection into the blastocyst24. The derivation of ESCs has comprised 
a valuable model system that provided insights into the molecular pathways and (epi)
genetic processes sustaining the pluripotent state28. An important observation was that 
a molecular circuitry of transcription factors (TFs) sustains the pluripotent state. These 
TFs are Oct4, Sox2 and Nanog (OSN) and are now established as the foundation of 
pluripotency119,286–289. These TFs do not act in isolation, but are in the center of a more 
complex network of pluripotency-sustaining proteins290. Through interacting with 
auxiliary pluripotency factors such as ESRRB, TFCP2L1, KLF4, KLF2, REX1 and MYC, the 
OSN factors orchestrate the processes that safeguard pluripotency27,110,120,139,291–294. 
Although serum ESCs are functionally pluripotent, the presence of undened serum in 
the culture medium results in the activation of many independent but also con§icting 
pathways. The consequence is that serum ESCs are very heterogeneous and a fraction 
of these ESCs are actually reminiscent of primed Epiblast Stem Cells (EpiSCs)26,27,295. These 
subpopulations potentially interchange their identity in culture, suggesting a sort of 
dynamic equilibrium296. As such, serum ESCs are referred to as a ‘metastable’ form of 
pluripotency29. Accumulated knowledge on the molecular pathways that sustain the 
pluripotent state of serum ESCs resulted in the development of a culture condition 
that was serum-free, chemically dened and relied on the use of two kinase inhibitors 
together with the optimal inclusion of LIF. This condition, referred to as ‘2i’, comprises 
ESCs that are homogeneous in terms of expression of pluripotency factors and are 
hallmarked by a round morphology and the absence of primed ESCs in culture28. 
2i and serum ESCs are supported by dierent molecular pathways
Both 2i and serum ESCs fulll the requirements to be called pluripotent, as proven by 
the ability to contribute to a developing blastocyst upon injection. However, serum 
ESCs display an altered epigenetic and transcriptional prole relative to the pre-
implantation blastocyst from which ESCs are derived, while 2i ESCs resemble their in 
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vivo origin well, as exemplied by global DNA hypomethylation33–35. 2i ESCs are therefore 
postulated to exist in the pluripotent ground state, while serum ESCs are referred to as 
‘naïve pluripotent’21,32,134. Furthermore, 2i ESCs share more similarities with early pre-
implantation development, while serum ESCs possess features of primed pluripotency. 
Finally, potentially 2i ESCs are more potent in populating the blastocyst upon injection, 
making 2i and serum ESCs also functionally distinct32,41. 
The distinction between 2i and serum ESCs is likely the direct consequence of the dierent 
pathways that are triggered by the culture conditions. Serum ESCs are dependent on 
LIF that acts by activating STAT3 signaling via the gp130/LIF-R complex297,298, which 
consequently functions through its critical mediator protein TFCP2L1. In addition, LIF 
functions through weakly activating the PI3K/AKT and MEK/ERK signaling299. The critical 
component of serum is BMP4, which activates SMAD signaling to activate the Inhibitor 
of Dierentiation genes. Removal of serum results in neuro-ectodermal dierentiation, 
while absence of LIF leads to non-neuronal dierentiation. As such, LIF and serum 
together are critical to maintain serum ESCs in the naïve state. In 2i ESCs, PD03 inhibits 
the phosphorylation and consequently activation of the MEK1/2 kinase, which abrogates 
MEK/ERK signaling. CHIRON targets GSK3, which inhibits b-catenin degradation leading 
to hyper-activation of the Wnt-signaling pathway28,300. Collectively, this shows that 
dierent pluripotent states can be maintained using distinct extracellular stimuli. 
These pathways that sustain the pluripotent state of serum and 2i ESCs act both 
overlapping and distinct downstream gene regulatory networks, nally converging on a 
network of pluripotency factors. The fundamental pluripotency factors OCT4 and SOX2 
are critical for all pluripotent states, as absence of either results in dierentiation119,301, 
while NANOG is not essential for maintenance of the pluripotent state but is critical 
for its acquisition20. The OSN factors physically interact and occupy the same genomic 
regions. These regions are frequently co-occupied by b-catenin, STAT3 and SMAD1, which 
are the downstream eectors of  WNT, STAT and BMP4 signaling, providing a direct link 
for how the external cues aect the pluripotency network302,303. Interestingly, while OCT4 
and SOX2 are similarly expressed in 2i and serum ESCs, many auxiliary factors such as 
KLF2, KLF4, ESRRB, PRDM14, TFCP2L1 and TBX3  are higher expressed in 2i ESCs21. As also 
shown in Chapter 3-4, this results in higher levels of these factors on the chromatin of 2i 
ESCs relative to serum ESCs, which might both re§ect and aid the stabilized pluripotent 
state of 2i ESCs. On the other hand, serum ESCs display higher levels of other auxiliary 
modules such as MYC and associated factors, which allow more rapid progression 
through the G1 cell-cycle phase and repression of FGF/ERK signaling304,305. As such, 2i and 
serum ESCs rely on parallel and diverging pluripotency modules. 
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Linking pluripotency factors and the epigenetic environment
As also mentioned in Chapter 1, 2i and serum ESCs contain a distinct epigenetic 
environment. Notable examples include global DNA hypomethylation, absence of 
long-range interactions, fewer nucleosome clutches and reduced promoter bivalency 
in 2i ESCs32,33,38,40. Whether this is directly linked to changes within the pluripotency 
network remains in question. Physical interaction between the pluripotency network 
and epigenetic complexes has been reported, such as direct interaction between 
SALL4 and the Nucleosome Remodeling and Deacetylase (NuRD) complex122 and KLF4 
with the histone acetyltransferase P300306. In addition, some evidence suggests that 
the pluripotency factors OCT4, ESRRB and TFCP2L1 can physically interact with NuRD, 
Polycomb Repressive Complex 1 (PRC1) and the SWItch/Sucrose Non-Fermentable 
(SWI/SNF) complex187,290. The implications of these putative interactions remain 
unclear, as dynamics of OSN binding on the genome in 2i and serum ESCs is unrelated 
to the localization of major epigenetic complexes such as Trithorax group (TrxG) and 
Polycomb Repressive Complex 2 (PRC2). Furthermore, as relocalization of OSN is 
directly linked to  dierentially activated MEK and WNT signaling in 2i and serum ESCs, 
and precedes rewiring of the epigenetic environment, this suggests that OSN or other 
core pluripotency factors rather induce transcriptional or local epigenomic changes 
that facilitate epigenetic dynamics between pluripotent states141. A notable example 
of this comprises the protein ESRRB, which can unlock silenced enhancers to allow 
epigenome remodeling by binding of P300 and deposition of histone acetylation307. This 
could for example be mediated by regulation of expression of histone demethylases 
such as KDM3A and KDM4C by OSN, that can demethylate H3K9me at promoters to 
allow increasing the expression of other pluripotency genes such as TFCP2L1303,308. How 
the increased expression of auxiliary pluripotency factors in 2i ESCs relative to serum 
ESCs is related to the distinct epigenome remains to be investigated. A detailed map 
of the genomic localization and interaction partners of each pluripotency factor in the 
transition from 2i to serum ESCs might provide insights into this. 
Epigenetic complexes are critical for maintenance and 
dierentiation of ESCs
To allow dierentiation of ESCs, the pluripotency network must be destabilized. First, 
the auxiliary pluripotency factors such as KLF2 and TBX3, together with NANOG, are 
downregulated, resulting in ESCs priming towards EpiSCs. Consequently, also OCT4 and 
SOX2 are downregulated to allow for induction of dierentiation64,309. As was shown in 
Chapter 2, this is accompanied by a drastic rewiring of the epigenome, which is likely 
required to achieve epigenetic restriction. For example, our ndings conrm previous 
observations of rewiring of the SWI/SNF complex from the ESC-version towards the 
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neuronal version 310. The notion that dynamics of SWI/SNF subunits is important 
is further highlighted by the observation that ESC-specic subunits such as BRG1 and 
DPF2 are important for ESC self-renewal, while dierentiation-induced subunits such as 
SMARCC2 are important for lineage specication311. Another notable example comprises 
DNA methylation, which is virtually absent in the pluripotent ground state but rapidly 
increases upon dierentiation and consequently modulates gene expression33–35. Our 
mass spectrometry data further shows that the increase in DNA methylation upon 
priming and dierentiation is the result of decreased occupancy of TET1/2, rather than 
increase of DNMT3, on the chromatin, which leads to less DNA demethylation and hence 
a more stable DNA methylation mark34,95. 
The importance of epigenetic complexes for propagation and dierentiation is re§ected 
in their role for maintenance and dierentiation of ESCs. For example, BRG1, a subunit of 
the chromatin remodeling complex SWI/SNF, is required for ESC maintenance as genetic 
ablation of BRG1 results in activation of lineage-specifying genes and consequently 
ESC dierentiation312–314. Other examples are SETDB1, which deposits H3K9me2/3, 
and ablation of SETB1 results in ESC death mainly due to compromised transposon 
expression315,316, and the H3K4me3 methyltransferase SET1A, for which knockout ESCs 
cannot be obtained317. It is interesting to note that of these, SETB1 is more important 
for silencing in 2i ESCs relative to serum ESCs318, which could be related to the global 
DNA hypomethylation33.  The role of epigenetics for development in vivo has also been 
repeatedly shown. Ablation or perturbation of major epigenetic protein complexes 
such as PRC1, PRC2, TrxG, SWI/SNF or the DNA methylation machinery results in early 
embryonic lethality175,181,319,320. The development of  mice is compromised by the inability 
to silence the pluripotency program, the failure to activate the correct lineage specifying 
gene expression programs or even due to compromised maintenance of the pluripotent 
cell population in the blastocyst175. Despite the severe phenotypes, it is often di¦cult to 
assess when the defects arise that result in embryonic lethality. To provide more insights 
into this, embryonic stem cells provide a valuable tool to study in vivo development in 
vitro. Maintenance and dierentiation of ESCs towards the three germ layers allows to 
investigate at which time point during development these epigenetic complexes are 
relevant, during ESC maintenance or rather during lineage commitment. 
Mass spectrometry approaches to study epigenetics
The expression level of epigenetic factors in pluripotency and dierentiation has been 
mainly assessed using RNA-sequencing approaches. However, the correlation between 
RNA and protein is only ~50-60%321,322 and total transcript levels do not provide information 
on the localization of proteins or the architecture of protein complexes30,323. Given the 
prime role of epigenetics during development, it will be critical to use mass spectrometry 
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methods to study the (epigenetic) mechanisms underlying the maintenance and exit 
of pluripotency on the level of the eector molecules, the proteins. With the chromatin 
proteomics approaches as used in Chapter 2-4¸ we aimed to use unbiased mass 
spectrometry proling as a tool to understand how epigenetic regulatory mechanisms 
are dynamic between cell states. Our data conrms several previous ndings on for 
example the dynamics of Polycomb complexes and the DNA methylation machinery on 
the chromatin during the transition within pluripotent states and onset of dierentiation. 
Moreover, we have identied a plethora of proteins associated with dierent cellular 
states, which we expect to provide a solid basis for future research that aims at 
understanding pluripotency and dierentiation. Yet, solely measuring the protein levels 
on the chromatin does not provide information on the activity or interaction partners 
of the proteins of interest. It will therefore be important to complement this approach 
with mass spectrometry approaches that are able to assess this in a robust manner. For 
example, by complementing these data with histone PTMs (as performed in Chapter 4), 
an integrative overview of the epigenetic environment is obtained including the catalytic 
product of epigenetic complexes. This allows to understand whether dynamics of or 
within a complex results in dierent total level of the histone modication. In addition, 
it will be highly informative to include measurements of the phosphoproteome and the 
ubiquitome, as the presence of phosphorylation or ubiquitination on epigenetic factors 
can alter their 3D conformation, catalytic activity or interaction partners324,325. A notable 
example of this comprises EZH2, which displays strongly decreased catalytic activity 
when phosphorylated at serine 21, but when phosphorylated at threonine 345 displays 
enhanced binding to long non-coding RNAs such as HOTAIR326,327. To test whether on 
a global scale proteins change interaction partners, the recently developed Thermal 
Proteome Proling (TPP) will be a useful approach328. This method uses thermal shifts to 
identify protein stability, which is a measure of whether a protein interacts with another 
protein or ligand. Assessing these shifts in dierent cellular conditions can as such 
identify whether the interaction behavior of a protein(complex) changes. Collectively, 
combining these approaches in dierent states of pluripotency and dierentiation 
will strongly advance our understanding of the epigenetic regulation of development. 
Additionally, genetic knockouts or chemical inhibition can be used in such work§ows 
to understand the global consequence of perturbing epigenetic protein complexes. For 
example, we have used this approach to identify novel PRC2 and PRC1-regulated proteins 
using ESCs knockout for EED, RING1B, MTF2 and JARID2 as well as several combinations 
with chemical inhibition of EZH2 and/or RING1B (van Mierlo et al., in preparation). 
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Deconstructing pluripotency regulation and dierentiation using 
multi-omics approaches
Our chromatin proteomics approach has provided signicant insights into the 
epigenetic regulation of pluripotency. For example, we have shown that the pluripotent 
ground-state, which was previously supposed to be an unrestricted state22, is actually 
characterized by higher levels of PRC2 and H3K27me3 relative to more primed versions 
of pluripotency. It is interesting to note that induction of dierentiation results in further 
downregulation of PRC2 (Chapter 2). This is in line with recent work which demonstrated 
that neural progenitor cells exhibit strong reduction of PRC279,89. There are various 
interesting implications of this downregulation. On one hand, it be could be related to 
the increased DNA methylation upon priming and early dierentiation329,330, as H3K27me3 
and DNA methylation are mutually exclusive on the genome, and forced expression of 
the DNA methyltransferases in a hypomethylated environment connes PRC2 to non-
methylated regions331. Alternatively, it could indicate that PRC2 has more target genes in 
pluripotency relative to dierentiating cells and as such less molecules are required to 
silence these loci upon early dierentiation. To understand why PRC2 is downregulated, 
it would be interesting to use ESCs overexpressing PRC2 and study the dierentiation of 
such ESCs. 
As also visible in Chapter 2, other protein complexes in addition to PRC2 exhibit rewiring 
upon dierentiation. To fully understand how dierentiation is regulated, it will be 
important to obtain the genomic distribution of all major epigenetic protein complexes 
and their catalytic product. An ideal experimental setup would comprise a time-course 
dierentiation of ESCs with a 24-hour resolution, such as recently performed to study 
reprogramming of somatic cells towards stem cells332. Inclusion of transcriptome and 
total proteome analysis will additionally allow to discriminate actively transcribed and 
silenced genes. It is especially important to include dierentiation towards all three germ 
layers (endo-, ecto- and mesoderm), as epigenetic heterogeneity has been observed 
between these lineages ve days after dierentiation of ESCs333. Collectively, these 
data will provide a solid foundation for future studies on the maintenance and exit of 
pluripotency. These data can subsequently be extended using small-scale knockout 
screens for the main epigenetic modiers. In particular, this will allow to investigate 
how the interplay between epigenetic factors regulates dierentiation. These knockout 
screens can additionally be performed on single-cell level to investigate cellular 
heterogeneity and dierentiation biases. Recently established techniques such as CRISP-
seq and PERTURB-seq, which combine CRISPR-Cas9 knockout screens with single-cell 
RNA and ATAC sequencing, will provide useful tools334–336. 
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From total chromatin approaches towards single locus biology
Although the approach as outlined above is highly informative on a global level, it remains 
to be explored what the predictive value of a chromatin proteome is for a conned locus 
or chromatin domain, as dierent loci could rely on distinct regulatory mechanisms. 
An example comprises the proximal and distal enhancer of OCT4 in ESCs, which both 
regulate OCT4 expression in a distinct manner, and utilization of the proximal versus 
distal enhancer can discriminate naïve and primed pluripotency337. How this specicity is 
achieved remains elusive, but binding of other TFs might be important. It will therefore in 
the future be important to develop methods to disentangle the chromatin environment 
on such a conned locus. ChIP-sequencing approaches using spike-in material provide 
a sensible option to achieve quantitative information on the regulatory landscape of a 
specic locus338. However, this approach relies on antibodies, which are often associated 
with non-specic binding, or genetic manipulation to introduce a protein tag. An 
alternative approach to study conned loci would be to try and purify one specic locus 
in the genome and measure the attached proteins. A signicant leap towards this was 
the purication of telomere repeats using DNA probes339, which also later resulted in the 
purication of major satellite repeats as well as the rDNA promoter159,340. To date, this 
method has not been adapted to allow purication of a single locus. Several other groups 
have in the last year used a dierent approach which relied on recruiting a catalytically-
inactive Cas9 protein (dCas9) coupled to a biotinylating protein fragment which resulted 
in the rst reports describing the purication of a small locus and the attached proteins, 
such as the TERT promoter341,342. Although these studies are highly promising, it remains 
in question whether the low enrichment (2-4 fold over background) achieved in these 
studies is su¦cient for accurate single-locus biology343. Future studies should aim to 
reduce background and amplify the specic signal using for example tandem a¦nity 
purication approaches. 
Towards understanding pluripotency regulation in dierent species
The rst ESCs that could be routinely cultured in vitro were derived from mouse embryos17,23. 
Since the derivation of mouse ESCs, several eorts have resulted in stable propagation 
of ESCs from multiple other species such as rat, pig, marmoset and human344–347. In line 
with mouse ESCs being derived as rst, the ground state of pluripotency was rst stably 
established in vitro using mouse ESCs28. The 2i/LIF culture conditions used to maintain 
the ground state for mouse ESCs were also found to be su¦cient, and required, to 
maintain rat ESCs in the ground state344. However, maintaining human ESCs (hESCs) in 
the ground state has proven more challenging. Characterization of the initially derived 
hESCs revealed these were more equivalent to primed ESCs in mouse, exemplied 
by multiple lines of evidence such as global DNA hypermethylation, morphological 
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similarity to EpiSCs and dependence on FGF/Activin for self-renewal. As such, these 
hESCs could not be considered as ‘naïve pluripotent’348–350. As the 2i cocktail used for 
rodent ground state ESCs does not prevent spontaneous dierentiation of hESCs, it was 
in question whether hESCs could be maintained in the naïve / ground state. However, 
several culture conditions have recently been developed that sustain the maintenance 
of hESCs in the putative naïve state. These culture media all use the 2i/LIF inhibitor 
cocktail supplemented with cocktails of other inhibitors including ROCK, BRAF, SRC, JNK, 
p38 and PKC inhibitors350–354. Although these advances towards establishing the human 
naïve / ground state in vitro are highly promising, there are no universal dening tests 
for naïve pluripotency in a human system, opposed to mouse ESCs where contribution 
to blastocyst development upon injection is a benchmark. Ongoing eorts have tried to 
test the human naïve state by injecting hESCs into developing mice, however, no human-
mouse chimeras have been obtained to date178, although it should be noted that this 
could be related to the distinct developmental timing of human and mouse355. Dening 
the human naïve state therefore mainly relies on dening molecular criteria. These 
currently include a transcriptional prole similar to preimplantation blastocysts, global 
DNA hypomethylation  and two active X-chromosomes29,178,356. We propose to include 
several molecular criteria as obtained in this thesis to further dene the human ground 
state relative to primed hESCs. These include non-promoter conned and higher levels 
of H3K27me3, facultative pericentric heterochromatin (low H3K9me3 and presence of 
PRC2) and increased glutathione activity. Of these criteria, decreased H3K9me3 over 
pericentric heterochromatin has been readily observed in the putative human ground 
state357,358. Moreover, we expect that comparing chromatin proteomes of human ESCs 
together with the histone code with those of mouse 2i, serum and EpiSCs might allow to 
further dene the ground state of human ESCs and potentially other species. 
In conclusion
Embryonic stem cells and their dierentiation is guided by an intricate interplay of all 
regulatory levels. The data obtained in this thesis provides new conceptual insights 
into pluripotency as well as dierentiation of ESCs. This will be relevant to advance our 
understanding of embryonic development of healthy organisms, but will simultaneously 
allow to pinpoint where and when developmental defects occur after disease-causing 
events such as genetic mutations or exposure to toxic compounds. In addition, as 
many processes that are deregulated in cancer cells mimic those present in ESCs, a 
thorough understanding of pluripotency might in the future aid in understanding, and 
consequently treatment, of cancer. Finally, a comprehensive understanding of ESCs will 
be important for future studies that focus on reprogramming of somatic cells to induced 
pluripotent stem cells (iPSCs)359, for which our data might provide additional ‘checkmarks’ 
to which iPSCs should qualify in order to be called fully reprogrammed. Ultimately, in the 
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future this will allow standardized practice for the clinic in which human iPSCs are used 
for regenerative and personalized medicine. 
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Summary 
The formation of a complete organism from a single fertilized cell is a complex and tightly 
regulated process. Regulation of embryonic development takes place at multiple levels 
in the cell, ranging from gene expression to posttranslational modications of proteins. 
An important phase during development is the blastocyst stage, in which pluripotent 
cells in the inner cell mass divide continuously without committing to any lineage 
(dierentiation), which is referred to as pluripotency. While several proteins and protein 
complexes have been identied that dictate the maintenance of or exit from pluripotency, 
it has remained largely enigmatic how pluripotency is regulated at the molecular level. 
In this Thesis, we focus on how this regulation takes place and use and develop several 
strategies to increase our knowledge on the molecular regulation of pluripotency. 
Chapter 1 describes the various regulatory levels present in every cell, which are required 
during embryonic development. This chapter focuses in particular on the chromatin 
(the DNA wrapped around histones) and describes how the chromatin can be modied 
structurally and chemically to allow or prevent expression of genes. Furthermore, this 
chapter explains how the inner cell mass from the blastocyst can be cultured in vitro in 
the form of embryonic stem cells (ESCs) and how ESCs can be used as a model system to 
mimic the blastocyst phase of embryonic development in a dish.
As regulating gene expression is essential for the maintenance and dierentiation of 
ESCs, it is critical to have a comprehensive overview of the chromatin landscape during 
pluripotency, during the preparation for dierentiation (‘priming’) and throughout 
dierentiation. In Chapter 2, we performed chromatin proteomics on embryonic stem 
cells (ESCs), primed embryonic stem cells (EpiSCs) and early dierentiated cells to 
obtain a snapshot of the chromatin landscape. We observed large changes between the 
dierent developmental states, including remodelling of major epigenetic complexes 
such as NuRD, PRC2 and TrxG. In addition, we have identied several novel candidate 
proteins associated with pluripotency and dierentiation. These ndings highlight and 
provide detailed insights into the plasticity of the chromatin environment in pluripotency 
and the exit thereof
The observations done in Chapter 2 have provided conceptual insights into how the onset 
of dierentiation is regulated. However, it has become evident that several epigenetic 
changes readily take upon transition from the pluripotent ground state to metastable 
pluripotency. In particular, it has become apparent that serum ESCs used in Chapter 2 
resemble a metastable state of pluripotency which mimics the peri-implantation state 
of the blastocyst. On the other hand, the pluripotent ground state, which is present in 
the inner cell mass, is resembled by ESCs cultured without serum in the presence of two 
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kinase inhibitors (‘2i ESCs’). Simply switching between serum medium and 2i medium 
allows mimicking the very rst changes that take place upon transitioning from ground 
state pluripotency to metastable pluripotency in vitro, which we used in Chapter 3 and 
Chapter 4. In Chapter 3 we have used stable isotopes (SILAC) to label 2i ESCs during cell 
culture which allowed to compare 2i and serum ESCs on the protein level in a quantitative 
manner. Moreover, we could perform this comparison at the subcellular level, meaning we 
compared the cytoplasm, the nucleus and the chromatin. The data obtained using SILAC 
strongly indicated altered glutathione metabolism between 2i and serum ESCs, which we 
validated using in vitro assays. This has important implications for our understanding of 
the pluripotent ground state in vivo. Our ndings indicate that during the blastocyst stage 
additional free radicals are generated which are potentially harmful for the developing 
embryo, which could suggest that the embryo is more sensitive at this stage. 
In Chapter 4, we further dive into the chromatin environment of 2i and serum ESCs by 
proling both the proteins attached to the chromatin and the histone modications using 
mass spectrometry. Integration of these two datasets revealed that 2i ESCs are enriched 
for the epigenetic protein complex PRC2 and its catalytic product, which is the histone 
modication H3K27me3. This is interesting as the PRC2 complex serves to ensure that 
genes associated with dierentiation are not expressed in ESCs. As previous reports had 
shown a reduction of PRC2 over developmental promoters in 2i ESCs, we performed 
quantitative ChIP-sequencing of H3K27me3 in 2i and serum ESCs. While we indeed 
observe a reduction over promoters, H3K27me3 was enriched outside promoters in 2i 
ESCs, forming a ‘carpet’ over the genome. To understand the function of the widespread 
H3K27me3, we used PRC2 mutant 2i ESCs and found that this carpet of H3K27me3 assists 
in preventing accumulation of dierentiation-associated epigenetic modications such 
as methylation 2i ESCs. We also provide evidence that a similar mechanism might take 
place in the embryo, which would attribute a functional relevance for the non-promoter 
associated H3K27me3 for the maintenance of pluripotency in vitro and in vivo. 
In Chapter 5, we try to disentangle how PRC2 can be attracted to the promoters of 
developmental genes. In particular, several modes of recruitment have been reported 
over the last years. PRC2 can bind directly to DNA via the facultative subunit MTF2 to 
its own product H3K27me3 via the core subunit EED and via the facultative subunit 
JARID2 to H2AK119ub, the catalytic product of PRC1. By systematically removing each 
of these recruitment mechanisms, or combinations thereof, we were able to obtain a 
detailed overview on the relevance of each of these axes and the context in which they 
are important. 
Given the large body of recent ground-breaking reports on PRC2 recruitment, we have 
summarized the current state of knowledge of PRC2 in ESCs in Chapter 6. We use 
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Summary
the recent literature to provide new concepts regarding PRC2 recruitment, including 
a suggestion for the putative Polycomb Response Element in mammals, of which the 
existence has long been speculated but to date had not been identied in mammals. 
In Chapter 7, we discuss the ndings described in this Thesis. We elaborate on the relation 
between observations on the chromatin with active signalling pathways, potential follow 
up experiments in vitro and in vivo and how the data obtained in mouse ESCs might be 
relevant for evaluating ground state pluripotency of other species including humans. 
Altogether, this Thesis provides important insights into the maintenance and exit of 
pluripotency. By focusing mainly on the chromatin landscape using dierent omics 
approaches, we have obtained a comprehensive overview of the chromatin environment 
in embryonic stem cells and identied novel epigenetic features associated with 
pluripotency. These data will provide a foundation for future research focusing on 
chromatin events associated with pluripotency and dierentiation both in vitro and in 
vivo. 
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Nederlandse samenvatting 
De formatie van een organisme vanaf een enkele bevruchte cel is een heel complex 
en strak gereguleerd proces. De regulatie van de embryonale ontwikkeling vindt 
plaats op meerdere lagen in de cel, variërend van de regulatie van genexpressie 
tot de posttranslationele modicatie van eiwitten. Een belangrijke fase tijdens de 
ontwikkeling in de blastocyst fase, waarin de cellen van de interne cel massa van de 
blastocyst continu delen zonder te veranderen in enig ander cel type (dierentiëren), een 
capaciteit die we pluripotentie noemen. Hoewel verscheidene eiwitten en complexen 
van eiwitten geïdenticeerd zijn die het onderhouden of het verlies van de pluripotente 
staat reguleren, blijft het onduidelijk hoe pluripotentie precies gereguleerd wordt op 
moleculair niveau. In dit proefschrift focussen wij op hoe deze regulatie plaatsvindt. We 
ontwikkelen en gebruiken verscheidene strategieën om onze kennis van de moleculaire 
regulatie van pluripotentie te verbreden. 
Hoofdstuk 1 begint door de verscheidene niveaus van regulatie in elke cel te beschrijven 
die nodig zijn voor embryonale ontwikkeling. Dit hoofdstuk richt zich vooral op het 
chromatine (het complex van DNA en histon eiwitten) en beschrijft hoe het chromatine 
structureel en chemisch gemodiceerd kan worden om de expressie van genen toe te 
staan of juist te voorkomen. Daarnaast beschrijft dit hoofdstuk hoe de interne cel massa 
van de blastocyst gekweekt kan worden in vitro in de vorm van embryonale stamcellen 
(ESCs) en hoe deze ESCs gebruikt kunnen worden als een modelsysteem om de blastocyst 
fase van de embryonale ontwikkeling na te maken in een kweekschaaltje. 
De regulatie van genexpressie is essentieel voor het onderhouden van de pluripotente 
staat alsmede de initiatie van dierentiatie. Daarom is het belangrijk om een compleet 
overzicht te hebben van het chromatine landschap tijdens pluripotentie, tijdens de 
voorbereiding van dierentiatie en tijdens de eigenlijke dierentiatie. In Hoofdstuk 2 
hebben wij metingen gedaan van alle eiwitten geassocieerd met het chromatine in ESCs, 
ESCs die zich voorbereiden op dierentiatie (EpiSCs) en tijdens vroege dierentiatie. 
Hier observeerden wij sterke veranderingen binnen belangrijke epigenetische 
eiwitcomplexen zoals NuRD, PRC2 en TrxG. Daarnaast hebben we verscheidene 
nieuwe eiwitten gevonden die geassocieerd zijn met pluripotentie en dierentiatie. 
De gedetailleerde bevindingen in Hoofdstuk 2 onderstrepen de plasticiteit van het 
chromatine milieu tijdens veranderingen van de pluripotente staat. 
De observaties zoals beschreven in Hoofdstuk 2 hebben conceptuele inzichten gegeven 
in hoe dierentiatie gereguleerd wordt. Echter is het ondertussen duidelijk geworden 
dat verscheidene van deze veranderingen op epigenetisch niveau al plaatsvinden tijdens 
de transitie van de pluripotente ‘basisstatus’ naar een meer ongebalanceerde vorm 
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van pluripotentie. Meer speciek, de ESCs gebruikt in Hoofdstuk 2 worden gekweekt 
met behulp van serum, wat een meer onstabiele staat van pluripotentie geeft die 
overeenkomt met het implantatie moment van de blastocyst in de baarmoeder. Aan de 
andere kant, als deze ESCs gekweekt worden zonder serum maar juist in een chemisch 
gedenieerd medium met twee kinase remmers (‘2i ESCs’), re§ecteren de ESCs de 
interne cel massa van de blastocyst in de pre-implantatie staat, hetgeen we aan refereren 
als de basisstaat van pluripotentie. Dit biedt de mogelijkheid om de transitie van deze 
basisstaat naar een onstabiele staat na te maken in een kweekschaaltje, gewoon door 
het medium te verwisselen, hetgeen we hebben gedaan in Hoofdstuk 3 en Hoofdstuk 
4. In Hoofdstuk 3 hebben we met behulp van stabiele isotopen (SILAC) 2i ESCs gelabeld 
tijdens de cel kweek wat de mogelijkheid bood om 2i en serum stamcellen op een 
kwantitatieve manier met elkaar te vergelijken. Dit hebben we gedaan op verschillende 
onderdelen van de cellen, namelijk het cytoplasma, de celkern en het chromatine.  De 
data zoals verkregen met SILAC gaf een sterke indicatie dat 2i ESCs een sterker glutathion 
metabolisme hebben, wat we ook met behulp van verscheidene in vitro testen hebben 
gevalideerd. Dit heeft belangrijke implicaties voor ons begrip van de pluripotente staat 
in vivo, omdat deze data impliceert dat tijdens het blastocyst stadium het embryo meer 
vrije radicalen genereert en dit zou potentieel schade kunnen bezorgen aan het embryo. 
In Hoofdstuk 4 duiken we dieper in het verschil tussen het chromatine milieu van 2i 
en serum ESCs. Dit hebben we gedaan door alle eiwitten die geassocieerd zijn met het 
chromatine, als wel alle aanwezige histon modicaties, te meten door middel van massa 
spectrometrie. Het samenvoegen van deze twee datasets resulteerde in de observatie 
dat 2i ESCs gekenmerkt worden door verhoogde aanwezigheid van het epigenetische 
eiwitcomplex PRC2 en de geassocieerde histon modicatie H3K27me3. Dit is met 
name interessant omdat het PRC2 complex ervoor zorgt dat genen die nodig zijn voor 
dierentiatie niet tot expressie komen in stamcellen. Omdat eerdere bevindingen hadden 
laten zien dat in 2i ESCs er relatief minder H3K27me3 op promoters van deze dierentiatie 
genen zit, hebben we op een kwantitatieve manier de locatie van alle H3K27me3 op het 
hele genoom bepaald. Hier vonden wij inderdaad een verlaging van H3K27me3 en PRC2 
over promoters van dierentiatie genen, maar wel een verrijking buiten deze promoters. 
Deze verrijking vormt een soort van ‘tapijt’ op het genoom. Om de functie van deze 
wijd uitgespreide H3K27me3 in 2i ESCs te bepalen, hebben we gebruik gemaakt van 2i 
ESCs waarin het PRC2 complex niet meer aanwezig is. Hier vonden we dat dit ‘tapijt’ 
van H3K27me3 nodig was om bepaalde epigenetische modicaties te onderdrukken 
die geassocieerd worden met de voorbereiding van dierentiatie, waaronder DNA 
methylatie. We hebben ook bewijs gevonden dat impliceert dat eenzelfde regulatie 
plaats vindt in het embryo, hetgeen een functie zou toedragen aan de niet-promoter 
geassocieerde H3k27me3 voor het onderhouden van pluripotentie in vitro en in vivo. 
Nederlandse samenvatting
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In Hoofdstuk 5 proberen we te begrijpen hoe PRC2 naar de promoters van dierentiatie 
genen gerekruteerd wordt. In de laatste jaren zijn namelijk verscheidene mechanismen 
van rekrutering geïdenticeerd. PRC2 kan direct aan DNA binden via het facultatieve 
complex eiwit MF2, binden aan zijn product H3K27me3 via EED en via het facultatieve 
complex eiwit JARID2 binden aan de H2AK119ub histon modicatie, welke gezet wordt 
door PRC1. Door systematisch deze mechanismen van rekrutering te verwijderen, of zelfs 
combinatie van meerderen, zijn we in staat geweest om een gedetailleerd overzicht te 
geven van dat relevantie van elk van deze manieren van rekrutering, en in welke context 
ze belangrijk zijn. 
Omdat er recent een redelijk aantal verhelderende studies zijn uitgevoerd die belangrijke 
nieuwe inzichten hebben gegeven in de rekrutering van PRC2, hebben we de huidige 
staat van kennis van PRC2 in ESCs samengevat in Hoofdstuk 6. We gebruiken de recente 
literatuur om nieuwe concepten aangaande PRC2 rekrutering te verschaen. Dit bevat 
onder andere de suggestie voor het mogelijke Polycomb responsieve element, waarvan, 
in tegenstelling tot ongewervelden zoals fruitvliegen, het bestaan in gewervelde 
organismen lang gespeculeerd werd maar nog nooit geïdenticeerd was. 
In Hoofdstuk 7 discussiëren we over de bevindingen gedaan in dit proefschrift. We 
wijden uit over de relatie tussen gebeurtenissen op het chromatine in verband met 
actieve signaleringswegen in de cel, mogelijke toekomstige experimenten in vitro en in 
vivo en hoe de data die wij hebben gegenereerd in muis ESCS relevant kunnen zijn voor 
de evaluatie van de pluripotente basisstaat in andere organismen zoals mensen. 
Geheel genomen verschaft dit proefschrift belangrijke inzichten in de moleculaire 
mechanismen die verantwoordelijk zijn voor het onderhouden en het verliezen van 
pluripotentie. Door vooral te focussen op het chromatine landschap hebben we een 
compleet overzicht verkregen van het chromatine milieu in embryonale stamcellen en 
hebben nieuwe epigenetische karakteristieken gevonden die geassocieerd zijn met 
pluripotentie. Deze data zullen een uitgangspunt vormen voor toekomstige studies die 
zich focussen op gebeurtenissen op het chromatine tijdens pluripotentie en dierentiatie 
zowel in vitro als in vivo.  
533641-L-bw-Mierlo
Processed on: 23-7-2019 PDF page: 194
194
Data management
All raw les of the sequencing and proteomics data generated during my PhD at the 
Radboud Institute for Molecular Life Sciences, present in Chapter 2-5, are backed 
up on a university-based server for at least 10 years. All published raw data les from 
proteomics experiments have been made available through the public PRIDE repository. 
The proteomics data used in Chapter 6 will be made available upon publication. All 
RNA-seq data (Chapter 4), ChIP-seq data (Chapter 4-5) and whole genome bisulte 
sequencing data (Chapter 4) are available through the public functional genomics data 
repository GEO (gene expression omnibus). The ChIP-seq data in Chapter 6 will be made 
available upon publication. To ensure interpretability of the data, all lenames, primary 
and secondary data, metadata and descriptive les used to provide the nal results are 
documented along with the data.
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